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Abstract 
Angiotensin converting enzyme, ACE (EC number 3. 4. 15. 1), is a zinc dependent 
dipeptidyl carboxypeptidase that has an essential role in mammalian blood pressure 
regulation as part of the renin-angiotensin aldosterone system. ACE acts to increase 
blood pressure through its actions on two peptides: angiotensin I and bradykinin. In light 
of this role ACE is a key target in the treatment of hypertension and ACE inhibitors 
have been widely used since the 1980s. Although these are effective drugs, a number of 
side effects are commonly associated with their use. These occur as a result of the 
inhibition of the roles of ACE in other physiological processes. 
 
Somatic ACE consists of two homologous domains, each with a functional peptidase 
active site. Only one of these domains, the C-domain, is required for blood pressure 
homeostasis. There is a great deal of interest in developing a new generation of ACE 
inhibitors to selectively target the C-domain, whilst leaving the N-domain active and 
able to fulfil the other biological functions of ACE.  
 
In the work presented here, AnCE, an ACE homologue from Drosophila melanogaster, 
has been used as a model to study the structural basis of ACE inhibition by a number of 
different inhibitory peptides. This has highlighted how interactions with active site 
residues could be exploited in the development of new, domain selective, inhibitors. 
 
ACE homologues in insects are thought to have a conserved role in reproduction. The 
ACE-like enzymes from Anopheles gambiae are of particular interest due to the role of 
this organism in the transmission of malaria. In the work presented here the recombinant 
expression of an ACE homologue from Anopheles gambiae is reported for the first time. 
This is an important step towards the structural and biochemical characterisation of 
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Angiotensin converting enzyme (EC number 3. 4. 15. 1), or ACE as it is commonly 
known, is a highly conserved enzyme that is well known for its role in mammalian 
blood pressure regulation as an integral component of the renin-angiotensin aldosterone 
system (RAAS). 
 
ACE primarily functions as a dipeptidyl carboxypeptidase, removing the two C-terminal 
residues from its peptide substrates. As a member of the M2 family of metalloproteases, 
ACE does this in a zinc dependent manner and contains the characteristic HExxH motif, 
the two histidines of which, plus an additional glutamate residue, co-ordinate the 
catalytic zinc ion (Corvol et al., 1995; Williams et al., 1994). 
 
1.2 The Role of ACE in the RAAS 
Skeggs et al., first identified ACE in 1954 during the course of their work on the peptide 
angiotensin. Angiotensin is a potent vasoconstrictor and plays a key role in increasing 
blood pressure as part of the RAAS. Skeggs et al., observed that some of their samples 
appeared to contain two “forms” of angiotensin both of which, when injected into live 
animals, resulted in rapid vasoconstriction (Skeggs et al., 1954). 
 
When the different forms of the peptide were applied to isolated kidneys however, only 
one had this effect. This indicated that one form of angiotensin was in fact inactive and 
that it was undergoing rapid conversion into the second, active form, presumably 
catalysed by an enzyme present at high concentrations in the blood plasma. This enzyme 
was named angiotensin converting enzyme and the inactive and active forms of the 
peptide as angiotensin I and angiotensin II, respectively (Skeggs et al., 1956). 
 
The production of angiotensin II by ACE is a key process in blood pressure regulation 
by the RAAS (Zaman et al., 2002). The RAAS, summarised in Figure 1.1, is a complex 
hormone system that is activated in response either to a decrease in blood pressure or 
blood volume, which triggers the release of the enzyme renin by the kidneys. The target 
for renin activity is angiotensinogen, which it cleaves to release the decapeptide 
angiotensin I (DRVYIHPFHL). 
 
Angiotensin I is a substrate for ACE, which removes the C-terminal dipeptide from this 
inactive precursor to generate the active peptide angiotensin II (DRVYIHPF). As a 
potent vasoconstrictor, angiotensin II causes an increase in blood pressure and also 
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stimulates the release of aldosterone from the adrenal cortex. This results in increased 
re-absorption of water and ions by the kidneys, ultimately leading to an increase in 
blood volume and blood pressure. 
 
Additionally, ACE acts on a second peptide, bradykinin (RPPGFSPFR). Bradykinin is a 
physiologically important peptide that has roles in a range of processes including 
inflammation and smooth muscle contraction. In terms of blood pressure regulation, 
bradykinin causes the dilation of blood vessels, and hence acts to decrease blood 
pressure. By removing the C-terminal dipeptide, ACE inactivates brady 











1.3 Functions of ACE Outside of the RAAS 
The role of ACE in blood pressure homeostasis has been studied for many years, but 
more recently, the significance of ACE in further biological processes has been realised. 
In addition to the systemic RAAS, the important of local, tissue-specific RAAS has 
become increasingly apparent in recent years. Local systems have been identified in 
tissues including the brain, the testes and the kidneys (Nilsson et al., 2000; Paul et al., 
2006; Sakai and Sigmund, 2005), highlighting the roles of ACE in a wide-range of 
physiological processes outside of blood pressure regulation (Gonzalez-Villalobos et al., 
2013). 
 
Additionally, an increasing number of peptides have now been identified as ACE 
substrates. This includes, but is not limited to GnRH (gonadotropin-releasing hormone), 
Aβ42 (amyloid beta peptide 42), angiotensin 1-9 and AcSDKP (N-acetyl-seryl-aspartyl-
lysyl-proline) (Anthony et al., 2012; Deddish et al., 1998; Rieger et al., 1993; Rousseau 
et al., 1995). Based on these observations it is clear that ACE has a wide-range of 
important physiological roles that we are only beginning to understand. 
 
1.4 Isoforms of Mammalian ACE: sACE and tACE 
The concept of ACE having roles in a wide range of biological processes is supported by 
the fact that there are two isoforms of mammalian ACE: somatic (sACE) and testis 
(tACE), with different, tissue-specific expression patterns (Wei et al., 1991).  
 
sACE is an integral membrane protein mainly located on the surface of endothelial cells 
(Caldwell 1976; Hooper and Turner, 1987; Hooper et al., 1987).  It consists of two 
domains arranged in tandem known as the N-(terminal) and C-(terminal) domains. The 
two domains are connected by a short linker sequence and there is an additional 
transmembrane sequence located at the C-terminus of the protein. The schematic 
diagram in Figure 1.2 illustrates this arrangement. 
 
The two domains of sACE are homologous, sharing 65 % overall sequence similarity, 
rising to 80 % in key catalytic regions. They both contain the characteristic HExxH 
motif and display functional peptidase activity (Soubrier et al., 1988).   
 
The second isoform, tACE, is transcribed from the same twenty-six exon gene as sACE, 
however tACE transcription is initiated from an intragenic promoter. Hence, the final 
transcript consists only of exons thirteen to twenty-six. The resulting protein has a single 
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catalytic domain, identical to the C-domain of sACE, including the C-terminal 
transmembrane sequence, Figure 1.2. In contrast to the widespread expression of sACE, 
tACE is confined to developing spermatids (Ehlers et al., 1989; Hubert et al., 1991; 








Figure 1.2: Domain Organisation in Human sACE and tACE. The conserved 
peptidase domain is shown in pale blue and labelled “HExxH”, which is the 
characteristic zinc-binding motif. sACE consists of two homologous catalytic domains 
arranged in tandem joined by a short linker sequence (LR). tACE is identical to the 
sACE C-domain apart from a unique 36 residue N-terminal sequence, shown in grey and 
labelled “NT”. sACE and tACE are both membrane bound as indicated by the C-
terminal transmembrane domain, shown in orange and labelled “TM”. 
 
 
1.4.1 Properties of the N- and C-domains of sACE 
Whilst sharing a high degree of overall sequence similarity, there are some clear 
distinctions between the two domains of sACE in relation to their biophysical and 
biochemical properties. The N-domain is significantly more thermally stable and 
resistant to proteolysis than the C-domain (Sturrock et al., 1992; Voronov et al., 2002) 
whilst being less sensitive to chloride activation (Wei et al., 1992). This difference in 
sensitivity to chloride ions could be very important. It suggests that in different 
biological environments the two domains will display different activity profiles, which 
may be especially relevant when considering the tissue-specific RAAS. 
Interestingly, a number of differences in substrate specificity have also been reported. 
Although both domains appear equally able to hydrolyse bradykinin, the C-domain 
processes angiotensin I to angiotensin II much more efficiently than the N-domain 
(Georgiadis et al., 2003).  
Outside of the RAAS, the N-domain hydrolyses GnRH, Aβ42, angiotensin 1-9, 
AcSDKP and the encephalin precursor Met5-Enk-Arg6-Phe7 more efficiently than the C-
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domain (Anthony et al., 2012; Deddish et al., 1997; Deddish et al., 1998; Rieger et al., 
1993; Rousseau et al., 1995).  
 
Based on these observations, it seems that the C-domain alone is sufficient for blood 
pressure regulation in vivo and indeed this has been shown to be the case in mouse 
knock out models (Bernstein et al., 2011; Fuchs et al., 2004; Fuchs et al., 2008). Taken 
together with the relationship between the C-domain of sACE and tACE, this indicates 
that sACE has arisen as the result of a gene duplication event. This would have enabled 
the N-domain to evolve and acquire new functions, exemplified by the observed 
differences in substrate specificity outlined above.  
 
1.5 ACE Inhibitors 
Due to its crucial role in blood pressure regulation, ACE is a key target in the treatment 
of hypertension and ACE inhibitors have been in widespread clinical use since the 1980s 
(Patchett et al., 1980). Given that the first ACE structure was not reported until 2003 
(Natesh et al., 2003), this means that the ACE inhibitors currently in use were designed 
with no structural information.  
 
ACE inhibitor design was instead based on an assumed similarity with carboxypeptidase 
A, which was one of the few crystal structures available at the time, and on the sequence 
of ‘bradykinin potentiating peptides’ isolated from the venom of the pit viper Bothrops 
jararaca that were observed to function as natural inhibitors of ACE (Byers and 
Wolfenden, 1973; Cushman et al., 1977; Cushman and Ondetii, 1999; Ferreira, 1965; 
Ferreira et al., 1970; Ondetti et al., 1971; Schmid and Herriot, 1976). It was observed 
that all of these peptides contained a C-terminal proline residue. This was therefore 
assumed to be an important feature and a proline moiety was incorporated into inhibitor 
design. 
 
The first widely used ACE inhibitor, captopril, is shown in Figure 1.3. It is a competitive 
inhibitor that co-ordinates the catalytic zinc ion through its sulphydryl group.  
Subsequent inhibitors have since been developed that use carboyxl rather than 
sulphydryl groups for zinc co-ordination. Although the carboxyl group does not form 
such a strong interaction with the zinc ion this is compensated for by the incorporation 
of additional functionalities to make further interactions with the active site. The ACE 
inhibitors lisinopril and enalaprilat are shown in Figure 1.3, both of which are currently 







Figure 1.3: Chemical Structures of the ACE Inhibitors Captopril, Lisinopril and 
Enalaprilat.!
     
 
1.5.1 Limitations of Current ACE Inhibitors 
Although these inhibitors have been widely used for over thirty years and are effective 
anti-hypertensive agents, there are problems associated with their use. This includes two 
phenomena known as “outside in signalling” and “ACE inhibitor escape”. 
 
Outside in signalling occurs when the use of ACE inhibitors actually increases ACE 
expression, counter-acting the effect of the inhibitors. “ACE inhibitor escape” tends to 
occur following long-term treatment and describes the circumstance where levels of 
angiotensin II are no longer reduced. This is thought to be the result of chymase 
expression in the heart being upregulated as chymase is also able to convert angiotensin 
I into angiotensin II (Kohlstedt et al., 2002; Kohlstedt et al., 2005; Wei et al., 2010). 
 
By far the most widespread problem with current ACE inhibitors is their propensity to 
cause side effects. As many as one in every five patients treated with the current 
inhibitors develop a severe dry cough, whilst a smaller number suffer from angioedema, 
which can potentially prove fatal (Bas et al., 2007; Steckelings et al., 2001). 
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These side effects are almost certainly the result of the function of ACE in other 
physiological processes being inhibited. For example, bradykinin has an important role 
in contraction of smooth muscle in the bronchus. ACE inhibition leads to the 
accumulation of bradykinin, which can cause bronchoconstriction, resulting in the 
persistent dry cough observed in many patients (Israili and Hall, 2002; Overlack, 1996; 
Vegter and de Jong-van den Berg, 2010). 
 
1.5.2 The Future of ACE Inhibitors 
The N-domain of sACE appears to have evolved to acquire novel functions and the C-
domain alone is apparently sufficient for in vivo regulation of blood pressure (Bernstein 
et al., 2011). This indicates that it may be beneficial to specifically target the C-domain 
in the treatment of hypertension, thus allowing the N-domain to remain active and retain 
its function in physiological processes outside of the RAAS. 
 
Crucially, given that both domains are equally able to cleave bradykinin, selective 
inhibition of the C-domain would prevent the accumulation of this peptide, which has 
been implicated in many of the most common side effects resulting from treatment with 
the current ACE inhibitors. 
 
Additionally, as more is understood about the physiological function of the N-domain, it 
may be desirable to develop inhibitors that selectively target this domain. For example, 
the peptide AcSDKP, which is cleaved primarily by the N-domain (Junot et al., 2001), 
has been shown to be involved in the regulation of proliferation of haematopoietic stem 
cells (HSCs) (Azizi et al., 1996; Bonnet et al., 1992; Lenfant et al., 1989). There is 
evidence to suggest that inhibiting AcSDKP cleavage by ACE could protect HSCs 
during aggressive chemotherapy regimes (Bogden et al., 1991).  
 
Similarly, AcSDKP has a role in fibrosis and inflammation, where it functions to inhibit 
the proliferation of fibroblasts. Knock out studies in mice have shown that deletion of 
the N-domain of sACE, and hence AcSDKP hydrolysis, can reduce lung injury 







Figure 1.4: Structure of Inhibitors Selective for a Single Domain of sACE. 
RXPA380, kAF and kAW are all selective inhibitors of the C-domain, whereas RXP407 
is a selective inhibitor of the N-domain. RXPA380 and RXP407 are phosphinic peptides 
and kAF and kAW are ketomethylene inhibitors. 
 
 
Whilst most of the inhibitors currently in use show very little selection for either of the 
two domains under physiological conditions (Wei et al., 1992), some domain selective 
inhibitors have been developed. This includes two phosphinic peptide inhibitors, 
RXPA380 (Georgiadis et al., 2003; Georgiadis et al., 2004) and RXP407 (Dive et al., 
1999), which are selective for the C- and N-domains respectively and two 
ketomethylene inhibitors kAW ((5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-
tryptophan) and kAF ((5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-
phenylalanine) that are selective inhibitors of the C-domain (Nchinda et al., 2006), 
Figure 1.4. The development of such inhibitors provides proof of principle evidence that 
domain specific inhibition could be possible. Structure-based inhibitor binding studies 
were central to the development of these compounds, and it is clear that this method will 
be essential for future developments. 
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1.6 Structural Studies on ACE 
1.6.1 Challenges in ACE Crystallisation 
The first ACE structure was not reported until 2003 (Natesh et al., 2003), almost fifty 
years after the initial discovery made by Skeggs et al. This is due to the fact that ACE is 
a very challenging enzyme to work with and a significant factor in this is the extensive 
glycosylation of both domains, which has been estimated at 30 % by weight and 
includes both N-linked and O-linked sites (Acharya and Sturrock, 2003; Ripka et al., 
1993).  
 
Whilst the initial tACE structure reported in 2003 was of the native protein, truncated to 
remove the transmembrane domain, the crystals used to collect the diffraction data were 
not reproducible. This was most likely as a result of the extensive glycosylation causing 
heterogeneity.  
 
In an attempt to overcome this problem, a study was performed in 2003 to investigate 
the importance of each of the predicted N-linked glycosylation sites in each domain of 
sACE; seven in the C-domain (tACE) and ten in the N-domain. By using a site-directed 
mutagenesis approach, it was revealed that only glycosylation at the first and third of 
these sites in the C-domain and at the third, eighth and ninth sites in the N-domain was 
required to produce stable, functional protein (Anthony et al., 2010; Gordon et al., 
2003).  
 
The crystal structures of both tACE and the N-domain of sACE have since been 
determined using constructs with the other N-linked glycosylation sites removed by 
mutation and with C-terminal truncations to remove the transmembrane region. As 
glycosylation at these sites has been shown to be essential for functional protein, the 
ACE constructs were unsuitable for E. coli expression and were instead expressed using 
chinese hamster ovary (CHO) cells to ensure correct post-translational processing 
(Corradi et al., 2006; Natesh et al., 2003). 
 
1.6.2 The Structure of tACE 
In 2003, the structure of human tACE (equivalent to the C-domain of human sACE) was 
reported (Natesh et al., 2003). The overall structure is shown in Figure 1.5 and 
illustrates how the molecule adopts an overall ellipsoid shape, formed by twenty-seven 
α-helices and six short β-strands. A long substrate-binding channel extends for 30 Å 




It is at the centre of this channel that the active site is located.  This is marked by the 
presence of the catalytic zinc ion, which is co-ordinated by residues His383, His387 and 
Glu411. Access to the active site appears to be controlled by N-terminal helices α1, α2 
and α3, which form a “lid” that caps the entrance to the substrate-binding channel, 
preventing entry of large, folded molecules, Figure 1.5. 
 
Two chloride ions are also visible in this structure. The first, Cl1, is located 20.7 Å from 
the active site zinc ion and bound by Arg186, Trp485, Arg489 and a water molecule. 
The second chloride ion, Cl2, is closer to the active site, located 10.4 Å from the zinc 
ion. It is bound to Tyr224, Arg522 and a water molecule. The co-ordination of both 
chloride ions is illustrated in Figure 1.5. 
 
1.6.3 The Structure of the N-domain 
The first structure of the N-domain of human sACE was reported three years later, in 
2006 (Corradi et al., 2006). As would be expected given the high degree of sequence 
identity, the overall structure is very similar to that of tACE (the C-domain), Figure 1.6. 
 
Again the molecule adopts an overall ellipsoid shape that is formed by twenty-seven 
helices and six short β-strands. The substrate binding channel and N-terminal lid are 
both conserved, as is the position of the catalytic zinc ion, which, in this case is co-
ordinated by His361, His365 and Glu389. 
 
One of the chloride ions, Cl2 is conserved from the tACE structure and is held in place 
by Tyr202, Arg500 and a water molecule. No chloride ion is present at the position of 
Cl1 in tACE. This is due to the substitution of Arg186 in tACE by His164 in the N–
domain, as illustrated in Figure 1.6. The absence of a second chloride ion in the N-
domain active site goes some way towards explaining the decreased sensitivity of the N-
domain to chloride concentration. 
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Figure 1.5: The Structure of Human tACE (PDB code 1O86). (a) Cartoon 
representation of the overall structure of tACE highlighting the prevalence of helical 
elements. The two chloride ions visible in the structure are shown as orange spheres and 
the catalytic zinc ion as a grey sphere. The zinc ion marks the location of the active site, 
at the centre of a long substrate-binding channel extending the length of the molecule. 
An “N-terminal lid” formed by helices α1, α2 and α3 caps the channel. (b) An 
alternative view of tACE to illustrate the function of the N-terminal lid. Helices α1, α2 
and α3 are shown as purple helices and the rest of the molecule as a surface 
representation in cyan. The location of the active site at the centre of the substrate 
binding channel is shown by the zinc ion in grey and the inhibitor lisinopril, which is 
shown as green sticks. (c) and (d) Residues involved in chloride ion binding are shown 
as cyan sticks and the chloride ions as orange spheres.  










Figure 1.6: The Structure of the N-domain of Human sACE (PDB code 2C6N). (a) 
Cartoon representation of the overall structure of the N-domain with the active site zinc 
ion and the single chloride ion shown as grey and orange spheres respectively. (b) 
Superposition of the N-domain structure, magenta, on the structure of tACE, cyan, 
illustrating the similarity between the overall structures. (c) There is no chloride ion 
present in the N-domain structure at the site of Cl1 in tACE due to the substitution of 
Arg186 for His164. The other chloride binding residues are conserved. tACE residues 
are shown as cyan sticks and N-domain residues in magenta. Residues are labelled with 
the corresponding colours. (d) The second chloride ion from tACE is conserved in the 








1.6.4 Structural Insights into the ACE Catalytic Mechanism 
Although no definitive mechanism for the cleavage of peptide bonds by angiotensin 
converting enzymes has been determined, it is widely accepted that it occurs via a 
general base mechanism involving nucleophilic attack on the carbonyl carbon of the 
scissile peptide bond.  
 
 





Figure 1.7: Proposed ACE catalytic mechanism. Conserved residue Glu384 abstracts 
a proton from a catalytic water molecule, activating it for nucleophilic attack on the 
carbonyl carbon of the scissile peptide bond. Nucleophilicity of the water is also 
enhanced by the catalytic zinc ion. The resulting transition state is stabilised by 
conserved residues Tyr520 and Ala354 (tACE residue numbering). 
 
 
Active site residue Glu384 (tACE numbering) has been implicated in catalysis, however 
structural data indicate that it is not positioned suitably for direct nucleophilic attack of 
the scissile bond. Instead, it has been suggested that Glu384 abstracts a proton from the 
catalytic water molecule, thus activating it for nucleophilic attack on the carbonyl 
carbon of the scissile bond. This results in the formation of an oxyanion intermediate, 
likely stabilised by the catalytic zinc ion and conserved residues Tyr520 and Ala354 
(Sturrock et al., 2004; Zhang et al., 2013). This is summarised in Figure 1.7. 
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In addition to its widely recognised role as a dipeptidyl carboxypeptidase, ACE has also 
been observed to release the C-terminal tripeptide from some substrates. The primary 
example of this being seen with the neuropeptide substance P (Skidgel et al., 1985). 
Furthermore, ACE is also able to act as an aminopeptidase towards the substrate GnRH 
(Jaspard et al., 1993). Neither of these activities is seen frequently, only occurring when 
the C-terminus of the protein is “protected”. For example in GnRH the penultimate 
residue is a proline. The unique nature of the proline side chain means that it has a 
secondary rather than a primary amine group, which protects the scissile bond from 
cleavage. This is in agreement with the observation that all of the bradykinin 
potentiating peptides isolated from the venom of B. jararaca have two proline residues 
at their C-termini (Ondetti et al., 1971).  
 
The structural and mechanistic basis of the amino peptidase and C-terminal tripeptidase 
activity of ACE remains poorly understood and further structural and activity based 
studies are required to investigate this further. 
 
1.6.5 The Structural Basis of Domain Specific Inhibition 
Studying the structures of the two domains of sACE has provided information that has 
been invaluable in understanding how subtle differences in the active site regions could 
be used in the development of inhibitors that selectively target either the N- or the C-
domain.  
 
1.6.5.1 Schechter and Berger Notation for Protease Cleavage Sites 
In developing domain specific inhibitors, the focus is on “subsites” that extend along the 
substrate-binding channel in either direction away from the catalytic zinc ion. During 
peptide hydrolysis, a peptide residue (Px) occupies each of these subsites (Sx). The 
peptide residues are numbered from the point of cleavage such that the scissile peptide 
bond is between residues P1 and P1’. The subsites of the enzyme are labelled S1 and S1’ 
accordingly so that the numbers correspond to the peptide residues by which they are 
occupied (Schechter and Berger, 1967). Figure 1.8 illustrates how this notation is 






Figure 1.8: Schematic Diagram of Angiotensin I Cleavage by ACE Using the 
Schechter and Berger Notation. The enzyme subsites are labelled Sx and occupied by 
the corresponding residues of angiotensin I (Px). The catalytic zinc ion is located 
between S1 and S1’ and the peptide is positioned for cleavage of the peptide bond 





RXPA380 is a phosphinic peptide that inhibits the C-domain of sACE with a Ki that is 
three orders of magnitude lower than for the N-domain. Hence it is a highly selective 
inhibitor of the C-domain (Georgiadis et al., 2004).  
 
The structure of RXPA380 bound to tACE (sACE C-domain) (Corradi et al., 2007) 
indicates that it is a competitive inhibitor of ACE and co-ordinates the catalytic zinc ion 
through the oxygen atoms of its phosphinyl group. It binds in an elongated conformation 
with its phenylalanine, phenylalanine, proline and tryptophan moieties occupying the S1, 
S2, S1’ and S2’ subsites, respectively. This is illustrated in Figure 1.9. 
 
Comparing this to the N-domain structure indicates why RXPA380 is a more potent 
inhibitor of the C-domain. The structure of tACE with RXPA380 illustrates that the 
phenylalanine residue at the P2 position forms an aromatic interaction with Phe391 in 
the S2 pocket. In the N-domain, Tyr369 replaces Phe391. Based on the structural data, 
the hydroxyl group of Tyr369 would be within 2 Å of the P2 phenylalanine, thus 
preventing it from binding in the conformation observed with tACE. The 
Phe391/Tyr369 substitution is therefore likely to be a key factor contributing to the 




                 
Figure 1.9: Binding of the C-domain Specific Inhibitor RXPA380 to ACE (PDB 
code 2OC2). (a) The structure of RXPA380 indicating the key moieties. (b) Binding of 
RXPA380 to the C-domain of ACE. RXPA380 is shown as green sticks and interacting 
C-domain residues as cyan sticks. The catalytic zinc ion is a grey sphere. (c) Key 
residues interacting with RXPA380 that are not conserved in the N-domain. Residues 
from the C-domain are shown in cyan and corresponding N-domain residues in magenta. 






                     
Figure 1.10: Binding of the N-domain Specific Inhibitor RXP407 to ACE (PDB 
code 3NXQ). (a) The structure of RXP407 indicating the key moieties. (b) Binding of 
RXP407 to the N-domain of ACE. RXP407 is shown as green sticks and interacting N-
domain residues as magenta sticks. The catalytic zinc ion is a grey sphere. (c) Key 
residues interacting with RXP407 that are not conserved in the C-domain. Residues 
from the N-domain are shown in magenta and corresponding C-domain residues in cyan. 






At the other end of the channel lies the S2’ pocket, which, in tACE is lined by Val379 
and Val380. These two valine residues contribute to a hydrophobic environment for the 
proline and tryptophan residues at the P1’ and P2’ positions, respectively, of the 
inhibitor. In the N-domain Val379 and Val380 are substituted by Ser357 and Thr358 
respectively. The hydrophobic nature of this pocket is thus not conserved and suggests 
that the presence of hydrophobic residues at the P1’ and P2’ positions is an important 
factor in C-domain selectivity. Furthermore, the structure illustrates that the proline and 
tryptophan residues are not fully occupying this active site pocket, thus, adding further 
bulky, hydrophobic groups to inhibitors at this position may further increase C-domain 
selectivity. RXPA380 binding to the tACE active site and a comparison with the N-
domain is shown in Figure 1.9. 
 
1.6.5.3 RXP407 
A second phosphinic peptide, RXP407, has been developed (Dive et al., 1999) which is 
a selective inhibitor of the N-domain of sACE and the structure of this complex was 
reported in 2010 (Anthony et al., 2010). Comparing this structure to the structure of 
tACE helps to explain the observed N-domain selectivity. 
 
As illustrated in Figure 1.10, RXP407 forms twelve hydrogen bond interactions with N-
domain active site residues, ten of which would be conserved in the C-domain. The two 
differences are both located in the S2 subsite, where Glu403 and Phe391 in the C-
domain replace N-domain residues Arg381 and Tyr369, respectively. The fact that these 
key distinguishing interactions are also located in the S2 pocket highlights this as an 
important region that could be exploited in the development of domain specific 
inhibitors. 
 
1.7 A New Generation of ACE Inhibitors 
As discussed in 1.5.1, although current ACE inhibitors are an effective treatment for 
hypertension and have been in use for many years, they are not perfect. Side effects 
caused by the inhibition of ACE activity in other physiological processes, notably the 
destruction of bradykinin, are a significant problem. 
 
It has been established that the C-domain of ACE is sufficient for in vivo regulation of 
blood pressure meaning that it would theoretically be possible to selectively target this 
domain and leave the N-domain active, preventing the accumulation of bradykinin. 
Structural studies of the binding of two phosphinic peptide inhibitors to the N- and C-
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domains of human sACE have provided proof of principle data that such domain 
selective inhibitors could be designed. 
 
1.7.1 Future Directions and Project Aims 
Much research effort is now focused on using a structure-based approach to develop 
domain-specific inhibitors. A key factor in this is considering natural compounds that 
display some level of ACE inhibition. This includes peptides isolated from the venom of 
the snake B. jararaca, peptides derived from haemoglobin that are known as 
haemorphins and some flavonoids, polyphenol compounds isolated from plant extracts. 
This is the basis of the work discussed in Chapters 3, 4, 5 and 6. Full project aims are 
outlined in section 1.11. 
 
1.8 Insect ACE homologues 
The function of ACE in mammalian blood pressure regulation is well known and has 
been extensively studied for a number of decades. It is however, becoming increasingly 
apparent that ACE is involved in a wide-range of physiological processes outside of the 
RAAS, as illustrated by the discovery of an ever-increasing number of additional ACE 
substrates such as GnRH and AcSDKP. 
 
The diverse range of functions of ACE has been brought to further prominence by the 
discovery of angiotensin-converting enzymes outside of mammals, notably in insects. In 
1994 an ACE-like enzyme was identified in the common housefly Musca domestica 
(Lamango and Isaac, 1994) and subsequently ACE homologues have been found in 
every insect genome that has been sequenced (Isaac et al., 2007). The conservation of 
angiotensin-converting enzymes throughout insects is indicative of an essential 
physiological role, however, insects do not have a circulatory system resembling that 
found in mammals. Hence, it is clear that insect ACE-like enzymes must have other 
essential functions. As yet it is not clear what these may be, although some proposals 
have been made, as discussed in section 1.9.1.1. 
 
1.9 ACE Homologues from Drosophila melanogaster 
The D. melanogaster genome codes for six potential ACE-like proteins, however based 
on sequence analysis it appears that only two of these would be functional, with the 
others lacking some essential residues. These two enzymes are known as AnCE and 




AnCE has been studied quite extensively over the last twenty years and has provided 
valuable information not only about the functions of ACE homologues in insects, but 
also about the structural basis of ACE interactions with substrates and inhibitors. 
 
AnCE is a single domain enzyme that shares 60 % overall sequence similarity and 40 % 
overall sequence identity with each of the catalytic domains of human sACE (sequence 
alignment shown in Figure 1.11). 
 
Interestingly, close analysis of the sequence around the active site binding pockets 
indicates that AnCE shares features with both the N and C-domains of sACE and does 
not appear to resemble one domain more closely than the other.  
 
sACE and tACE are both localised to the surface of endothelial cells due to the presence 
of a C-terminal transmembrane domain. As illustrated in Figure 1.11, this domain is not 
present in AnCE. Instead, there is a seventeen-residue signal sequence at the N-terminus 




Figure 1.11: Domain Organisation in Drosophila melanogaster AnCE. The 
conserved peptidase domain is shown in pale blue and labelled “HExxH”, which is the 
characteristic zinc-binding motif. Like tACE, AnCE consists of a single catalytic 
domain. However it lacks a C-terminal transmembrane domain (TM) and instead has an 
N-terminal secretion signal (SS), indicating that unlike sACE and tACE it is not 
membrane bound, but is instead secreted. 
 
1.9.1.1 Possible Functions of AnCE 
Like ACE, AnCE tends to function as a dipeptidyl carboxypeptidase, although peptidase 
and tripeptidase activity at both the N- and C-termini has been observed on occasion 
(Isaac et al., 2007; Lamango et al., 1996; Siviter et al., 2002). AnCE has been shown in 
vitro to hydrolyse two of the main substrates of human ACE, angiotensin I and 
bradykinin. However given that no homologous peptides have been identified in D. 
melanogaster, it is still not clear what the true biological function of AnCE is. 
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AnCE must be involved in a physiological process that is essential for survival, as Ance 
mutant embryos die during early larval stages (Isaac et al., 2007). Based on observed 
high levels of Ance expression in the gut epithelium and amniosera, it has been 
suggested that AnCE may have a role in processing peptides that are required for 
contraction of gut and heart muscle (Cornell et al., 1995; Tatei et al., 1995).  
 
In addition to this, AnCE has also been found to be concentrated around the 
reproductive organs in both male and female flies, immediately suggesting a role in 
reproduction.  A role for AnCE in spermatogenesis has been proposed, based on the fact 
that male D. melanogaster that are homozygous for a hypomorphic Ance allele are 
infertile and that this appears to be the result of sperm failing to develop properly (Isaac 
et al., 1998; Isaac et al., 1999; Schoofs et al., 1998).  
 
AnCE expression has also been shown to be concentrated in the secondary cells of the 
accessory glands of the testis. These glands produce peptides that mix with the sperm 
and seminal fluid and induce behavioural and physiological changes in the female after 
mating. The expression of AnCE in this region therefore suggests that it may have a role 
in the female after mating. To this end, Dup99B has been suggested as a potential AnCE 
substrate. This is because following the removal of the C-terminal dipeptide, Dup99B 
can induce egg laying in females (Rylett et al., 2007). 
 
Interestingly, other insect ACE homologues have also been implicated in reproduction. 
For example, an ACE-like enzyme in the mosquito Anopheles stephensi is required for 
egg laying where is it thought to process a peptide required for contraction of the 
oviduct (Ekbote et al., 1999). It seems increasingly likely that insect ACE homologues 
have some kind of a conserved role in reproduction (Ekbote et al., 2003a; Ekbote et al., 
2003b; Hurst et al., 2003; Macours and Hens, 2004; Vercruysse et al., 2004; Wijffels et 
al., 1996). 
 
1.9.1.2 AnCE as a Structural Model 
Whilst the study of AnCE continues to provide invaluable information pertaining to the 
functions of angiotensin converting enzymes outside of blood pressure regulation, AnCE 
has also been used extensively as a structural model for human ACE, and it is in that 
respect that it has been used in the work presented here. 
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As discussed in section 1.6.1, human ACE is a very challenging enzyme to work with, 
namely due to its extensive glycosylation and membrane localisation. Although 
minimally glycosylated truncated constructs lacking the transmembrane domain have 
been used successfully in structural studies, the degree of glycosylation that is essential 
for active, stable protein still causes problems with heterogeneity during crystallisation 
and necessitates the use of expensive, higher eukaryotic systems for protein expression.  
 
AnCE has been successfully expressed using the methylotropic yeast Pichia pastoris, 
and the purified protein yields consistent, diffraction quality crystals. The first crystal 
structure (form I) of AnCE was reported in 2003 (Kim et al., 2003) and has since been 
followed by a series of higher resolution structures in a different crystal form (form II) 
(Akif et al., 2010) of both the native enzyme and in complex with a wide range of 
inhibitors and substrates. 
 
Given the high degree of overall sequence similarity between AnCE and each domain of 
sACE, it is not surprising that the overall topology of the structures is very similar. 
AnCE is also predominantly helical, consisting of twenty-one α-helices, nine 310 helices 
and only two short β-strands (compared with twenty-seven α-helices and six short β-
strands in tACE), which together form the ellipsoid shaped molecule that is now 
characteristic of angiotensin-converting enzymes, Figure 1.12. 
 
Glycan chains are visible at three N-linked glycosylation sites in the form II structure; 
Asn53, Asn196 and Asn311, all of which are located on the surface of the molecule. The 
sequence alignment in Figure 1.13 indicates that the glycosylation site at Asn53 is 
conserved in the two domains of human sACE.  
 
Like ACE, AnCE activity has also been reported to be sensitive to chloride 
concentration (Williams et al., 1996), however unlike ACE no chloride ions are present 
in the AnCE structure. The Cl1 binding site that is found only in the C-domain is not 
conserved in AnCE, with chloride binding residues Arg186, Trp485 and Arg489 
replaced by Tyr170, Phe469 and Arg473 respectively. The Cl2 chloride binding site is 
found in both domains of human sACE and chloride co-ordination is via 
Arg522/Arg500 and Tyr224/Tyr202 in the N-/C-domains, respectively. Surprisingly, as 
illustrated by the sequence alignment in Figure 1.12, both of these residues are 
conserved in AnCE as Arg506 and Tyr208, yet no chloride ion is visible in any of the 
AnCE structures that have been reported (Akif et al., 2010). 
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Figure 1.12: The Structure of Drosophila melanogaster AnCE (PDB code 2X8Y). 
The overall topology of the structure is well conserved from human ACE (Figures 1.5 
and 1.6) and is predominantly helical. The catalytic zinc ion (grey sphere) marks the 
location of the active site at the centre of the substrate binding channel, capped by three 
helices forming an “N-terminal lid”. N-linked glycosylation, shown as green sticks, is 
visible at Asn53, Asn196 and Asn311. 
 
The structure of AnCE in complex with a wide range of ACE inhibitors has been 
reported, including lisinopril, angiotensin II and the phosphinic peptide inhibitors 
RXPA380 and RXP407. In all cases the general mode of binding is conserved from 
human ACE, indicating that AnCE is a suitable model for studying the structural basis 
of ACE inhibition and substrate specificity. It is in this manner that AnCE has been used 
in the work presented here, in order to study the binding of novel ACE inhibitors such as 
the natural inhibitory peptides from B. jararaca venom (Chapter 3) and the haemorphin 




Figure 1.14: Sequence Alignment for AnCE and the N- and C-domains of Human 
sACE. Conserved zinc binding residues are highlighted in yellow. Putative 
glycosylation sites are marked in red, which highlights the conservation of AnCE site 
Asn53. Cl1 binding residues are shown in magenta and Cl2 in cyan, illustrating that the 
latter are conserved in AnCE even though no chloride is present in the structure. AnCE 
secondary structure elements are labelled. Residue numbering is for AnCE. Figure 




The second ACE homologue produced by D. melanogaster is distinct from AnCE in 
terms of both catalytic and physiological activity. The genes coding for these two 
enzymes show very different expression patterns, with Acer expression seen in neither 
the amniosera nor the midgut, but in heart cells, where it is known to be required for 
both heart development and heart function in adult flies (Houard et al., 1998; Liao et al., 
2014; Taylor et al., 1996). Further roles for ACER have also been suggested in the 
regulation of circadian rhythms (Carhan et al., 2011; Ishimoto et al., 2012), however the 
mechanisms underpinning these processes are still not clear.  
 
ACER shares 66 % overall sequence similarity and 48 % sequence identity with AnCE. 
It also has the same domain organisation; a short signal sequence at the N-terminus 
followed by the conserved peptidase domain. There is no evidence of a transmembrane 
domain, indicating that like AnCE, and in contrast to human ACE, ACER is a secreted 




Figure 1.14: Domain Organisation in Drosophila melanogaster ACER. The 
conserved peptidase domain is shown in pale blue and labelled “HExxH”, which is the 
characteristic zinc-binding motif. Like tACE and AnCE, ACER consists of a single 
catalytic domain. Like AnCE, and in contrast to sACE and tACE, it does not have a C-
terminal transmembrane domain (TM) and instead has an N-terminal secretion signal 
(SS), indicating that ACER is a secreted rather than a membrane bound protein.!
 
 
Based on the sequence alignment shown in Figure 1.15, it seems that the N-linked 
glycosylation site at Asn53, which is also found in the N- and C-domains of human 
sACE, may be conserved from AnCE, but that the other two sites, at Asn196 and 
Asn311, are absent. 
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In spite of their predicted overall similarity, AnCE and ACER do display some profound 
differences in substrate specificity. Crucially, whilst both are able to hydrolyse 
bradykinin, although AnCE does so at a significantly faster rate, only AnCE is able to 
cleave angiotensin I, a major substrate of human ACE. This indicates that there must be 
some important differences in the active site substrate binding pockets of these two 
enzymes (Coates et al., 2000; Taylor et al., 1996). 
 
No structure has yet been reported for ACER, although a model was proposed in 2005 
(Bingham et al., 2005), which was used to develop hypotheses to explain the observed 
differences between AnCE and ACER. 
 
The predicted conservation of glycosylation from AnCE in ACER indicates that this will 
be essential for protein function and stability. Hence, in order to ensure correct post-
translational processing, it will be necessary to produce ACER using eukaryotic 
systems. Previous attempts to express ACER using Pichia pastoris, the system used for 
AnCE, have yielded mixed results. One of the aims of the work presented here is to 
work towards the expression of ACER using higher eukaryotic systems, with the long 
term aim of being able to use this protein in structural studies to try and understand the 
structural basis for the observed differences in substrate specificity of AnCE and ACER. 
This work is presented in Chapter 8. 
 
1.10 ACE Homologues from Anopheles gambiae 
As one of the key vectors involved in the transmission of the malaria-causing parasite 
Plasmodium falciparum, the mosquito Anopheles gambiae is an exceedingly important 
organism to study. A recent study of the A. gambiae genome has revealed that it codes 
for ten different ACE homologues, or AnoACEs. This is the highest number found in 
any insect genome thus far, meaning that A. gambiae is also an important organism to 
study in order to learn more about angiotensin converting enzymes, particularly in 
insects (Burnham et al., 2005; Holt et al., 2002). 
 
The large number of ACE homologues in A. gambiae indicates that angiotensin 
converting enzymes are likely to be involved in a wide range of physiological processes. 
By studying these, it may be possible to learn more about the functions of ACE 




All of the ACE-like enzymes identified in insects previously are single domain, secreted 
enzymes like AnCE and ACER. Intriguingly, one of the ten enzymes from A. gambiae, 
AnoACE9, appears to consist of two catalytic domains arranged in tandem, as seen in 
human sACE (Burnham et al., 2005). This discovery indicates that this arrangement has 
been selected for on more than one occasion, therefore must surely be in some way 
advantageous. By studying AnoACE9 from A. gambiae it may be possible to begin to 
understand the biological benefits of such an arrangement. 
 
As outlined in section 1.9.1.1, there is a considerable amount of evidence implicating 
insect ACE homologues in reproduction. If this is indeed a conserved role adopted by 
one or more of the enzymes from A. gambiae, then it may ultimately be possible to 
design ACE inhibitors specific for AnoACE. These could potentially be used in 
insecticides to help control the mosquito population and consequently the spread of 
malaria. 
 
At this stage, work on these enzymes has been limited to a single genomics based study 
of gene expression patterns (Burnham et al., 2005). Hence, there is no indication at 
present as to which, if any, of the AnoACEs may have a role in reproduction. 
 
The aim of the work on ACE homologues from A. gambiae that is presented in this 
thesis is to focus on one of the enzymes, AnoACE3, and to work towards its expression 
and purification. The long-term aim would then be to use this enzyme for structural and 
activity based studies in order to learn more about its functions and catalytic properties. 
Ultimately, it would be helpful to be able to do this for all of these enzymes, however 
AnoACE3 was chosen as a starting point because it is one of the three AnoACEs for 
which the expression is upregulated following a blood meal, indicating that it is likely to 
have an important biological role of some description (Burnham et al., 2005).  
 
1.10.1 AnoACE3 
The domain organisation of AnoACE3 is shown in Figure 1.16. Like AnCE and ACER 
it is predicted to be a secreted protein with a single catalytic domain. This is indicated by 
the presence of a signal sequence towards the N-terminus and a conserved peptidase 
domain, including zinc binding motif, downstream of this. There is also an additional 
sequence at the very N-terminus of the protein that is conserved neither in AnCE nor in 
ACER. The function of this sequence is completely unknown and database searches 




The sequence alignment in Figure 1.15 highlights the fact that the three N-linked 
glycosylation sites in AnCE all appear to be conserved in AnoACE3. This indicates that 
a eukaryotic system will be required for AnoACE3 expression so as to produce correctly 
folded, functional protein.  
 
In the first instance this will be attempted using Pichia pastoris, as this has previously 
been used successfully for AnCE expression. However given the difficulties that have 
been encountered with ACER expression in this system, it may be necessary to move 
towards higher eukaryotic systems as has been the case for the expression of the human 
enzyme. 
 
Figure 1.15: Sequence Alignment of AnCE and ACER from Drosophila 
melanogaster and AnoACE3 from Anopheles gambiae. Alignment is for the 
conserved peptidase regions only and residue numbers are based on the AnCE sequence. 
Conserved zinc binding residues are highlighted in yellow. The three N-linked 
glycosylation sites found in AnCE are shown in red and highlighted in green where they 






Figure 1.16: Domain Organisation of AnoACE3 from Anopheles gambiae. 
AnoACE3, like AnCE and ACER, is predicted to have a single catalytic domain, shown 
in pale blue and marked by the conserved HExxH motif. It is also predicted to be 
secreted, shown by the signal sequence (SS, pale green) at the N-terminus, also found in 
AnCE and ACER. Compared to AnCE and ACER, AnoACE3 contains an additional 
sixty residue sequence at its N-terminus, the function of which is unknown. This is 
shown in purple and labelled “X”.!
 
 
1.11 Summary of Project Aims 
• To use the Drosophila melanogaster ACE homologue AnCE as a model to study the 
structural basis of ACE inhibition by a range of different inhibitors, particularly 
focusing on how interactions between inhibitors and the active site could be 
exploited in the development of domain specific inhibitors. 
 
• To work towards the expression of two further insect ACE homologues: ACER 
from Drosophila melanogaster and AnoACE3 from Anopheles gambiae. This will 
involve the use both of the methylotropic yeast Pichia pastoris and higher 







































2.1 Chemicals and Reagents 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich 
(MO, USA). 
 
2.2 Cell Lines 
2.2.1 Bacterial Strains 
In the work presented here, all of the proteins were expressed using eukaryotic systems; 
hence bacterial strains were used only during cloning steps. For work performed at the 
University of Bath E. coli One Shot Top 10 chemically competent cells (InvitrogenTM) 
were used for cloning and propagation. For work performed at the OPPF (Oxford 
Protein Production Facility, Harwell Science and Innovation Campus, Didcot, Oxon, 
UK) One Shot® OmniMAXTM 2 T1R chemically competent E. coli cells (Life 
Technologies) were used for this purpose. 
 
2.2.2 P. pastoris 
All yeast expression work was performed using the P. pastoris GS115 strain purchased 
from Invitrogen.  
 
2.2.3 Higher Eukaryotic Cell Lines 
The human embryonic kidney 293T/17 (HEK293T) cell line purchased from ATCC 
(American Type Culture Collection) and the Spodoptera frugiperda Sf9 cell line 
purchased from Life Technologies were used for protein expression in higher eukaryotic 
systems. 
 
2.3 Expression Plasmids 
Vector maps for all of the plasmids used in this work are included in Appendix A. 
 
2.3.1 P. pastoris 
The pPIC9 plasmid (Invitrogen) was used for AnCE expression in P. pastoris. Key 
features of this plasmid include an ampicillin resistance gene for selection of positive 
transformants during initial cloning stages in E. coli, an α-factor secretion signal for 
secreted expression of the target protein and the AOX1 promoter for methanol-induced 
target protein expression. 
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Trials of AnoACE3 expression in P. pastoris were performed using the pPICZα vector 
(Invitrogen). The pPICZα vector retains all of the key features of the pPIC9 vector 
whilst including an optional C-terminal polyhistidine tag. 
 
2.3.2 Higher eukaryotes 
Expression in HEK293T and Sf9 cells was performed using plasmids from the pOPIN 
vector suite kindly provided by Prof. Ray Owens at the OPPF. A summary of these 























































































Table 2.1: Features of the Vectors used for Protein Expression in Higher 
Eukaryotes. 
 
2.4 Cell Culture 
2.4.1 E.coli 
Three different types of media were used for E. coli growth: lysogeny broth (LB: 1 % 
w/v tryptone, 0.5 % w/v yeast extract, 0.5 % w/v NaCl), super optimal broth with 
catabolite repression (SOC: 2 % w/v tryptone, 0.5 % w/v yeast extract, 0.05 % w/v 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) and power broth 
(Athena Enzyme Systems, MD, USA). The medium type used for specific steps is 
clearly stated in the relevant methods sections. For growth in petri dishes the chosen 
media was prepared with the addition of 1 % agar. Where stated, medium was 
supplemented with either 100 µg ml-1 ampicillin or 50 µg ml-1 carbenicillin for selection. 
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2.4.2 P. pastoris 
For protein expression P. pastoris was initially grown in buffered glycerol-complex 
medium, BMGY (1 % yeast extract, 2% tryptone, 100 mM potassium phosphate pH 6.0, 
1.34 % yeast nitrogen base (YNB), 4 × 10-5 % biotin, 1 % glycerol). In order to induce 
expression this was replaced with buffered methanol-complex medium, BMMY (1 % 
yeast extract, 2% tryptone, 100 mM potassium phosphate pH 6.0, 1.34 % YNB, 4 × 10-5 
% biotin, 0.5 % methanol). 
 
When individual colonies were required, typically for inoculation of expression cultures, 
yeast extract peptone dextrose, YPD medium (1 % yeast extract, 2 % tryptone, 2 % 
dextrose) with 2 % agar was used to enable growth in petri dishes. 
 
A number of other types of media were used for specific purposes. These are detailed as 
they arise in the text. 
 
2.4.3 HEK293T Cells 
HEK293T cells were cultured at 37 oC in a 5 % CO2/95 % air environment in T75 or 
T25 tissue culture plates (Corning Inc.). Cells were maintained in Dulbecco’s modified 
eagle medium (DMEM, Life Technologies) supplemented with 10 % foetal bovine 
serum (FBS), 1 % L-glutamine and 1 % non-essential amino acids. Following 
transfection, the serum content of the medium was reduced to 2 % FBS. 
 
2.5 General Analytical Methods 
2.5.1 Agarose Gel Electrophoresis of DNA Samples 
1 % agarose gels were prepared by addition of agarose to Tris acetate EDTA (TAE) 
buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA). DNA samples were prepared for 
analysis by addition of 6 × blue/orange loading dye (Promega, WI, USA) in a 1:6 ratio. 
Electrophoresis was typically carried out for 45-60 minutes at 100 V in TAE buffer. A 1 
kb or 100 bp DNA ladder standard (Promega, WI, USA) was run alongside samples to 
facilitate accurate estimation of their size. 
 
2.5.2 SDS-PAGE of Protein Samples 
Protein samples were prepared for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) by mixing with an equal volume of 2 × Laemmli sample 
buffer (0.01 % bromophenol blue, 4 % w/v sodium dodecyl sulphate (SDS), 20 % 
glycerol, 120 mM Tris-HCl, pH 6.8) and heating to 95 oC for 10 minutes. 15 µl of the 
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prepared sample were loaded into the wells of a 12 % bis-tris acrylamide gel. Gels were 
run at 180 V for 60 minutes in a Mini-Protean tetra cell (Bio-Rad, CA, USA) containing 
approximately 1 litre of running buffer (50 mM MOPS, 40 mM Tris-HCl, 1 mM EDTA, 
0.1 % w/v SDS, pH 7.7). A 2-212 kDa molecular weight marker (New England BioLabs 
Inc.) was run concurrently to facilitate the accurate estimation of sample molecular 
weight. 
 
Gels were visualised by Coomassie staining (0.25 % w/v Coomassie Brilliant Blue, 10 
% v/v glacial acetic acid, 45 % v/v methanol) at room temperature for 2-3 hours with 
agitation by rocking. After rinsing with distilled water a destaining solution (25 % 
methanol, 7 % glacial acetic acid) was added prior to incubation at room temperature 
with agitation for a further 2-3 hours until bands on the gel were clearly visible. 
 
2.5.3 Western Blotting 
SDS-PAGE was performed as detailed above but with the addition of the PageRuler 
prestained protein ladder (Thermo Fisher Scientific, MA, USA) in place of the 2-212 
kDa molecular weight marker. The gel was transferred to a nitrocellulose membrane 
(0.45 µm pore size, GE Healthcare, UK) in 25 mM Tris base, 192 mM glycine, 20 % 
methanol, pH 8.8 at 150 mA for 60 minutes. Following transfer membranes were 
blocked in a solution of 5 % milk in PBS (phosphate buffered saline) + 1 % Tween 
either for 1 hour at room temperature or for 16 hours at 4 oC with gentle agitation by 
rocking. Primary antibodies, conjugated with horseradish peroxidase (HRP), were 
prepared at the appropriate dilution in the blocking solution and added to the membrane. 
The membrane was then incubated with gentle agitation either for 1 hour at room 
temperature or for 16 hours at 4 oC. 
 
After incubation with the primary antibody the membrane was washed for 3 × 10 
minutes in PBS + 1 % Tween prior to application of the PierceTM ECL western blotting 
substrate (Thermo Fisher Scientific, MA, USA). The membrane was incubated with the 
substrate for 5 minutes at room temperature after which time excess substrate was 
removed by blotting with tissue prior to detection. 
 
2.6 General Methods in Structural Biology 
2.6.1 Introduction 
Structural biology techniques enable the visualisation of biological molecules at the 
atomic level. Thus, they are exceedingly powerful methods that can provide a wealth of 
information about the molecular mechanisms underpinning biological processes. The 
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application of structural biology techniques to proteins has been central to many medical 
advances. A key example of this is the development of insulin analogues for the 
treatment of diabetes (Pandyarajan and Weiss, 2012). 
 
Structural biology techniques have been especially useful in drug design and 
development when applied to enzymes (Hardy and Malikayil, 2003; Williams et al., 
2005). Key examples of drugs developed using a structure-based approach include HIV 
protease inhibitors (Turner et al., 1998), neuraminidase inhibitors such as Tamiflu 
(Oseltamivir) and Relenza (Zanamivir)  (Stoll et al., 2003) and angiotensin converting 
enzyme inhibitors (Acharya et al., 2003), the latter of which represents a signficiant part 
of the work presented in this thesis. 
 
A number of methods exist for determining protein structures, the most widely used 
being electron microscopy (EM), nuclear magnetic resonance (NMR) and X-ray 
crystallography. Traditionally, EM has only been suitable for use on very large 
macromolecules and is limited in terms of the maximum resolution that can be achieved. 
However, recent developments have seen the number of EM entries in the Protein Data 
Bank (PDB) more than double in the last four years with structures now being reported 
at close to 3 Å resolution (Amunts et al., 2014; Fischer et al., 2015; Yu et al., 2011). 
Conversely, NMR is only suitable for use with much smaller proteins, typically less than 
35 kDa. This technique is also developing rapidly though and is being used increasingly 
for larger proteins. 
 
 
Figure 2.1: Percentage of Protein Data Bank Entries by Experimental Technique. 







EM, 0.73% Other, 0.24% 
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In spite of the recent developments in NMR and EM, X-ray crystallography remains the 
most widely used method for structural studies of macromolecules. Of the ~111, 000 
entries listed in the Protein Data Bank in August 2015, ~99, 000 were determined by X-
ray crystallography, compared to ~ 11, 000 and ~ 800 for NMR and EM respectively 
(Figure 2.1). The main advantages of X-ray crystallography include the fact that it can 
be applied to samples ranging from small molecules to large macromolecular 
complexes, and that unlike NMR where samples must be labelled with isotopes, X-ray 
crystallography does not necessarily involve any such modifications, which can make 
sample preparation more straightforward and less expensive. 
 
The main drawback of X-ray crystallography is that it is entirely dependent on the 
formation of diffraction quality crystals. Although a plethora of techniques exist for 
producing and optimising such crystals, it is still far from an exact science and there is 
no way of predicting under which conditions a given molecule will crystallise. In spite 
of this drawback, X-ray crystallography does remain the dominant method in structural 
biology and it is the method that was employed to obtain the structural data reported in 
this work. 
 
The different processes involved in protein crystallography projects are described in the 
following sections. The flow chart in Figure 2.2 outlines these steps and the order in 





















Protein crystallisation X-ray diffraction data collection 
Data processing and 
model building Structure refinement 
Structure validation and 
deposition to the PDB 
Protein purification 
Figure 2.2: General Workflow in a 
Structural Biology Experiment.!
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2.6.2 Sample Preparation 
2.6.2.1 Protein Expression 
The major requirement for protein crystallography is a large quantity of pure protein. 
Initially, this was very often a limiting factor as target proteins had to be isolated from 
their original source organism. However, the advent of recombinant DNA technology 
has revolutionised this step with the vast majority of protein structures now being solved 
using proteins produced by recombinant expression.  
 
Escherichia coli remains the most commonly used system for recombinant protein 
expression. As of August 2015, 77 % of all Protein Data Bank (PDB) entries cite using 
E. coli as the expression system. The major advantages of this system being that as a 
prokaryote genomic manipulation is relatively straight forward, it grows rapidly, is 
relatively inexpensive and can yield large quantities of recombinant protein. The major 
disadvantage of using E. coli, and indeed other prokaryotic systems, is that they are 
unable to perform many of the post-translational modifications found on eukaryotic 
proteins and lack chaperones that may be required for correct protein folding. It has been 
estimated that 65 % of human proteins do not show soluble expression in E. coli (Hirose 
et al., 2011), which is particularly problematic given than human proteins are so often 
the targets of research for drug development. 
 
As more protein structures are published, research is increasingly moving to focus on 
more challenging targets, such as large complexes, membrane proteins and those which 
undergo extensive post-translational modifications. This often necessitates the use of 
eukaryotic systems for recombinant protein expression. 
 
One such system is the yeast Pichia pastoris. P. pastoris is in many ways an ideal 
expression system. It is a eukaryote, which means that it can carry out post-translational 
modifications, but compared to higher eukaryotes it is relatively inexpensive to grow 
and easy to genetically manipulate. It can be grown in a laboratory environment in shake 
flasks in a very similar manner to E.coli. P. pastoris is often chosen over other yeasts 
such as Saccharomyces cerevisiae due to the potential for obtaining higher protein 
yields. 
 
P. pastoris is a methylotropic yeast, meaning that it can grow using methanol as its sole 
carbon source. It is this feature that is exploited in recombinant protein expression. The 
first step in methanol metabolism by P. pastoris is oxidation by the enzyme alcohol 
oxidase to form formaldehyde. In the presence of methanol and the absence of glycerol, 
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transcription of the alcohol oxidase gene, AOX1 is initiated. Recombinant protein 
expression can be coupled to the AOX1 promoter, meaning that target protein expression 
can easily be induced by addition of methanol to the growth medium (Ellis et al., 1985; 
Kouz et al., 1989; Tschopp et al., 1987). Following the method outlined in section 2.7.1, 
P. pastoris was used to produce the D. melanogaster ACE homologue, AnCE, in this 
work. 
 
Whilst P. pastoris is a useful system in some circumstances, there are still many 
instances where expression by higher eukaryotes is the only option for obtaining 
sufficient quantities of correctly processed, functional protein. Two of the most 
commonly used cell lines for this purpose are HEK293T cells (human embryonic 
kidney) and the Sf9 cell line derived from the moth Spodoptera frugiperda, both of 
which were used in this work. Although there are many advantages associated with 
using higher eukaryotes in terms of correct processing of the target protein, these cell 
lines are much more challenging and expensive to work with, requiring specialised 
tissue culture suites. 
 
2.6.2.2 Protein Purification 
After the target protein has been expressed using the chosen system, it must then be 
purified. Typically the first step in a purification process will either involve ion 
exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) or 
affinity chromatography. IEX involves a protein molecule with a net surface charge 
interacting with an oppositely charged matrix and then being eluted by increasing ionic 
strength. Depending on the degree of surface charge at a given pH, different molecules 
will interact with the matrix to different extents, thus enabling separation. A similar 
principle is applied in HIC. Here a protein molecule with exposed hydrophobic groups 
interacts with a hydrophobic matrix and is then eluted by decreasing ionic strength. As 
most proteins do not have an abundance of surface hydrophobic residues this technique 
can be a very effective method of separation.  
 
Affinity chromatography is currently the most widely used technique for protein 
purification. It exploits an interaction between the protein and a specific molecule that is 
immobilised on a matrix. This is a ligand that the protein is able to bind to either 
naturally or due to the addition of an affinity tag. A common example of such a tag is 
the polyhistidine tag, which binds to nickel and other divalent cations. Affinity 
chromatography is a very powerful tool that can yield very pure protein samples even 
from crude cell lysates. 
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After an initial purification step it is quite common for a final “polishing” step to be 
performed to ensure that the sample is as homogenous as possible. Typically this is in 
the form of size exclusion chromatography (SEC) whereby molecules are separated 
based on their size. 
 
After purification it is important to confirm the identity of the protein before beginning 
crystallisation trials. Techniques for this include but are not limited to: sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), which separates proteins 
based on size, western blotting, which uses antibodies to identify target proteins, and 
mass spectrometry, which, when combined with trypsin or pepsin digestion, can be used 
to determine protein sequence in a technique known as peptide mass fingerprinting. 
 
2.6.2.3 Protein Crystallisation 
Crystals consist of a regular arrangement of identical repeating units in three dimensions 
forming a lattice. In a perfect crystal, each repeating unit is in an identical environment 
forming identical non-covalent interactions with neighbouring units. The building block 
of the crystal lattice is known as the unit cell, and crystals are essentially repeating 
arrangements of identical unit cells. Unit cells are related to each other by symmetry 
operations, which define the space group of the crystal. There are 230 possible crystal 
space groups, however the chirality of protein molecules means that protein crystals can 
adopt only 65 of these. 
 
Whilst crystals can be thought of as being built-up from repeating arrangements of unit 
cells, the unit cell is not necessarily the empirical building block of the lattice. The 
smallest unit from which the entire lattice can be built by applying only symmetry 
operations is known as the asymmetric unit, and unit cells often contain more than one 
asymmetric unit. It is also important to recognise that in the case of protein crystals it 
does not necessarily follow that the asymmetric unit comprises one protein molecule.  
 
Obtaining diffraction quality crystals is very often the rate-limiting step in structure 
determination. Protein crystals will only grow under very specific conditions. These 
vary widely between different proteins and are impossible to predict.  
 
The process of crystallisation can be understood by studying the phase diagram in 
Figure 2.3. This is an indicator of the solubility of a protein at a given concentration for 
a specific adjustable parameter. This is often temperature, pH or precipitant 
concentration. The phase diagram is divided into two main regions separated by the 
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solubility curve. Below the solubility curve the solution is undersaturated; protein 
molecules are fully solvated hence it is energetically favourable for them to remain in 
solution. Above the curve the solution is supersaturated and the protein will be driven 
out of solution in a bid to reduce the free energy of the system. 
 
 






Figure 2.3: Phase Diagram for Protein Crystallisation. A diagram illustrating the 
effect of protein concentration and adjustable parameters on protein solubility. The plot 
is separated by the solubility curve (blue) into two regions. Below the curve the solution 
is undersaturated and the protein will remain in solution. Above the curve the solution is 
supersaturated. The supersaturated region can be further divided by the supersolubility 
curve (green). Below the supersolubility curve is the metastable zone where crystal 
growth can occur. Directly above this is the nucleation zone where crystal nuclei can 
begin to form. Above this is the precipitation zone where the solution is so saturated that 
the protein will precipitate out of solution. The aim of crystallisation experiments is to 
gradually increase the effective protein concentration to bring the solution into the 
nucleation zone so that crystal nuclei form and for this to then reduce the saturation 
bringing the solution into the metastable zone for crystal growth. This is illustrated by 





























The aim of crystallisation experiments is to gradually alter the conditions of a protein 
solution so that the solubility limit of the protein is exceeded and crystals can form. The 
critical event in crystal growth is the formation of stable nuclei that are the precursors of 
crystals. These will only form in a very specific region of the phase diagram known as 
the nucleation zone. Above this zone the solution is too saturated and the protein 
molecules will aggregate and form precipitate. Below this region the solution is 
undersaturated and crystallisation will never occur. Ideally, the occurrence of nucleation 
will then cause the solution to be less saturated and drop into the metastable zone. It is 
here that crystal growth can occur as protein molecules add to the nuclei in an ordered 
manner. 
 
A number of different methods exist for achieving protein crystallisation. Currently the 
most commonly used is the vapour diffusion technique. Here the protein is mixed with a 
solution containing a precipitant to form a drop. This drop is then sealed in an enclosed 
chamber with a reservoir containing a higher concentration of said precipitant. This 
establishes a concentration gradient between the drop and reservoir. As the system 
moves towards equilibrium, water will gradually diffuse from the protein drop to the 
reservoir, increasing the effective protein concentration and gradually moving the 
protein solution towards the supersaturated region of the phase diagram.  
 
A number of different variants of the vapour diffusion technique exist. The most 
common are hanging and sitting drop vapour diffusion, illustrated in Figure 2.4. In 
hanging drop vapour diffusion the protein/precipitant drop is suspended over a well 
containing the reservoir solution, whilst in the sitting drop set-up the drop is placed on a 



















The conditions that will give rise to crystals vary widely between different proteins and 
are impossible to predict. For this reason it is now commonplace to begin by screening 
hundreds, if not thousands of conditions using high throughput robots and commercial 
screens. Experiments are checked regularly for any sign of crystal formation, at which 
point the conditions can be optimised to try and improve crystal growth. Typically, this 
involves iteratively varying parameters such as protein concentration, precipitant 
concentration, pH, temperature, salt and buffer. 
 
As well as being the critical step in crystal formation, nucleation is often also the most 
difficult state to achieve. Seeding is a very useful technique that effectively bypasses 
this process. By artificially introducing nuclei into the drop, the level of supersaturation 
that is required is decreased, reducing the likelihood of the protein forming aggregates. 
There are three types of crystal seeding: macroseeding, where a single large crystal is 
introduced into the drop, microseeding, where small crystal fragments are introduced 
and streak seeding where an implement, typically a whisker, is used to transfer crystal 
nuclei into the drop. 
 
2.6.3 X-ray Diffraction Data Collection and Processing 
2.6.3.1 X-rays and Diffraction 
X-rays are a form of electromagnetic radiation with wavelengths (λ) in the range 10-11 to 
10-8 m, or 0.1 to 100 Å. Depending on their wavelength, X-rays are classified as either 
hard or soft, with soft X-rays having wavelengths greater than ~ 2 Å, and hard X-rays 
below this value. Macromolecular crystallography typically uses hard X-rays for which 
λ = 0.5-1.6 Å. This is the same order of magnitude as most of the relevant interatomic 
bonds (e.g. C-C ~ 1.5 Å) allowing visualisation of structures at the atomic level. 
 
The wave nature of X-rays means that they can be diffracted and it is this property that 
is exploited in X-ray crystallography. During data collection, the majority of X-rays will 
pass straight through the crystal and be captured by the beam stop, providing no useful 
information. The X-rays that are important are those that are diffracted by atoms in the 
crystal. Inside the crystal many diffraction events occur, resulting in a large number of 
diffracted X-rays that interfere with each other. If diffracted rays are not in phase, then 
the result will be destructive interference and the waves will cancel each other out so 
that no signal is detected.  
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In contrast, if two waves are in phase with each other, constructive interference will 
occur and the signal will be amplified. This is where the repeating nature of the crystal 
lattice is so important. As illustrated in Figure 2.5, for there to be constructive 
interference between two waves their path lengths must differ by nλ, where n is a whole 
number integer. That is to say, that the difference between the path lengths must be a 
multiple of the wavelength. Applying this to a crystal lattice, this means that X-rays 
diffracted from planes throughout the crystal that are separated by a specific distance, d, 
will all be in phase. This will result in constructive interference and a greatly amplified 
signal that can be detected. These planes are known as Bragg planes and Bragg’s law, 






Figure 2.5: Bragg’s Law. For two waves with wavelength λ to remain in phase after 
diffraction from two planes in a crystal separated separated by a distance d, the 
additional distance travelled by the second wave (green) must be an integer multiple of 
the wavelength. This is expressed by Bragg’s law: nλ = 2d sin θ 
 !
 
The wavelength of the X-rays is unchanged following diffraction but their phase and 
amplitude will differ from that of the original incident wave. This is governed by the 
distribution of scattering matter, electron density, in the crystal. The diffracted waves 
can be defined by structure factors, which are complex numbers that describe their 









nλ = 2d sin θ 
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By performing a mathematical operation known as a Fourier transform, it is possible to 
calculate the distribution of electron density within the crystal, based on the amplitude 
and phase of the scattered waves. 
 
2.6.3.2 X-ray Diffraction Data Collection 
2.6.3.2.1 X-ray Sources 
Diffraction data are collected from protein crystals using X-rays that are generated either 
from an “in-house” source or by a synchrotron. 
 
In-house X-ray sources are very often rotating copper anodes.  These work by 
accelerating a beam of electrons towards a copper anode in a vacuum. The energy 
transfer that occurs when the electrons reach the anode ejects an electron from the inner 
shell of the atom. Consequently, an electron from a higher energy level is then able to 
drop down and occupy the now vacant, lower energy level position. This is accompanied 
by the release of energy in the form of an X-ray photon.  
 
Each metal produces X-rays of a characteristic wavelength, which is governed by the 
energy levels of its electrons. For copper this wavelength is 1.54 Å. 
 
The intensity of the X-rays produced by such sources is limited by the rate at which heat 
can be conducted away from the site of bombardment. For this reason, the copper anode 
is usually a rotating, hollow cylinder that is cooled from inside by jets of water. 
 
Although in-house sources can be used to collect good quality X-ray diffraction data, 
increased access to synchrotrons in the last few decades has lead to synchrotron 
radiation becoming the dominant source of X-rays for protein crystallography 
experiments. Synchrotron radiation is produced by using a magnetic field to accelerate 
electrons, which are travelling at close to the speed of light, in a circular path. The result 
is an intense X-ray beam that is emitted at a tangent to the path of the electrons. 
 
There are a number of advantages that come from using synchrotrons over in-house X-
ray sources.  The radiation that is emitted is much more intense than that produced by 
laboratory sources, consequently, complete datasets can be detected in a matter of 
minutes. Furthermore, whereas the wavelength of the X-rays produced by rotating anode 
sources is fixed and determined by the choice of metal, the wavelength of X-rays 
produced by synchrotrons can be adjusted using undulators and wigglers.  This is crucial 
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for methods such as multi-wavelength anomalous dispersion (MAD), a powerful tool for 
solving the phase problem, which is described in section 2.6.3.3.1.3. 
 
All of the diffraction data presented in this thesis were collected at the United 
Kingdom’s national synchrotron facility: Diamond Light Source (DLS), Harwell 
Science and Innovation Campus, Didcot, Oxon, UK. 
 
2.6.3.2.2 Radiation Damage 
Radiation damage to the crystal presents a significant problem in diffraction experiments 
and data are often collected at 100 K in order to minimise this effect. Prior to data 
collection it is commonplace to rapidly cool the crystals. It is important that this is a 
very fast process so as to avoid temperatures at which ice formation can occur, as this 
can disrupt the crystal lattice.  The addition of cryoprotectant solutions, often containing 
glycerol, glucose or polyethylene glycols (Berejnov et al., 2006; Garman and Mitchell, 
1996) can help to prevent ice formation and protect crystals during freezing. 
 
2.6.3.2.3 Measures of Data Quality 
The final structure can only ever be as good as the data that are collected hence it is 
exceedingly important to have an indication of the quality of the raw data. A number of 
different statistical values are generally used for this purpose. 
 
2.6.3.2.3.1 R factors 
Depending on the symmetry of the crystal, there are certain reflections that should have 
the same intensity. This is described by Friedel’s law and these reflections are known as 
Friedel pairs.  
 
Rsym is a statistical measure of the differences between the intensity of symmetry related 
measurements. A low Rsym is indicative of good agreement between these measurements 
and hence reliable data. A second value, Rmerge is often reported and is closely related to 
Rsym. Rmerge takes into consideration the fact that normally during data collection the 
same reflection will be measured many times and so also includes these in the 
calculation. 
 
A significant problem with Rmerge exists though in that it is dependent on the redundancy 
of the data. If the redundancy is low than the value for Rmerge will automatically be lower, 
but at the same time the data are less accurate. Similarly, excluding reflections will 
improve Rmerge whilst having a detrimental effect on the quality of the final structure. A 
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slightly improved value, Rpim (precision indicated merging R factor) can be used which 
also takes into account the precision of the averaged measurement (Diederichs and 
Karplus, 1997; Weiss and Hilgenfield, 1997; Weiss, 2000). 
 
2.6.3.2.3.2 Completeness and Redundancy 
As outlined above, R factors are intrinsically linked to the completeness and the 
redundancy of the data hence it is essential that these values be considered. 
 
The completeness of the data is a measure of the total number of unique reflections that 
are recorded as a fraction of the total number of unique reflections that are required to 
generate a complete set of reflections. This is of course dependent on crystal symmetry. 
Generally speaking, overall completeness should be greater than or equal to 95 %. 
 
Redundancy is a slightly different concept, which presents the total number of 
reflections that are measured as a fraction of the total number of unique reflections that 
are measured. This is to take into consideration the fact that measuring a number of 
different, symmetry related, reflections will give more reliable data than measuring the 
same reflection many times. 
 
2.6.3.3 Data Processing and Structure Solution 
Having collected the diffraction data, the first step in data processing is to index and 
then integrate this data. During indexing the unit cell dimensions are determined, which 
are then used during integration, when the intensity of the diffraction spots are 
measured. In the work presented in this thesis MOSFLM (Battye et al., 2011; Leslie and 
Powell, 2007) was used to perform indexing and integration. 
 
Following integration the data are then scaled and merged. This involves merging 
reflections that are equivalent, scaling the data to account for errors during collection 
and combining all of the integrated values to produce the structure factors. The program 
Aimless (Evans, 2006; Evans, 2007), part of the CCP4 suite (Winn et al., 2011) was 
used to scale and merge all of the data collected in this thesis.  
 
2.6.3.3.1 The Phase Problem 
As detailed in section 2.6.3.1, the distribution of electron density in the crystal can be 
calculated by performing an inverse Fourier transform on the structure factors of the 
diffracted X-rays. This requires knowledge of the amplitude and phase of these waves.  
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The amplitude is proportional to the square of the intensity, hence is calculated based on 
the intensity recorded by the detector. The detector cannot measure the phase of the 
waves, thus this information is lost. This is known as the phase problem and is one of 
the biggest issues faced in X-ray crystallography. 
 
2.6.3.3.1.2 Multiple Isomorphous Replacement 
Multiple isomorphous replacement (MIR) is a method for solving the phase problem 
that was pioneered by Max Perutz (Green et al., 1954; Perutz et al., 1960). In MIR 
heavy atoms, typically mercury (binds to thiol groups on cysteine residues), uranium 
(binds carboxyl groups on aspartic and glutamic acid residues) or platinum (binds to 
histidine residues), are incorporated into the crystals. This can either be at the point of 
setting up the crystallisation experiment or by soaking the crystals once grown in 
solutions containing the heavy metal atoms. It is imperative for the success of this 
method that binding of the heavy metals does not alter the crystal lattice; the native and 
derivative crystals must be isomorphous. Data are collected from both the native crystal 
and the heavy atom derivative. Comparing the data enables the position of the heavy 
atoms to be established, meaning that the amplitude and phase can be calculated. This 
information is then used to calculate the phases for the native data. 
 
2.6.3.3.1.3 Multi-wavelength Anomalous Dispersion 
A related method for solving the phase problem, also using heavy metals, is multi-
wavelength anomalous dispersion (MAD). The major advantage of MAD is that it only 
requires data from a single crystal, which can negate the problem of non-isomorphism 
following heavy atom soaks.  
 
At wavelengths close to the absorption edge of the heavy metal of choice, strong 
absorption of the incident X-ray means that the phase of X-rays diffracted from the 
heavy metals is shifted relative to those diffracted from the other atoms in the crystal. 
This is known as anomalous scattering. In MAD, multiple (typically three) datasets are 
collected from a single crystal at different wavelengths, one of which must be close to 
the absorption edge of the heavy metal (Hendrickson et al., 1988; Hendrickson, 1991).   
 
MAD has become much more accessible with the advent of synchrotron beamlines with 
tuneable wavelengths. Selenium is very often the atom of choice for MAD phasing. This 
is because it can be easily and reliably incorporated into proteins by recombinant 
expression in selenomethionine containing media by methionine auxotrophs. Single-
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wavelength anomalous dispersion (SAD) is a related technique that only requires data 
collection at a single wavelength (Hendrickson et al., 1990). 
 
2.6.3.3.1.4 Molecular Replacement 
The method used for solving the phase problem in the work presented here is molecular 
replacement (MR). This is a very different technique to those outlined above and is 
entirely dependent on an existing structure of a related protein, typically a homologue, 
which is used as a model. The basic premise of MR is to determine the rotation and 
translation functions that must be applied to the search model in order to correctly orient 
it in the unit cell of the target protein. Once this has been achieved phases can be 
calculated and used to produce an electron density map for the target protein (Rossmann 
and Blow, 1962). 
 
2.6.3.4 Structure Refinement and Validation 
2.6.3.4.1 Refinement 
After the phase problem has been solved, a model of the structure is produced based on 
interpretation of the electron density map. This model must then be refined; adjustments 
are made to the structure to ensure that it is the best possible representation of the 
experimental data and to minimise errors in the final structure. Refinement is usually 
carried out using computational software, with REFMAC (Murshudov et al., 2011), part 
of the CCP4 suite (Winn et al., 2011), being a widely used example. 
 
The first step in the refinement process is typically rigid body refinement. Here the 
model is moved as a single, rigid entity to find the position in which it best fits the 
electron density. At this stage the positions of every atom relative to each other are 
fixed. 
 
Following rigid body refinement it is common to perform iterative rounds of model 
building, where manual adjustments are made to improve the “fit” of the structure to the 
density, and restrained refinement. Whereas in rigid body refinement the positions of 
atoms relative to each other are fixed, in restrained refinement a certain degree of 
movement is permitted. This is governed by a set of restraints that are imposed, 
primarily to ensure that the model remains physically reasonable. Typically this 
includes, but is not limited to, restraints on bond length, bond angle, planarity and 
distances between atoms (to ensure that they do not clash).  
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In addition to visual inspection of the model, the progress of refinement is followed 
using statistical analysis. The R (reliability) factor is an exceedingly important value that 
measures the agreement between the model and the experimental data, and Rcryst is 
frequently reported for protein structures.  
 
Broadly speaking, a lower R factor is indicative of better agreement between the model 
and the experimental data, with a theoretically “perfect” model having an R factor of 
zero. Thus, Rcryst is expected to decrease during the refinement process.  
 
Unfortunately, Rcryst is by no means a perfect measure of model quality. A significant 
problem exists in that Rcryst is calculated using information that is also used in 
refinement. This means that it is susceptible to large systematic errors and over-fitting. 
For example, a study performed in 1995 demonstrated that tracing a protein backbone 
completely incorrectly, in this example backwards, could, if data were not of very high 
resolution, still result in seemingly acceptable R factors (Kleywegt et al., 1995). 
 
A second measure, Rfree, was introduced in 1992 in order to overcome this problem 
(Brünger, 1992; Brünger, 1993). The Rfree value is calculated using a subset, normally 5-
10 %, of reflections that are set aside at the outset and hence never used in refinement. 
Considering the difference in the values reported for Rfree and Rcryst can therefore provide 
information as to whether the model is actually being improved through refinement. The 
Rfree value is always expected to be greater than the Rcryst value, but a large disparity 
indicates a problem with the refinement process. There is no firm rule as to what is an 
acceptable difference between Rfree and Rcryst, which is significantly influenced by 
resolution (Tickle et al., 1998). Generally speaking the Rfree value should not exceed ~ 
35 % and should be approximately 1.2 times greater than Rcryst (Kleywegt and Brünger, 
1996). 
 
2.6.3.4.2 Structure Validation 
After refinement, it is commonplace to perform some form of geometric validation of 
the final model. This routinely includes calculating the root mean square deviation 
(RMSD) of bond lengths and angles from ideal values and checking for adherence to the 
Ramachandran plot (Ramachandran et al., 1963). More thorough geometric validation is 
often performed using software such as Molprobity, which performs functions that 
include analysis of contacts between atoms to check for clashes, checking adherence to 
the Ramachandran plot, detecting cis-peptides and identifying unusual rotamers (Davis 
et al., 2007; Chen 2010). 
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2.7 General Protocols for AnCE 
AnCE is one of two angiotensin converting enzyme homologues from Drosophila 
melanogaster (section 1.9.1). It is used for the structural studies presented in Chapters 3, 
4, 5 and 6. General protocols for AnCE expression, purification and crystallisation that 
were used for this work are outlined in the following sections. Variations to this protocol 
for individual experiments are detailed as they arise in the appropriate chapters.  
 
2.7.1 Recombinant Expression by P. pastoris 
P. pastoris GS115 cells transformed with the Ance coding sequence in the pPIC9 vector 
were kindly provided by Prof. Elwyn Isaac, University of Leeds. Recombinant 
expression of AnCE by P. pastoris was performed according to the previously 
established protocol (Houard et al., 1998; Akif et al., 2010). 
 
Briefly, a single colony of the transformed GS115 cells was used to inoculate 25 ml 
BMGY media in a 100 ml baffled flask. This culture was incubated for 24 hours at 30 oC 
with orbital shaking at 250 rpm. Two 500 ml subcultures in 2 litre baffled flasks were 
prepared by inoculation with 1 % of the overnight culture and incubated at 30 oC, 250 
rpm for a further 24 hours until the optical density at 600 nm was between 2 and 6. This 
culture was harvested by centrifugation at 3000 g, 18 oC for 5 minutes using the 
Beckman CoulterTM Avanti J-25 centrifuge and JLA 16.250 rotor. The supernatant was 
discarded and the cell pellets resuspended in a total volume of 200 ml BMMY media to 
induce expression. The 200 ml culture was returned to the incubator at 30 oC, 250 rpm 
for 48 hours. In order to maintain the concentration of methanol required for induction, 
every 24 hours methanol was added directly to the culture to a final concentration of 0.5 
%, compensating for losses through evaporation and consumption.  
 
Following 48 hours of induction the culture was harvested by centrifugation at 3000 g, 4 
oC using the Beckman CoulterTM Avanti J-25 centrifuge and JLA 16.250 rotor. The cell 
pellets were discarded and the supernatant retained for immediate use in purification 
steps. 
 
2.7.2 Purification by HIC 
The AnCE expression supernatant was treated with an equal volume of 3 M ammonium 
sulphate, 20 mM Tris pH 8.0 (to give a final ammonium sulphate concentration of 1.5 
M) and incubated for 10 minutes at room temperate before centrifugation at 4000 g, 4 oC 
for 10 minutes using the Beckman CoulterTM Avanti J-25 centrifuge and the 16.250 
rotor.  
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10 ml phenyl sepharose 6 fast flow high sub resin (GE Healthcare, UK) were packed in 
an XK 16/60 column and equilibrated with buffer A (1.5 M ammonium sulphate, 20 
mM Tris pH 8.0). The supernatant from the ammonium sulphate treatment was applied 
to the column and washed with buffer A until the absorbance at 260 nm reached a stable 
baseline. Elution was performed with a step gradient of decreasing salt: 0.45 M and then 
0 M ammonium sulphate. The absorbance at 280 nm was recorded and used to monitor 
elution. 3 ml fractions were collected and analysed by SDS-PAGE. As illustrated in 






Figure 2.6: AnCE Purification by HIC. (a) Chromatogram for purification of AnCE 
by HIC. The blue trace shows the absorbance at 280 nm, used to monitor protein elution. 
The green trace shows the concentration of elution buffer. The peak eluted at 0.45 M 
ammonium sulphate was analysed by SDS-PAGE. This gel is shown in (b) and confirms 
that the elution peak contains AnCE, illustrated by the bands at the expected molecular 
weight of ~70 kDa. 
 








Figure 2.7: AnCE Purification by SEC. (a) Chromatogram for the application of 
pooled fractions from HIC to the SEC column. The blue trace shows the absorbance at 
280 nm, used to monitor protein elution. Fractions from the peak labelled “AnCE” were 
analysed by SDS-PAGE. This gel is shown in (b) and confirms that this peak contains 
pure AnCE, shown by the bands at ~70 kDa, the expected molecular weight of AnCE. 
 
 
AnCE ~ 70 kDa 
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2.7.3 Purification by SEC 
Fractions from HIC confirmed by SDS-PAGE to contain AnCE were pooled together 
and dialysed for 18 hours at 4 oC against an excess of size exclusion buffer (150 mM 
NaCl, 20 mM Tris, pH 8) using 12-14 kDa molecular weight cut-off dialysis membrane 
(Medicell International Ltd). The dialysed sample was concentrated to a final volume 
not exceeding 1.5 ml by centrifugation at 3000 g, 4 oC, in a Heraeus centrifuge (Thermo 
Fisher Scientific, MA, USA) using 30 kDa molecular weight cut-off Amicon Ultra-15 
centrifugal filter units (Merck Millipore). The concentrated sample was then applied to a 
Superdex-200 16/60 column (GE Healthcare, UK) pre-equilibrated with gel filtration 
buffer. Monitoring the absorbance at 280 nm was used to follow the elution. 1.5 ml 
fractions were collected and the presence of pure AnCE confirmed by SDS PAGE 
analysis, with an example gel shown in Figure 2.7. Using the technique described above, 
pure AnCE was concentrated to 17.5 mg ml-1 before being split into 50 µl aliquots and 
rapid frozen in liquid nitrogen prior to storage at -80 oC. 
 
2.7.4 Crystallisation 
AnCE crystallisation was performed using the hanging drop vapour diffusion technique 
that is described in section 2.6.2.3. Previous experiments by Akif et al., used high 
throughput crystallisation screens to identify a condition in which AnCE crystallises: 
1.2-1.3 M sodium citrate, 0.1 M HEPES, pH 7.5; this is the condition that was used to 
grow the AnCE crystals used in Chapters 3, 4 and 5 (Akif et al., 2010). 
 
Crystallisation experiments were performed in 24 well plates (Molecular Dimensions 
Ltd., Newmarket, UK). 500 µl of the reservoir solution (1.2-1.3 M sodium citrate, 0.1 M 
HEPES pH 7.5) were used in each case. A drop was prepared containing 1 µl reservoir 
solution and 1 µl 17.5 mg ml-1 AnCE. In the case of inhibitor binding studies, the 
inhibitor was pre-incubated with AnCE before the drop was prepared. The drops were 
suspended over the reservoirs on 20 mm siliconised cover slips and sealed using high 
vacuum grease. Experiments were incubated at 21 oC. 
 
Typically diffraction quality crystals such as those shown in Figure 2.8 grew within 7 
days. These crystals belong to the space group h3 and contain one AnCE molecule per 
asymmetric unit. Due to the high concentration of citrate in the condition, complete 
datasets can be collected at 100 K without the use of a cryoprotectant. Diffraction from 
these crystals is routinely recorded to at least 2.0 Å, as illustrated by the example 




Figure 2.8: AnCE Crystals Grown using the Hanging Drop Vapour Diffusion 
Technique. The crystals shown are in 2 µl drops containing 1 µl 17.5 mg ml-1 AnCE and 
1 µl reservoir solution. The reservoir solution contains 1.26 M sodium citrate and 0.1 M 
HEPES pH 7.5. Crystallisation experiments were performed at 21 oC and crystal 
typically appeared within 7 days. 
 
                 
 
Figure 2.9: Example of X-ray Diffraction Data collected from an AnCE crystal. 


















Chapter 3: Crystal Structures of AnCE in 
Complex with Natural Inhibitory Peptides 















3.1.1 Requirement for a New Generation of ACE Inhibitors 
Angiotensin converting enzyme is a well-established target in the treatment of 
hypertension. This is primarily achieved through the use of ACE inhibitors; small 
molecules that bind to the enzyme’s active site and competitively inhibit its activity 
(Cushman and Ondetti, 1999; Zaman et al., 2002). ACE inhibitors such as captopril 
have been widely used since the 1980s, however, as outlined in section 1.5.1, these 
drugs are frequently associated with side effects caused by the inhibition of the roles of 
ACE in other physiological processes (Israili and Hall, 1992; Nussberger et al., 1998; 
Steckelings et al., 2001). 
 
It is increasingly being recognised that the C- and N-domains of sACE have evolved 
separately to acquire divergent functions. It is the C-domain that is primarily responsible 
for blood pressure regulation in vivo, converting angiotensin I into the hypertensive 
peptide angiotensin II much more efficiently than the N-domain (Georgiadis et al., 
2003).  
 
Both domains of ACE have been shown to hydrolyse the peptide bradykinin with equal 
efficiency. This is important, because the accumulation of bradykinin associated with 
ACE inhibition has been implicated in many of the side effects associated with the use 
of ACE inhibitors, not least the persistent dry cough that afflicts so many patients (Bas 
et al., 2007). 
 
Additionally, it is apparent that the N-domain is involved in many other physiological 
processes outside of blood pressure regulation, cleaving a number of other peptide 
substrates more effectively than the C-domain. This includes peptides such as Aβ42, 
which has been implicated in Alzheimer’s disease, and AcSDKP (Rousseau et al., 
1995), which is involved in the regulation of the proliferation of HSCs (haematopoietic 
stem cells) (Lenfant et al., 1989). 
 
With this in mind, a significant amount of research is currently focused on the design 
and development of a new generation of ACE inhibitors that selectively target only one 
of the catalytic domains. Inhibitors specific for the C-domain could be used to treat 
hypertension whilst potentially avoiding many of the side effects currently associated 
with ACE inhibitors. Similarly, in some cases, it may be beneficial to selectively target 
the N-domain, leaving the C-domain active in blood pressure regulation. One example 
of this is in aggressive chemotherapy treatments, where there is evidence to suggest that 
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inhibiting AcSDKP hydrolysis, a function of the N-domain, can protect HSCs (Bogden 
et al., 1991). 
 
The development of two phosphinic peptide inhibitors, RXP407 and RXPA380, which 
selectively inhibit the N- and C-domains of sACE, respectively, has provided proof of 
principle data that such domain specific inhibition could be possible (Dive et al., 1999; 
Georgiadis et al., 2004). A key process in developing selective inhibitors is identifying 
and exploiting different features of the active site pockets of the two domains. As 
detailed in section 1.6.5, information obtained from structural studies was crucial in 
understanding the basis for domain-specific inhibition by RXPA380 and RXP407 and 
will no doubt be invaluable in future inhibitor development. 
 
3.1.2 Bradykinin Potentiating Peptides 
The bradykinin potentiating peptides (BPPs) from the venom of the pit viper Bothrops 
jararaca are natural inhibitors of angiotensin converting enzymes. They have been 
studied since the 1970s and analysis of the sequences of these peptides played a pivotal 
role in the design of the original ACE inhibitors. All of the BPPs have a conserved IPP 
motif at their C-terminus that is critical for ACE inhibition (Ferreira, 1965; Ferreira, 
1970; Ondetti et al., 1971).  
 
In 2002 a study was performed by Cotton et al. to investigate the inhibition of the two 
domains of sACE by three BPPs. The Ki values obtained for each peptide with each 
domain are illustrated in Table 3.1 and the sequences of the peptides are included in 
Table 3.2 (Cotton et al., 2002).  
 
The data obtained indicate that whilst all three peptides are effective inhibitors of the C-
domain, only BPPc inhibits the N-domain with equal potency. Both BPP9a and BPPb 
are selective inhibitors of the C-domain and BPPb is an exceedingly poor inhibitor of 
the N-domain. 
 
Based on sequence analysis, Cotton et al. proposed that the residue at the P2 position of 
the BPPs was crucial for domain selectivity. BPPc, which inhibits both domains equally, 
has a small proline side chain at this position, whereas the glutamine and lysine residues 
at P2 in BPPb and BPP9a have much larger side chains that may in some way impede 
binding to the N-domain whilst enhancing C-domain binding and hence inhibition. 
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Peptide Ki for N-domain (nM) Ki for C-domain (nM) 
BPP9a 100 1 
BPPb 10, 000 30 
BPPc 80 80 
 
Table 3.1: Ki Values for the Inhibition of Each Domain of sACE by Three Different 
BPPs, as Determined by Cotton et al., 2002. 
 
Peptide P9 P8 P7 P6 P5 P4 P3 P2 P1 P1’ P2’ 
BPP9a   PCA Trp Pro Arg Pro Gln Ile Pro Pro 
BPPb PCA Gly Leu Pro Pro Arg Pro Lys Ile Pro Pro 
BPPc PCA Gly Leu Pro Pro Gly Pro Pro Ile Pro Pro 
BPP12b PCA Gly Pro Pro Pro Arg Pro Gln Ile Pro Pro 
BPPn PCA Gly Leu Trp Pro Arg Arg Lys Ile Pro Pro 
 
Table 3.2: Sequences of BPPs Indicating the Residues at Each Position According 
to the Notation Developed by Schechter and Berger Described in Section 1.6.5.1 
(Schechter and Berger, 1967). PCA denotes N-terminal pyroglutamate residues.!
 
3.1.3 Aims 
The aim of this work is to use X-ray crystallography to study the binding of a number of 
BPPs to the D. melanogaster ACE homologue AnCE and in doing so to learn more 
about how these peptides interact with the active site residues and how this may explain 
the domain selectivity that has been reported. AnCE is an ideal model for this as the 
active site pockets share some common features with both the N- and C-domains of 
human sACE, thus it will be possible to make informed comparisons.  
 
To date, the only structures of angiotensin converting enzymes in complex with BPPs 
are of AnCE (Akif et al., 2012) and human tACE (Masuyer et al., 2012), both bound to 
BPPb. Comparisons with these structures will form an important part of the analysis of 
the structures of AnCE with other BPPs presented here. 
 
The sequences of the peptides used in this study are detailed in Table 3.2. In addition to 
the naturally occurring peptides BPP9a, BPPc and BPP12b, an additional peptide, BPPn 
has been designed. As shown by the sequences in Table 3.2, all of the naturally 
occurring BPPs used here have a proline residue at the P3 position. In BPPn this has 
been substituted by an arginine. The aim of doing this is to investigate the significance 
of this position on the inhibitory properties of the peptide. The adjacent P2 position has 
already been implicated in domain selectivity, hence, extending this to the next position 
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is a logical next step towards understanding the key features of these peptides required 
for ACE inhibition. 
 
3.2 Methods 
3.2.1 Protein Expression, Purification and Crystallisation 
AnCE expression and purification was achieved following the general protocol that is 
described in section 2.7. P. pastoris was used to produce recombinant AnCE, which was 
then purified in a two-step process consisting of hydrophobic interaction 
chromatography followed by size exclusion chromatography.  
 
Purified AnCE was concentrated to 17.5 mg ml-1 and co-crystallised with the peptides 
BPP9a, BPPc, BPP12b and BPPn (Table 3.2) using the hanging drop vapour diffusion 
method, as described in section 2.7.4. All of the BPPs were purchased from Sigma-
Aldrich with the exception of BPPn, which was purchased from GL Biochem 
(Shanghai) Ltd. 
 
Immediately prior to crystallisation, 20 mM of each peptide was added to 17.5 mg ml-1 
AnCE in a 1:4 ratio of peptide:protein and incubated at 4 oC for approximately 30 
minutes. Hanging drops were prepared with 1 µl of the protein and peptide mixture and 
1 µl of the reservoir solution (1.2-1.3 M sodium citrate, 0.1 M HEPES, pH7.5). These 
drops were suspended on glass coverslips over wells containing 500 µl of the reservoir 
solution and sealed using high vacuum grease. Crystallisation experiments were 
incubated at 21 oC and observed regularly.  
 
Where crystals did not appear within the normal time frame for AnCE under these 
conditions (7 to 10 days) the crystallisation experiments were repeated with slight 
variations to the experimental parameters. This included decreasing the concentration of 
the protein (5-17.5 mg ml-1) and the peptide (2-20 mM), altering the ratio of peptide: 
protein (1:4 to 1:19) and reducing the incubation temperature to 19 oC.  
 
Where these variations still did not yield crystals, seeding was used to try and induce 
nucleation.  Two methods were tried: streak seeding and micro-seeding. In both cases 
the “seeds” were derived from native AnCE crystals grown under the conditions 
outlined in section 2.7.4. 
 
For the streak seeding experiments, drops were prepared as outlined above, placed over 
the reservoir solution and allowed to equilibrate at 21 oC for 4 to 6 hours. Following this, 
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a whisker was used to transfer “seeds” from the native AnCE crystals to the new drops 
by passing through the length of the drop. The drops were then once again sealed over 
the reservoirs and incubated at 21 oC. 
 
For the micro-seeding experiments, a seed stock was prepared by thoroughly 
resuspending a 2 µl drop containing native AnCE crystals in 10 µl of reservoir solution. 
The crystals in the drop were then crushed by vigorous agitation using a “seed-bead” 
(Hampton Research, CA, USA). Dilutions of the resulting suspension were prepared in 
the range 1 × 10-1 to 1 × 10-3 using the reservoir solution. 1 µl of these solutions was 
then added to drops prepared as detailed above that had been allowed to equilibrate at 21 
oC for 4-6 hours. The drops containing the seeding solution were incubated at 21 oC and 
observed regularly. 
 
3.2.2 X-ray Diffraction Data Collection 
The crystallisation condition used to grow the crystals of AnCE with the BPPs has been 
used on many previous occasions (Akif et al., 2010). It has previously been established 
that the relatively high concentration of sodium citrate present in the condition (1.2-1.3 
M) provides adequate cryo-protection, thus no further cryo-protectant solutions were 
added to the crystals prior to data collection. 
 
In place of a cryo-protectant, 1 µl of the reservoir solution was added to the drop prior to 
crystal mounting. This was to prevent the drop from drying out whilst also maximising 
the citrate concentration. Crystals were mounted directly into litholoops (Molecular 
Dimensions Ltd., Newmarket, UK) before rapid freezing in liquid nitrogen for 
transportation to the synchrotron. 
 
All X-ray diffraction data were collected using beamline i03 at DLS. Crystals were 
mounted for data collection using the sample changer robot and diffraction data were 
recorded using a Pilatus3 6M detector.  All data were collected at 100 K.  
 
3.2.3 Data Processing and Structure Solution 
Diffraction data were integrated using MOSFLM (Battye et al., 2011; Leslie and Powell, 
2007) prior to scaling with Aimless (Evans, 2006; Evans, 2007), part of the CCP4 suite 
(Winn et al., 2011). Phases were calculated by molecular replacement using Phaser 
(McCoy et al., 2007) with the native AnCE structure, PDB code 2X8Y (Akif et al., 
2010), as the search model.  
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Following production of initial structural models by molecular replacement, iterative 
rounds of model building and refinement were performed using Coot (Emsley et al., 
2011) and REFMAC (Murshudov et al., 2011), respectively. 5 % of residues were 
separated for use as the Rfree set in cross-validation.  
 
A key part of the model building process was placing peptide residues into the 
difference density in the substrate-binding channel. Water molecules were added where 
Fo-Fc electron density peaks exceeded 3σ and potential hydrogen bonds could be made.  
 
Molprobity (Chen et al., 2010) was used to validate the quality of the final structures 
and LigPlot+ (Laskowski and Swindells, 2011) was used to study interactions between 
the peptides and the active site residues. RMSD calculations were performed using the 
molecular graphics program Pymol (The PyMOL Molecular Graphics System, Version 
1.7.4, Schrödinger, LLC), which was also used to create all of the figures. 
 
3.3 Results 
3.3.1 Co-crystallisation of AnCE with the BPPs 
Crystals of AnCE with both BPP9a and BPPn appeared in all drops (1.2-1.3 M sodium 
citrate, 0.1 M HEPES, pH 7.5) within 10 days of incubation at 21 oC. Figure 3.1 shows 
an example of a typical crystal mounted in a litholoop immediately prior to data 
collection. 
                    
Figure 3.1: A Crystal of AnCE with BPPn Mounted in a Litholoop Immediately 
Prior to Data Collection. The 100 µm scale bars provide an indication as to the size of 
the crystal. 
 
Crystallisation with BPP12b and BPPc proved to be much more challenging. Initial 
experiments using the standard conditions failed to yield any diffraction quality crystals 
and only precipitate was visible in the drops. Attempts to overcome this by decreasing 
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protein and peptide concentration, reducing incubation temperature and varying the ratio 
of peptide: protein, as outlined in section 3.2.1 all failed to yield crystals of any 
description.  
 
3.3.2 X-ray Diffraction Data Collection 
Diffraction data for AnCE with BPP9a and BPPn were collected at DLS on 21st 
November 2014 using beamline i03, as summarised in Table 3.3. A total of six datasets 
were collected for AnCE with BPP9a (AnCE_BPP9a_1-6) and three for AnCE with 
BPPn (AnCE_BPPn_1-3), an example diffraction image is shown in Figure 3.2. All 
datasets were initially processed in the space group h3 using MOSFLM and Aimless. 
The statistics obtained are summarised in Table 3.4. 
 
             !
           
 
Figure 3.2: X-ray Diffraction Pattern Produced by a Crystal of AnCE with BPP9a. 














AnCE_BPP9a_1 24th November 2014 i03 Pilatus3 6M 600 87-207 86.72-1.70 93.0 
AnCE_BPP9a_2 24th November 2014 i03 Pilatus3 6M 600 0-120 49.98-2.21 99.9 
AnCE_BPP9a_3 24th November 2014 i03 Pilatus3 6M 900 0-180 28.98-1.96 99.6 
AnCE_BPP9a_4 24th November 2014 i03 Pilatus3 6M 600 160-280 39.15-2.67 99.6 
AnCE_BPP9a_5 24th November 2014 i03 Pilatus3 6M 600 85-205 38.17-2.04 99.4 
AnCE_BPP9a_6 24th November 2014 i03 Pilatus3 6M 600 0-120 84.75-2.00 99.7 
AnCE_BPPn_1 24th November 2014 i03 Pilatus3 6M 600 0-120 84.64-1.96 99.6 
AnCE_BPPn_2 24th November 2014 i03 Pilatus3 6M 600 0-120 86.82-1.72 98.2 
AnCE_BPPn_3 24th November 2014 i03 Pilatus3 6M 1000 150-300 38.15-1.83 99.9 
 
 
Table 3.3: Summary of Data Collected for AnCE with the Peptides BPP9a and BPPn and Statistics following initial processing with MOSFLM and 
Aimless. The two “best” datasets that were used for further downstream processing are highlighted in yellow. !
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3.3.3 Data Processing and Structure Solution 
Data for AnCE_BPP9a_1 and AnCE_BPPn_2 were initially processed in the space 
group h3 using MOSFLM and Aimless. Phases were then calculated by molecular 
replacement performed using Phaser with the native AnCE structure, PDB code 2X8Y, 
as the search model. In both cases there was one molecule per asymmetric unit of the 
crystal. Full data processing statistics are included in Table 3.4. 
 
 AnCE_BPP9a AnCE_BPPn 
Beamline at DLS i03 i03 
Detector Pilatus3 6M Pilatus3 6M 
Wavelength (Å) 0.976 0.976 
Space group h3 h3 
Unit cell parameters 
a, b, c (Å) 
α, β, γ (o) 
 
173.40, 173.40, 102.60 
90.00, 90.00, 120.00 
 
173.01, 173.01, 101.85 
90.00, 90.00, 120.00 
Molecules per asymmetric unit 1 1 
Resolution range (Å) 86.72-1.70 86.82-1.72 
♯Rmerge (%) 6.0 (61.1) 23.4 (70.00) 
+Rpim (%) 5.1 (51.7) 23.4 (70.00) 
Mean I/σ(I) 7.8 (1.3) 2.4 (0.6) 
Completeness (%) 93.0 (96.5) 98.2 (94.3) 









Multiplicity 2.8 (2.7) 2.4 (2.1) 
Wilson B factor (Å2) 29.28 27.69 


















§Rcryst/♯♯Rfree (%) 17.54/19.68 17.26/19.73 
R.M.S deviation from ideal values 
Bond lengths (Å) 
















#!!!"#$" = !Σ!!"Σ! !!! ℎ!" − ! ! ℎ!" /Σ!!"Σ!!!(ℎ!"), where Ii(hkl) is the intensity of 
ith measurement and <I(hkl)> is the average of symmetry-related observations of a 
unique reflection. 
+!!"# = !Σ!!" !!!! Σ!!!! !! ℎ!" − ! ℎ!" /Σ!!"Σ!!!(ℎ!") 
§!!"#$% = !Σ! !!!!! /Σ!!!, where Fo and Fc are observed and calculated structure factor 
amplitudes of reflection h, respectively. 
##Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections. 
 
Table 3.4: Data Processing Statistics for AnCE with BPP9a and BPPn. Outer shell 
values are shown in parentheses.  
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The structures of the resulting models of AnCE bound to each of the two peptides are 
identical to that of the native AnCE structure, as illustrated by the superposition in 
Figure 3.3. The structures are predominantly helical and form an ellipsoid shape. 
Electron density is visible for N-linked glycan chains at Asn53, Asn196 and Asn311, the 
same three locations as in the original AnCE structure.  
 
The active site, marked by the location of the zinc ion, is located at the centre of the 
catalytic channel, which extends almost the entire length of the molecule and is capped 
by a “lid” formed by helices α1, α2 and α3. Following rigid body refinement clear 
electron density was visible at the centre of the active site channel in both models, and 
this was deemed to be due to the binding of BPP9a and BPPn, as appropriate. 
 
The high degree of overall similarity between the native AnCE structure and the 
structures with BPP9a and BPPn (RMSD values of 0.138 and 0.142, respectively) 
indicates that there is no significant movement of secondary structure elements upon 
peptide binding. Careful comparison of the models with the native structure also shows 
that there is no movement of active site residues induced by peptide binding. The details 
of the interactions made by the peptides with the enzyme are outlined in the following 
sections. 
                                    
Figure 3.3: Superposition of the Structure of AnCE with BPP9a (cyan) and BPPn 
(magenta) and the Native AnCE Structure (PDB code 2X8Y) (green). All key 
structural features are conserved, including N-linked glycosylation at Asn53, Asn196 
and Asn311, which is shown as green sticks. The location of the active site at the centre 
of the substrate- binding channel is indicated by the zinc ion, shown as a grey sphere. 
The channel is capped by helices α1, α2 and α3, which form the “N-terminal lid”, 
limiting access to the active site. 
2+ 
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3.3.4 Description of BPP9a Binding to the AnCE Active Site 
Following molecular replacement and initial rounds of refinement, a significant amount 
of difference density was visible in the AnCE active site region. As illustrated in Figure 
3.4, this density extends in both directions away from the catalytic zinc ion and appears 
to be long enough to accommodate a six-residue peptide backbone. Based on this, the 
six C-terminal residues of BPP9a were modelled such that the arginine, proline, 
glutamine, isoleucine, proline and proline residues occupied the S4, S3, S2, S1, S1’ and 
S2’ pockets respectively. 
 
Figure 3.4 illustrates that whilst the side chains of the five C-terminal residues fit the 
difference density very well, the side chain of the final residue, the P4 arginine is not 
accommodated by the difference density. Removing this residue completely resulted in a 
significant amount of difference density where the main chain of the arginine is located. 
This is a clear indication that this residue is indeed present in the structure and so should 
be included. It is likely that the arginine is present but that the side chain is not visible 
because it is highly mobile. No further density was visible beyond the S4 region of the 
active site hence it was not possible to add any further residues to the N-terminus of 
BPP9a.  
 
As outlined in Table 3.5, BPP9a bound at this position forms a number of interactions 
with the AnCE active site. Beginning at the C-terminus of the peptide, the oxygen atoms 
belonging to the carboxyl group of the P2’ proline residue form hydrogen bond 
interactions with the side chains of Gln265, Lys495 and Tyr504. These interactions are a 
common feature of peptide binding to the active site of angiotensin converting enzymes 
and act as an anchor to hold the C-terminus of the peptide in place. 
 
The P1’ proline residue also participates in conserved peptide binding interactions with 
the active site; the proline carbonyl oxygen atom interacts with the side chains of His337 
and His497. 
 
Moving slightly further along the peptide chain, the carbonyl oxygen atom of the P1 
isoleucine forms a hydrogen bond interaction with the hydroxyl group of Tyr507 and 
also completes the co-ordination of the catalytic zinc ion.  
 
The N-terminal portion of the peptide makes fewer interactions with the active site 
residues. The main point of contact in this region is between the peptide backbone at the 
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P2 glutamine and the protein backbone at Ala340. This is another interaction that is 
commonly found in peptide binding to ACE homologues (Akif et al., 2012). 
 
Beyond this, the side chain of the last peptide residue for which electron density is 
visible, the arginine at P4, appears to interact with the side chain of Asp501 and the 
protein backbone at Ala500. However, due to the poor difference density for the 
arginine side chain it was very difficult to model accurately, hence it is not clear how 
significant these interactions may actually be.  A complete list of interactions occurring 
between BPP9a and the AnCE catalytic site is presented in Table 3.5 and summarised in 
Figure 3.5. 
                   
 
Figure 3.4: Fo-Fc Map for BPP9a Binding to AnCE. Fo-Fc map is shown as a grey 
mesh contoured at 3σ and the peptide BPP9a as green sticks. Density for the peptide 
backbone and side chains of P2’ to P3 is unambiguous. There is little density visible for 
the P4 Arg side chain, most likely due to the highly flexible nature of the side chain. 
 
BPP9a atom Interacting atom Distance (Å) 
P2’ Pro OXT Water 2.84 
P2’ Pro O Lys495 NZ 2.72 
P2’ Pro O Gln265 NE2 3.07 
P2’ Pro O Tyr504 OH 2.60 
P1’ Pro O His337 NE2 2.94 
P1’ Pro O His497 NE2 2.95 
P1 Ile O Tyr507 OH 2.68 
P1 Ile O Zn2+ 2.53 
P2 Gln O Ala340 N 2.79 
P2 Gln OE1 Water 2.85 
P2 Gln N Ala340 O 2.95 
P4 Arg NH1 Water 2.69 
P4 Arg NH1 Asp501 O 2.80 
P4 Arg NH1 Ala500 O 3.06 
P4 Arg NH2 Ala500 O 3.01 





      
                  
Figure 3.5: BPP9a Binding to AnCE. (a) Visualisation of the interactions between 
BPP9a and the AnCE active site residues. Peptide residues are shown as green sticks and 
labelled in green, AnCE residues are shown as cyan sticks with black labels. The active 
site zinc ion is shown as a grey sphere and key water molecules as orange spheres. (b) 
Schematic representation of the interactions shown in (a), here water molecules are 





























3.3.5 Description of BPPn Binding to the AnCE Active Site 
The difference density present at the active site of the structure of AnCE with BPPn is 
far less extensive than that seen for AnCE with BPP9a. The density is located close to 
the catalytic zinc ion and whilst it appears to occupy a region around the S1’ and S2’ 
pockets it does not extend very far along the catalytic channel at all. 
 
Based on these observations, the C-terminal tripeptide of BPPn was modelled into the 
active site such that the isoleucine, proline and proline residues adopted the P1, P1’ and 
P2’ positions, respectively. As illustrated in Figure 3.6 the tripeptide is well 
accommodated by the density, indicating that it has been correctly positioned. 
 
Following placement of the tripeptide there was some residual density remaining around 
the S1 and S2 subsites, Figure 3.6. Attempts were made to place an additional lysine 
residue at the N-terminus of the peptide, however there was insufficient density to 
justify this. Removing the flexible side chain of the lysine residue and reducing the 
occupancy of the peptide backbone to 0.5 both failed to provide a solution. Ultimately, 
water molecules were placed in the density. 
 
The C-terminal tripeptide of BPPn adopts a very similar position in the AnCE active site 
to the equivalent residues in the BPP9a peptide. The two C-terminal proline residues 
form identical interactions with the S2’ and S1’ pockets of the enzyme. This includes 
interaction of the C-terminal carboxyl group with Lys495 and Tyr504 and of the P1’ 
proline carbonyl oxygen with the side chains of His337 and His497. BPP9a and BPPn 
both interact with the catalytic zinc ion via the carbonyl oxygen of their P1 isoleucine 
residue. 
 
The interactions formed by the P1 residues in the two structures vary somewhat and this 
is a reflection of the slightly different positions adopted by the peptides at this point. The 
P1 isoleucine in BPPn is considerably closer to the zinc ion and is able to make an 
additional interaction via its amide nitrogen. This change in position also means that it 
makes additional contacts with His371 and Glu368 that are not seen in the BPP9a 
structure. A complete list of interactions formed by BPPn with the AnCE active site is 
included in Table 3.6 and illustrated in Figure 3.7. 
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Figure 3.6: Fo-Fc Map for BPPn Binding to AnCE. Fo-Fc map is shown as a grey 
mesh contoured at 3σ. The three C-terminal residues of BPPn; isoleucine, proline and 
proline are shown as green sticks and are accommodated well by the density. Some 
residual density remains at the N-terminus of the peptide, however this was not 





BPPn atom Interacting atom Distance (Å) 
P2’ Pro OXT Water 2.77 
P2’ Pro O Tyr504 OH 2.65 
P2’ Pro O Lys495 NZ 2.69 
P1’ Pro O His 497 NE2 3.12 
P1’ Pro O His337 NE2 2.82 
P1 Ile O Tyr507 OH 2.59 
P1 Ile O His367 NE2 3.20 
P1 Ile O Zn2+ 2.46 
P1 Ile N Zn2+ 2.30 
P1 Ile N His371 NE2 3.23 
P1 Ile N Glu368 OE2 2.82 
P1 Ile N Water 2.60 
 
 



















Figure 3.7: Binding of BPPn to the AnCE Active Site. (a) and (b) display the key 
interactions occurring  between peptide and protein residues. BPPn residues are shown 
as green sticks and labelled accordingly. AnCE residues are shown as magenta sticks in 
(a) and brown sticks in (b) and labelled in black. The catalytic zinc ion is displayed as a 
grey sphere and water molecules involved in binding are shown as orange spheres in (a) 


























3.4.1 The Structure of AnCE with BPP9a 
It is clear by studying the difference density in Figure 3.4 that a significant portion of the 
peptide BPP9a is present in the AnCE active site in this structure. The five C-terminal 
residues (PQIPP) are accommodated comfortably by the density and are observed to 
form a number of interactions with active site residues. This includes the conserved 
interactions of the C-terminus of the peptide with Gln265, Lys495 and Tyr504 that acts 
as an anchor to hold the peptide in place. 
 
The difference density for the sixth residue, the arginine at P4 is not quite so 
unambiguous. Whilst there is clear density to accommodate the peptide backbone, there 
is very little at all for the side chain. Removing this residue completely resulted in a 
significant amount of difference density remaining following refinement. This indicates 
that this residue is definitely present and that the peptide is not being cleaved at this 
position.  
 
The absence of observable density for the side chain is almost certainly due to the 
flexible nature of the long arginine side chain. In the absence of strong interactions 
holding it in a specific conformation, it is free to sample all of the space in the rather 
large S4 cavity. This means that it will be present in multiple conformations throughout 
the crystal and hence not visible in the final structure.  
 
The N-terminal portion of the BPP9a peptide may also not be visible for a similar 
reason. As illustrated in Figure 3.5, the majority of interactions between BPP9a and the 
active site involve the C-terminal portion of the peptide and are concentrated in the S1’ 
and S2’ pockets. In fact, beyond the isoleucine at the P1 position, interactions are limited 
to two hydrogen bonds between the P2 glutamine and Ala340 and a possible stacking 
interaction between P3 proline and Trp341. 
 
After this point, the substrate-binding channel opens out quite significantly. It is 
therefore likely that the remaining peptide residues, not constrained by strong 
interactions with the active site residues, are free to exist in multiple different 
conformations in this space. Hence, like the side chain of the P4 arginine, they are not 
visible in the crystal structure, even though they are still present.  
 
A second possible explanation for the absence of the N-terminal residues also exists, 
whereby AnCE has acted as an aminopeptidase and proteolytically removed these 
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residues. Although angiotensin converting enzymes normally function as dipeptidyl 
carboxypeptidases to remove the C-terminal dipeptide from their substrates, as discussed 
in section 1.6.4, ACE has been reported to act as an aminopeptidase towards certain 
substrates, such as GnRH (Jaspard et al., 1993; Skidgel et al., 1985).  
 
This aminopeptidase activity normally occurs when the C-terminus of the protein is 
“protected” from hydrolysis. The presence of proline residues at the C-terminus of 
BPP9a means that that is the case here, as the unique nature of the proline side chain 
means that there is a secondary rather than a primary amine group, protecting the scissile 
bond from cleavage.  
 
Although it is not impossible that the results observed here are as a consequence of ACE 
acting as an aminopeptidase towards BPP9a, it is quite unlikely. This is because the final 
residue that is visible at the N-terminus of the peptide chain, arginine, is flanked on 
either side by proline residues at the P3 and P5 positions. In the same way that the C-
terminal proline residues make the BPPs resistant to the carboxypeptidase actions of 
ACE, surely a proline residue at the P5 position would protect the peptide bond between 
positions P4 and P5 residues from any aminopeptidase activity.  
 
3.4.1.1 Comparison of the Structure of AnCE with the Peptides BPP9a and BPPb 
The structure of AnCE in complex with the related peptide BPPb has previously been 
determined (Akif et al., 2012). The sequence of BPPb is very similar to that of BPP9a, 
with small variations at the P2 and P6 positions where glutamine and tryptophan in 
BPP9a are replaced by lysine and proline in BPPb, respectively (Table 3.2). 
 
Interestingly, both peptides bind to the AnCE active site in the same conformation and 
form identical interactions with the protein residues. This includes at the P2 position, 
where the main chain atoms of lysine and glutamine from the two peptides both interact 
with the protein backbone at Ala340, Figure 3.8. 
 
In both structures, only the six C-terminal residues of the peptide are visible (RPKIPP in 
BPPb and RPQIPP in BPP9a). The fact that this is also the case in the BPPb structure 
supports the hypothesis that the residues are not visible because they are disordered, 
rather than as a result of peptide bond cleavage by AnCE. This is because the additional 
proline residue at the P6 position of BPPb, replacing tryptophan in BPP9a, would surely 
provide further protection to the N-terminus against aminopeptidase activity. 
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Figure 3.8: Binding of BPP9a and BPPb to AnCE. The peptides BPP9a and BPPb are 
shown as green and coral sticks, respectively and the residues at each position are 
annotated in the corresponding colours. Both peptides adopt the same conformation on 
binding to AnCE and hence form identical interactions with active site residues. This 
includes at the P2 position, where glutamine in BPP9a is substituted for lysine in BPPb. 
Here the only contact between the peptides and the protein is between the peptide 
backbone and the main chain of Ala340. The Ala340 residue is included as cyan sticks 
to illustrate this. 
 
3.4.1.2 Structural Insights into Domain Specific Inhibition by BPPs  
The structure of human tACE (equivalent to the C-domain of sACE) with BPPb has 
previously been reported (Masuyer et al., 2012) and is the only structure of an ACE 
homologue and a bradykinin potentiating peptide in which the entire peptide is visible. 
Peptide binding in this instance is accompanied by some significant structural changes: 
the zinc ion is absent and helices α1 and α2 of the N-terminal lid and the proximal loop 
region located at the entrance to the substrate binding channel have moved to 
accommodate the N-terminal residues of the peptide.  
 
By comparing this structure to the structures of AnCE with BPP9a and BPPb (Akif et 
al., 2012) it is possible to understand more about the importance of specific residues that 
are involved in active site interactions. Consequently, this provides some explanation as 
to why the full-length peptide is visible in the tACE structure but not in the AnCE 
structure. Furthermore, by comparing the interactions formed by these peptides in the 
AnCE and tACE active sites and considering the conservation of these residues in the N-
domain, it is possible to suggest which residues may be involved in the domain 
selectivity of these peptides.  
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3.4.1.2.1 The Importance of the P2 Peptide Residue in Domain Selective Inhibition 
Both BPPb and BPP9a have been identified as C-domain selective inhibitors and the P2 
position has been implicated in this (Cotton et al., 2002). The structures of AnCE with 
BPPb and BPP9a indicate that the interaction with the active site formed by the lysine 
and glutamine residues at this position, respectively, is limited to two hydrogen bonds 
between the peptide main chain and Ala340. Thus, this interaction is largely sequence 
independent and should be conserved in both domains of sACE. 
 
The lysine at P2 of BPPb forms an additional salt bridge with tACE active site residue 
Glu403. Glu403 is not conserved in AnCE and is instead replaced by Thr387, which 
would be unable to replicate this interaction. Comparison with the structure of the 
human N-domain indicates that Arg381 replaces Glu403, which would also not be able 
to replicate this interaction, Figure 3.9. This explains why both BPP9a and BPPb have a 
higher affinity for the C-domain of sACE compared to the N-domain and confirms the 
importance of the P2 residue.  
 
In AnCE, the side chain of residue Thr387 is relatively small, and whilst unable to form 
a salt bridge with the P2 lysine of BPPb like that seen with Glu403 in tACE, it does not 
appear to obstruct peptide binding in any way (Figure 3.9).  
 
Conversely, the large, positively charge side chain of Arg381 in the N-domain is likely 
to clash with the P2 lysine of BPPb, decreasing the affinity of the peptide for the N-
domain active site. The presence of the smaller glutamine side chain at P2 in BPP9a is 
unlikely to pose such a problem, which would explain why BPP9a is a slightly better 
inhibitor of the N-domain than BPPb. These interactions are illustrated in Figure 3.9. 
 
Interestingly, bradykinin, a peptide substrate that is hydrolysed with equal efficiency by 
both the N- and C-domains of human sACE (Georgiadis et al., 2003) has a serine 
residue at the P2 position. The small serine side chain would not clash with Arg381 in 
the N-domain whilst also not forming a salt bridge with Glu403 in the C-domain. This 
may help to explain the observed absence of domain selectivity. Angiotensin I, which is 
hydrolysed more efficiently by the C-domain than the N-domain, has a proline residue at 
the P2 position. The P2 proline would not be expected to interact with Glu403, but may 
clash with the long, polar side chain of Arg381, and this may contribute to the domain 






Figure 3.9: Key Features of BPP Binding to the N- and C-domains of sACE and to 
AnCE. The BPPb peptide from the structure with tACE is shown as orange sticks with 
the residues labelled in black. The P2 lysine forms a salt bridge with tACE Glu403 
(purple sticks) that is not replicated in AnCE where Glu403 is replaced by Thr387 (cyan 
sticks). Arg381 at this position in the N-domain (grey sticks) is likely to clash with the 
positive lysine side chain, explaining why BPPb is a poor inhibitor of the N-domain. In 
BPP9a the P2 lysine is replaced by glutamine, shown as green sticks. The smaller 
glutamine side chain should reduce the clash with Arg381 in the N-domain, hence why 
BPP9a is a slightly better inhibitor of the N-domain than BPPb. The P6 proline residue in 
BPPb appears to form a stacking interaction with Trp59 (purple sticks) in the C-domain, 
helping to stabilise the N-terminal portion of the peptide. This interaction is not 
conserved in AnCE and the N-domain, where Trp59 is replaced by Thr40 (blue sticks) 
and Leu32 (grey sticks), respectively. The absence of this stabilising interaction may 
explain why the N-terminal portion of BPP9a is not visible in the structure with AnCE 
(Figure 3.4). The zinc ion is shown as a grey sphere as a point of reference. 
 
3.4.1.2.2 The Importance of the P6 Peptide Residue in Domain Selective Inhibition 
The only structure of an ACE homologue with a BPP in which the N-terminal portion of 
the peptide is visible is that of tACE with BPPb. Studying the N-terminal portion of 
BPPb, there are surprisingly few interactions with tACE active site residues. Those that 
are present are all water-mediated and only involve the protein backbone, thus should be 
conserved in AnCE, and indeed in the N-domain.  
 
The only exception to this is an interaction between the hydroxyl group of the Tyr360 
side chain and the carbonyl oxygen of the proline at the P5 position. This tyrosine 
residue is conserved in both AnCE (Tyr344) and the N-domain (Tyr338) thus this 
interaction should be conserved and so does not explain the observed differences in 
peptide binding, nor the selective inhibition of the C-domain. 
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The structure presented by Masuyer et al., indicates that a stacking interaction exists 
between tACE Trp59 and the proline residue at P6 of BPPb. This tryptophan residue, and 
consequently this interaction, is conserved neither in AnCE nor in the N-domain and is 
replaced by Thr40 and Leu32, respectively, Figure 3.9. 
 
All of the BPPs have either a tryptophan (BPP9a and BPPn) or a proline (BPPb, BPP12b 
and BPPc) residue at the P6 position, indicating that this may be an important stabilising 
interaction, helping to keep the peptide bound in a single conformation. The absence of 
an equivalent interaction between AnCE and BPP9a and BPPb may explain why the N-
termini of these peptides is not visible in the crystal structures. 
 
It is possible that the absence of this interaction between BPPs and the N-domain may 
contribute to the C-domain selectivity observed for BPP9a and BPPb. However a proline 
residue at this position is conserved in BPPc, which is an equally effective inhibitor of 
both domains. 
 
Perhaps more relevant is the observation that BPP9a has a tryptophan residue at P6. 
BPP9a is an exceptionally potent inhibitor of the C-domain (Table 3.1) and the 
increased strength of the interaction between the two tryptophan residues compared to a 
tryptophan and a proline may well be a contributory factor. 
 
3.4.2 The Structure of AnCE with BPPn 
Analysis of the difference density shown in Figure 3.6 indicates that the C-terminal 
tripeptide of BPPn can confidently be placed in the active site such that the S1, S1’ and 
S2’ pockets are occupied by the isoleucine, proline and proline residues respectively. 
This is in keeping with the common mode of peptide binding seen in previous ACE 
structures (Masuyer et al., 2012).  
 
In contrast to the structure of AnCE with BPP9a, it was not possible to place any further 
residues at the N-terminus of the peptide. There are two possible reasons for this; the 
peptide is being hydrolysed or the N-terminal portion is too flexible to see in the crystal 
structure. 
 
As discussed in relation to the structure of AnCE with BPP9a (section 3.4.1), it is 
possible that the presence of only the C-terminal tripeptide is due to hydrolysis of BPPn 
by AnCE. In this case this would most likely be due to AnCE displaying C-terminal 
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tripeptidase activity. This is theoretically possible, as ACE has been reported to cleave 
the C-terminal tripeptide from substrates when the C-terminal dipeptide is protected. 
The primary example of this is seen with substance P (Skidgel et al., 1985).  
 
In the case of BPPn, the C-terminal proline residues should prevent AnCE acting as a 
dipeptidyl carboxypeptidase, hence, it is feasible that it has instead cleaved the peptide 
bond between the P1 and P2 residues. This would have produced two peptide fragments; 
PCA-LWPRRK and IPP, the latter of which has remained bound to the active site.  
 
Analysis of the difference density in the active site suggests that this is unlikely to have 
occurred. There is some remaining density following the N-terminal isoleucine residue 
(Figure 3.6). Although, as detailed in section 3.3.5, this density is not sufficient to 
accommodate an additional peptide residue, it does indicate that there is “something” 
there. Therefore, the most likely explanation for the results observed is that the 
remainder of the peptide is present, but due to a lack of interactions with the active site 
channel, it is highly mobile and hence not visible in the structure. 
 
This is the same effect that is observed in the structures of AnCE with BPPb and BPP9a, 
albeit occurring with much more of the peptide. This indicates that BPPn is unable to 
replicate some of the interactions formed by BPP9a and BPPb with the active site that 
are important in stabilising the peptide. 
 
3.4.2.1 The Importance of the P3 Proline Residue in ACE Inhibition by BPPs 
As indicated in Table 3.2, the sequence of BPPn differs from that of BPPb and BPP9a at 
the P3 position. The proline residue that is conserved in BPPs was replaced by an 
arginine in BPPn. The aim of doing this was to investigate the role of this position in 
inhibitor binding. The fact that the P3 proline is conserved in all of the BPPs indicates 
that it may be an important inhibitory feature; so mutating it to arginine, which has a 
large positively charged side chain, should help to clarify whether this is the case. 
 
The fact that only the C-terminal tripeptide of BPPn is visible in the AnCE active site 
indicates that the proline residue at the P3 position is indeed an important conserved 
feature of BPPs. Considering the structure of AnCE with BPPb and BPP9a, this residue 
potentially forms a stacking interaction with Trp341 that would be conserved in both the 
N- and C-domains with Trp335 and Trp357, respectively (Figure 3.10). The large polar 
side chain of arginine would be unable to replicate this, and the loss of this stabilising 
interaction appears to result in the N-terminal portion of the peptide being disordered. 
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Interestingly, an aromatic residue is conserved at the P3 position in two of the major 
ACE substrates: histidine in angiotensin I and phenylalanine in bradykinin. 
 
              
 
Figure 3.10: The Importance of the P3 BPP Proline Residue. The six C-terminal 
residues of BPP9a from the structure with AnCE are shown as green sticks and the 
active site zinc ion as a grey sphere. Trp341 in AnCE, cyan sticks, forms a stacking 
interaction with the proline at position P3. Structural and sequence analysis indicates that 
this would be conserved in the N-domain with Trp335, grey sticks, and in the C-domain 
with Trp341, purple sticks. 
 
 
This is only a hypothesis, based on the structural data that are available. The next step in 
this work would be to obtain kinetic data to investigate the effect that this mutation has 
on the potency of BPPn as an ACE inhibitor. Based on the structural information 
available, it is likely that it would be a very poor inhibitor of the N-domain due to the P3 
substitution being compound by the P2 lysine clashing with Arg381, and a moderate to 
weak inhibitor of the C-domain and AnCE. 
 
An interesting future experiment would also be to replace the P3 proline residue with a 
larger aromatic side chain, for example tryptophan to see if this increases the potency of 
the peptide as an inhibitor of ACE. 
 
3.4.3 Failure to Crystallise AnCE with BPPc and BPP12b 
Unfortunately, no crystals were obtained for AnCE in complex with BPPb and BPPc. 
This is very unusual; the crystallisation condition used here typically yields diffraction 
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quality crystals of AnCE within only a few days and has previously been used to 
crystallise AnCE with a wide range of inhibitors (Akif et al., 2010).  
 
The fact that crystals could not be obtained using this condition for AnCE with BPP12b 
and BPPc indicates that binding of these peptides may be causing some significant 
structural rearrangements. This in turn may affect crystal contacts between molecules, 
altering the conditions under which the protein will crystallise.  
 
This hypothesis is supported by the crystal structure of tACE with BPPb reported in 
2012 (Masuyer et al., 2012). Here, as illustrated in Figure 3.11, binding of the peptide 
has caused significant movement of secondary structure elements in order that the full 
peptide may be accommodated in the substrate-binding channel.  
 
                      
 
Figure 3.11: Structural Changes Observed on BPPb Binding to tACE, as Reported 
by Masuyer et al., 2012 (PDB code 4AA2).  Cartoon representation of the structure of 
tACE bound to BPPb (purple) is superposed on the native tACE structure (green). BPPb 
residues occupying the substrate-binding channel are shown as cyan sticks. Clear 
movement of helices α1 and α2, components of the N-terminal lid, and the proximal 
loop region occur on peptide binding, as indicated by the red arrows.   
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Examination of the sequences of BPP12b and BPPc compared to the other BPPs (Table 
3.2) indicates that both of these peptides are very proline rich. In addition to the 
conserved proline residues at positions P2’, P1’, P3 and P5, BPPc has two further proline 
residues at P2 and P6 and BPP12b at P6 and P7.  
 
The unique cyclic nature of the proline side chain means that free rotation around the 
peptide bond is greatly restricted. The abundance of proline residues in BPPc and 
BPP12b is therefore likely to make these peptides very rigid in nature and it is quite 
possible that substantial conformational changes may be required to accommodate these 
peptides in the catalytic channel, explaining why complexes of AnCE with BPPc and 
BPP12b have not been observed to crystallise under “standard” conditions.  
 
Further attempts have been made to crystallise AnCE with BPPc and BPP12b and 
recently, a second condition in which AnCE forms diffraction quality crystals has been 
identified. This work is outlined in Chapter 6. 
 
3.5 Conclusions and Future Directions 
The properties of bradykinin potentiating peptides isolated from the venom of B. 
jararaca as potent ACE inhibitors are well known. Indeed, these peptides formed the 
basis of the development of the very first ACE inhibitors (Cushman and Ondetti, 1999). 
 
More recently, two of these peptides, BPP9a and BPPb, have been identified as selective 
inhibitors of the C-domain of sACE, and the residue at the P2 position has been 
implicated in this (Cotton et al., 2002).  
 
Here, the structure of the D. melanogaster ACE homologue, AnCE has been reported 
with BPP9a. Comparing this structure to the structures of tACE and AnCE with BPPb 
has provided further evidence of the importance of this position in C-domain selectivity.  
 
The N-terminal residues of BPP9a were not visible in the structure with AnCE and this 
was thought to be due to high flexibility resulting from a lack of interactions with the 
active site. Comparison with the structure of tACE with BPPb highlighted an interaction 
between proline at P6 and Trp59, which is conserved neither in AnCE nor in the N-
domain. This suggests that the P6 peptide position may also have an important role in 
ACE inhibition and domain selectivity, the first time that this position has been 
implicated in this way.  
 
! 83 
A new peptide, BPPn, was designed in order to investigate the role of the conserved 
proline at position P3 in the BPPs. The structure of AnCE with BPPn only showed clear 
density for the three C-terminal residues, thus indicating that interactions of the P3 
proline with the ACE active site might be important for peptide binding and inhibition. 
A conserved tryptophan residue has been identified that is likely to be responsible for 
this.  
 
Having established that peptide residues P2, P3 and P6 might be involved in peptide 
binding and inhibition, future work should include inhibition assays to study the effects 
of mutating these on inhibition of AnCE and each domain of sACE. Similarly, it would 
be interesting to extend this work to look at the effects of mutating other peptide 
residues to investigate their roles in inhibition.  
 
This could include studying the peptides BPP12b and BPPc, which are both particularly 
proline rich. Initial attempts to crystallise AnCE with BPP12b and BPPc have proved 
unsuccessful. This could be as the result of structural rearrangements occurring on 
peptide binding, similar to those observed for tACE with BPPb (Masuyer et al., 2012). 
In an attempt to overcome this, experiments have been initiated to try and find a new 
condition in which AnCE crystals can be obtained. This is detailed in Chapter 6. 
 
In conclusion, the work presented here provides more information about the structural 
basis of ACE inhibition by bradykinin potentiating peptides from B. jararaca that could 
be used in work towards the development of new inhibitors. It is also an illustration of 





















Chapter 4: Crystal Structures of AnCE in 

















The requirement for a new generation of ACE inhibitors that selectively target only one 
of the two domains of the enzyme has been discussed in some detail in sections 1.5.1 
and 3.1.1. 
 
The design of the original ACE inhibitors was greatly influenced by studying the natural 
inhibitory peptides from the venom of the pit viper B. jararaca. In the same way, 
analysis of the structural basis of domain inhibition by these peptides has now been able 
to provide important information about ways in which subtle differences in the active 
site pockets of the N- and C-domains could be exploited to develop domain specific 
inhibitors (Chapter 3). 
 
Haemorphins are a group of naturally occurring peptides that are produced by the 
enzymatic cleavage of the β-chain of haemoglobin (Brantl et al., 1986). Originally 
isolated from bovine blood, they are also present in humans and some have been shown 
to function as ACE inhibitors (Lantz et al., 1991). The fact that they are derived from 
haemoglobin suggests that they may have a role in local regulation of ACE activity in 
vivo as part of tissue specific RAAS (Fruitier-Arnaudin et al., 2002). 
 
4.1.1 Spinorphin 
Spinorphin was the first haemorphin shown to have ACE inhibitory properties. It is a 
heptapeptide with the sequence LVVYPWT, corresponding to residues 32-38 of the β-
chain of human haemoglobin. Spinorphin was originally isolated in 1993 from bovine 
spinal cord as an inhibitor of enkephalin degrading enzymes, but it is also found in 
human cerebrospinal fluid (CSF).  During the course of this initial work spinorphin was 
identified as an inhibitor of ACE, with an IC50 of 2.7 µM reported (Nishimura and 
Hazato, 1993). 
 
In spite of the lack of sequence identity between spinorphin and the BPPs from B. 
jararaca, the reported IC50 values are of the same order of magnitude. It would therefore 
be interesting to study ACE inhibition by spinorphin from a structural perspective, to try 
and learn more about the mechanism of inhibition and whether this could be applied to 
the design of new, more effective ACE inhibitors. 
 
4.1.2 Tynorphin 
A second peptide, tynorphin, was developed in 2000. Tynorphin is a truncated derivative 
of spinorphin consisting of the five central residues: VVYPW. Tynorphin was designed 
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in an attempt to develop a more potent inhibitor of one of the other enzymes inhibited by 
spinorphin, DPPIII (dipeptidyl peptidase III). Whilst removal of the N-terminal leucine 
and C-terminal threonine residues did make tynorphin a more potent inhibitor of DPPIII, 
tynorphin has actually been shown to be a much weaker inhibitor of ACE than 
spinorphin, thus indicating that these terminal residues are in some way important for 
ACE inhibition (Yamamoto et al., 2000). Structural studies on ACE inhibition by 
tynorphin could be used to help to understand this, thereby providing more information 
about essential features of ACE inhibitors. 
 
4.1.3 Aims 
The aim of this work is to use the D. melanogaster ACE homologue AnCE as a model 
to study the structural basis of ACE inhibition by spinorphin and tynorphin. In particular 
to understand the importance of the terminal residues in spinorphin that appear to have 
such a profound effect on its inhibitory properties. The long-term aim would be to use 
this information to aid the design of a new generation of ACE inhibitors.  
 
4.2 Methods 
4.2.1 Protein Expression, Purification and Crystallisation 
Recombinant AnCE was expressed by P. pastoris and purified using a two step protocol 
involving hydrophobic interaction chromatography followed by size exclusion 
chromatography as detailed in section 2.7. 
 
Purified AnCE was co-crystallised with spinorphin or tynorphin (Tocris Bioscience, 
Bristol, UK) using the hanging drop vapour diffusion technique following the general 
protocol and conditions for AnCE, outlined in section 2.7.4.  
 
Immediately prior to crystallisation 17.5 mg ml-1 AnCE was incubated with 10 mM of 
spinorphin or tynorphin in a 1:4 peptide:protein ratio and incubated on ice for 
approximately 30 minutes. Hanging drops were then prepared containing 1 µl of the 
protein and peptide mixture and 1 µl of the reservoir solution. Drops were suspended 
over 500 µl of reservoir solution and incubated at 21 oC. 
 
4.2.2 X-ray Diffraction Data Collection 
Previous diffraction experiments with AnCE have shown that the relatively high 
concentration of sodium citrate (1.2-1.3 M) used in the crystallisation solution is 
sufficient for cryo-protection (Akif et al., 2010). For this reason no additional cryo-
protectant solutions were added to the drop prior to crystal harvesting. Instead 1 µl of the 
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reservoir solution was added to maximise sodium citrate concentration and to prevent 
the drop from drying out. 
 
Crystals were mounted directly into litholoops (Molecular Dimensions Ltd., 
Newmarket, UK) and flash frozen in liquid nitrogen for transportation to the 
synchrotron. All data were collected at DLS. 
 
Four separate data collection experiments were performed using crystals grown under 
identical conditions. In all cases samples were mounted using the sample changer robots 
on the beamlines and diffraction data were collected at 100 K. 
 
The first data were collected on 30th June 2012 using beamline i04 and an ADSC CCD 
Q315 detector. A single dataset for AnCE with tynorphin was collected. The 
crystallisation and data collection for this sample were both performed by previous 
group member Dr Geoffrey Masuyer. 
 
The remaining data were collected on 24th May 2015 on beamline i03, 2nd July 2015 on 
beamline i04 and 25th July 2015 on beamline i02. These datasets were recorded using 
Pilatus3 6M, Pilatus 6M-F and Pilatus 6M detectors respectively. 
 
4.2.3 Data Processing and Structure Solution 
All datasets collected were initially processed using the xia2 pipeline at DLS (Winter, 
2010). The “best” datasets from each visit were then selected based primarily on 
resolution and completeness. For these datasets integration was performed using 
MOSFLM (Battye et al., 2011; Leslie and Powell, 2007) and scaling using Aimless 
(Evans, 2006; Evans, 2007). Initial phases were calculated by molecular replacement 
with Phaser (McCoy et al., 2007) using the native AnCE structure, PDB code 2X8Y 
(Akif et al., 2010), as a search model. 
 
Iterative rounds of model building and refinement were performed using Coot (Emsley 
et al., 2011) and REFMAC (Murshudov et al., 2011), respectively with 5 % of residues 
separated for use as the Rfree set in cross-validation. This process included manually 
building spinorphin and tynorphin residues into difference density in the active site. 
Water molecules were added where Fo-Fc electron density peaks exceeded 3σ and 
potential hydrogen bonds could be made. The quality of the final structure was validated 
using MolProbity (Chen et al., 2010). LigPlot+ (Laskowski and Swindells, 2011) was 
used to study interactions between the inhibitors and the active site. All figures were 
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prepared using Pymol (The PyMOL Molecular Graphics System, Version 1.7.4, 
Schrödinger, LLC), which was also used to perform RMSD calculations. 
 
4.3 Results 
4.3.1 Co-crystallisation of AnCE with Spinorphin and Tynorphin 
Crystals appeared in all drops (1.2-1.3 M sodium citrate, 0.1 M HEPES, pH 7.5) within 
7 days of incubation at 21 oC. An image of one of these crystals mounted in a litholoop 
immediately prior to data collection is shown in Figure 4.1. 
 
                        
 
Figure 4.1: A Crystal of AnCE with Spinorphin Mounted in a Litholoop 
Immediately Prior to Data Collection. The size of the crystal is indicated by the 100 
µm scales bars in the bottom right of the image. 
 
4.3.2 X-ray Diffraction Data Collection 
X-ray diffraction data for the two complexes were collected on four visits to DLS. Four 
datasets were collected for AnCE in complex with tynorphin: AnCE_Tyn_1-4, and 
seven for AnCE with spinorphin: AnCE_Spin_1-7. All datasets were successfully 
processed in the space group h3 using the xia2 pipeline (Winter, 2010) at DLS. A 
summary of the data collected and the statistics from xia2 processing are presented in 
Table 4.1 and an example of a diffraction image is shown in Figure 4.2. 
 
Based on the statistics obtained from the processing with xia2, one dataset for each 
complex from each synchrotron visit was selected for further processing. This selection 
was based on the maximum resolution that could be achieved whilst retaining acceptable 
values for completeness and Rmerge. The datasets chosen were AnCE_Tyn_1, 





Figure 4.2: An Example of a Diffraction Image Collected for AnCE with 





Dataset name Collection 
date 








AnCE_Tyn_1 30th June 2012 i04 ADSC CCD Q315 120 0-120 85.84-2.16 99.7 
AnCE_Tyn_2 2nd July 2015 i04 PILATUS 6M-F 720 150-330 86.68-2.01 99.7 
AnCE_Tyn_3 25th July 2015 i02 PILATUS 6M 774 111-227.1 49.66-1.71 99.5 
AnCE_Tyn_4 25th July 2015 i02 PILATUS 6M 774 99-215.1 49.64-1.99 98.7 
AnCE_Spin_1 24th May 2015 i03 PILATUS3 6M 1800 0-180 60.85-3.06 99.7 
AnCE_Spin_2 24th May 2015 i03 PILATUS3 6M 1800 0-180 49.97-2.30 99.9 
AnCE_Spin_3 24th May 2015 i03 PILATUS3 6M 1800 180-360 28.51-4.23 97.1 
AnCE_Spin_4 24th May 2015 i03 PILATUS3 6M 1800 0-180 86.15-2.00 99.8 
AnCE_Spin_5 2nd July 2015 i04 PILATUS6M-F 900 20-200 88.76-2.07 99.9 
AnCE_Spin_6 25th July 2015 i02 PILATUS 6M 920 160-252 86.68-1.90 95.8 
AnCE_Spin_7 25th July 2015 i02 PILATUS 6M 1500 57-282 60.75-2.10 97.7 
 
Table 4.1: Summary of Data Collection and Processing Using Xia2 for AnCE in Complex with Tynorphin and Spinorphin. The datasets highlighted in 
yellow are those that were selected for further processing based on resolution and completeness. !
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4.3.3 Data Processing and Structure Solution 
The raw data images from the six selected datasets highlighted in Table 4.1 were 
processed using MOSFLM (Battye et al., 2011; Leslie and Powell, 2007) and Aimless 
(Evans, 2006; Evans, 2007) in the space group h3. Phases were calculated by molecular 
replacement performed using Phaser (McCoy et al., 2007) with the native AnCE 
structure (Akif et al., 2010) as the search model. In each case there was one molecule 
per asymmetric unit in the crystal. 
 
The models resulting from molecular replacement were all subjected to an initial round 
of rigid body refinement using REFMAC (Murshudov et al., 2011). Following this, 
clear density for glycosylated sugars was visible at residues Asn53, Asn196 and Asn311 
and for the catalytic zinc ion co-ordinated by residues His367, His371 and Glu395. 
These were added to the model accordingly. Spinorphin and tynorphin residues were 
also placed in the active site based on interpretation of the electron density. This process 
is discussed in detail for each dataset in the following sections. Further rounds of 
refinement were then performed prior to structure validation using Molprobity (Chen et 
al., 2010). Data processing statistics are summarised in Tables 4.2 and 4.3. 
 
The overall topology of each structure is identical to that of 2X8Y (RMSD values 0.115-
0.228 Å) with no evidence of any large-scale movement of secondary structure 
elements. Each molecule therefore has a predominantly helical structure. Key features 
include the characteristic N-terminal lid over the active site that is formed by helices α1, 
α2 and α3 and a long substrate-binding channel extending almost the entire length of the 
molecule. The catalytic zinc ion is found at the centre of this channel, marking the 
location of the active site. 
 
4.3.4 Analysis of Active Site Difference Density and Inhibitor Binding 
All structures contained some difference density in the active site into which spinorphin 
and tynorphin residues were placed. The extent of this density varied significantly 









 AnCE_Tyn_1 AnCE_Tyn_2 AnCE_Tyn_3 
Beamline at DLS i04 i04 i02 
Detector ADSC CCD Q315 PILATUS 6M-F PILATUS 6M 
Wavelength (Å) 0.980 0.980 0.979 
Space group h3 h3 h3 
Unit cell parameters 
a, b, c (Å) 
 


















1 1 1 
Resolution range (Å) 85.84-2.16 86.68-2.01 86.74-1.80 
♯Rmerge (%) 18.3 (65.0) 6.2 (42.7) 6.7 (57.2) 
+Rpim (%) 17.5 (61.8) 4.8 (35.5) 5.8 (49.8) 
Mean I/σ(I) 2.9 (1.4) 11.8 (2.3) 7.3 (1.4) 
Completeness (%) 99.7 (97.9) 99.7 (95.3) 99.1 (99.3) 












Multiplicity 3.1 (3.0) 4.5 (3.0) 3.1 (3.1) 
Wilson B  factor (Å2) 23.65 35.19 29.28 
























§Rcryst/♯♯Rfree (%) 18.75/22.27 17.47/20.62 18.36/21.13 
R.M.S deviation from 
ideal values 
Bond lengths (Å) 






























#!!!"#$" = !Σ!!"Σ! !!! ℎ!" − ! ! ℎ!" /Σ!!"Σ!!!(ℎ!"), where Ii(hkl) is the intensity of 
ith measurement and <I(hkl)> is the average of symmetry-related observations of a 
unique reflection. 
+!!"# = !Σ!!" !!!! Σ!!!! !! ℎ!" − ! ℎ!" /Σ!!"Σ!!!(ℎ!") 
§!!"#$% = !Σ! !!!!! /Σ!!!, where Fo and Fc are observed and calculated structure factor 
amplitudes of reflection h, respectively. 
##Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections. 
 
Table 4.2: X-ray Data Collection, Processing and Refinement Statistics for AnCE 





 AnCE_Spin_4 AnCE_Spin_5 AnCE_Spin_6 
Beamline at DLS i03 i04 i02 
Detector PILATUS3 6M PILATUS 6M-F PILATUS 6M 
Wavelength (Å) 0.980 0.980 0.979 
Space group h3 h3 h3 
Unit cell parameters 
a, b, c (Å) 
 


















1 1 1 
Resolution range (Å) 86.15-2.00 88.76-2.07 86.68-1.90 
♯Rmerge (%) 9.6 (68.4) 5.4 (31.3) 11.8 (66.3) 
+Rpim (%) 8.6 (60.4) 4.2 (26.4) 11.8 (66.1) 
Mean I/σ(I) 6.3 (1.5) 13.9 (3.6) 3.8 (1.1) 
Completeness (%) 99.5 (99.6) 99.9 (99.2) 95.8 (95.0) 












Multiplicity 3.3 (3.3) 4.7 (3.9) 1.9 (1.8) 
Wilson B  factor (Å2) 33.52 35.70 26.26 
























§Rcryst/♯♯Rfree (%) 18.17/21.10 16.47/19.25 17.27/20.14 
R.M.S deviation from 
ideal values 
Bond lengths (Å) 






























#!!!"#$" = !Σ!!"Σ! !!! ℎ!" − ! ! ℎ!" /Σ!!"Σ!!!(ℎ!"), where Ii(hkl) is the intensity of 
ith measurement and <I(hkl)> is the average of symmetry-related observations of a 
unique reflection. 
+!!"# = !Σ!!" !!!! Σ!!!! !! ℎ!" − ! ℎ!" /Σ!!"Σ!!!(ℎ!") 
§!!"#$% = !Σ! !!!!! /Σ!!!, where Fo and Fc are observed and calculated structure factor 
amplitudes of reflection h, respectively. 
##Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections. 
 
Table 4.3: X-ray Data Collection, Processing and Refinement Statistics for AnCE 








4.3.4.1.1 Position 1 
Data for AnCE_Tyn_1 were processed to 2.16 Å resolution. Although a total of 120 
diffraction images were collected, only the first 100 of these were used in data 
processing. Including the final 20 images caused the Rmerge to increase to an 
unacceptably high value and by excluding these images it was possible to reduce this 
whilst retaining the 2.16 Å resolution. Removing these images did not have an adverse 
effect on the completeness of the data, which remained at 99.7 % overall. A complete 
summary of the statistics from data processing is included in Table 4.2.  
 
Initial analysis of the electron density at the active site, after placement of the zinc ion, 
indicated that the full tynorphin peptide might be bound. This was based on the 
observation that the density appeared to extend for the length of a pentapeptide. To this 
end an attempt was made to fit tynorphin into the active site electron density, with the 
valine, valine, tyrosine, proline and tryptophan residues occupying the S3, S2, S1, S1’ and 
S2’ subsites respectively. This arrangement positioned the peptide bond between the 
tyrosine and proline residues directly above the catalytic zinc ion with the proline 
carbonyl oxygen partaking in zinc ion co-ordination. 
 
Following a round of restrained refinement it was clear that there was insufficient 
electron density for the peptide bond between the tyrosine and proline residues. To try 
and overcome this, the occupancy of the peptide was reduced from 1.0 to 0.5 however 
this still did not solve the problem. The conclusion was therefore drawn that although it 
is possible that some intact peptide is bound, in the majority of molecules the enzyme 
has cleaved the tyrosine-proline bond. The pentapeptide was therefore fitted in the 
density as two fragments: VVY and PW (Figure 4.4). The placement of the dipeptide 
and tripeptide fragments outlined below is referred to as “position 1”. 
  
In position 1, the PW dipeptide sits with the proline and tryptophan residues occupying 
the S1’ and S2’ subsites respectively. The terminal oxygen of the tryptophan residue 
forms a water-mediated interaction with the side chain of Lys495. Further interactions 
between the second tryptophan oxygen and the side chains of Lys495, Gln265 and 
Tyr504 anchor the C-terminus of the dipeptide in this position in the active site. 
Additionally, the carbonyl oxygen of the proline forms hydrogen bond interactions with 
the side chains of His497 and His337. The interactions described here are routinely 




The S1’ and S2’ region of the active site is very hydrophobic. The side chains of Phe441 
and Phe511 form a hydrophobic pocket that accommodates the hydrophobic PW 
dipeptide well. Furthermore, the proline side chain is able to form stacking interactions 
with His337 and His367, which will further contribute to dipeptide binding.  The 
interactions between the PW dipeptide and the active site are summarised in Table 4.4 
and Figure 4.3. 
 
The VVY tripeptide sits directly along from the PW dipeptide, occupying the S1, S2 and 
S3 subsites, respectively. The terminal oxygen of the tyrosine, introduced by cleavage of 
the Tyr-Pro peptide bond, appears to co-ordinate the catalytic zinc ion and also interacts 
with the side chains of His367 and His371. The second tyrosine oxygen atom forms 
water-mediated interactions with the side chains of Glu395 and Tyr507, as well as a 
direct interaction with the hydroxyl group of Tyr507. Interactions between the enzyme 
and the valine residues are mainly water mediated, however these residues do occupy a 
hydrophobic pocket formed by Ser339, Trp341, Phe375, Tyr496 and Val502. These 
interactions are summarised in Table 4.4 and Figure 4.3. 
 
 








P1 Tyr OXT Zn2+ 2.03 P2’ Trp NE1 Gln266 OE1 2.75 
P1 Tyr OXT His367 NE2 3.28 P2’ Trp OXT Water 2.96 
P1 Tyr OXT His371 NE2 3.16 P2’ Trp O Water 2.96 
P1 Tyr O Water 3.20 P2’ Trp O Lys495 NZ 2.64 
P1 Tyr O Tyr507 OH 2.36 P2’ Trp O Gln265 NE2 3.11 
P1 Tyr N Water 2.84 P2’ Trp O Tyr504 OH 3.00 
P2 Val O Ala340 N 3.06 P1’ Pro O His497 NE2 3.16 
P2 Val N Ala340 O 3.22 P1’ Pro O His337 NE2 2.90 
P3 Val O Water 2.74 
P3 Val O Water 2.90 
P3 Val N Water 2.74 
P3 Val N Water 2.75 
 
 
Table 4.4: List of Interactions Formed by the VVY Tripeptide and PW Dipeptide 










      
 
 
       
 
 
Figure 4.3: Interactions Formed by the VVY Tripeptide and PW Dipeptide 
Fragments of Tynorphin at “Position 1” in the AnCE Active Site (AnCE_Tyn_1 
data). (a) Interactions formed by the VVY fragment of tynorphin at the S1, S2 and S3 
subsites. Key water molecules are shown in orange and the active site zinc ion is in grey. 
The tripeptide and protein residues are shown as green and cyan sticks, respectively. (b) 
Interactions between the PW fragment of tynorphin and the S1’ and S2’ subsites. The 
colour scheme is as described for (a). For reference the VVY tripeptide from (a) is 





































4.3.4.1.2 Position 2 
Fitting the two fragments in position 1 meant that the residues were well accommodated 
by the difference density however unoccupied electron density remained around some of 
the side chains, Figure 4.4. This was most noticeable at the P2 and P1’ positions, 
currently occupied by valine and proline respectively, and indicated that fragments of 
the peptide were likely to be bound in more than one position. 
 
The difference density map in Figure 4.4 shows where this extra side chain density was 
observed. It is clear from this that some form of aromatic side chain must also occupy 
the S2 subsite and the terminal tynorphin tryptophan residue fitted well here. A number 
of different attempts were made to place the tynorphin peptide, and different fragments 
thereof, in this residual density. Ultimately, the peptide was broken down into the same 
two fragments as for position 1: PW and YVV. The PW dipeptide was placed at the P3 
and P2 positions and VVY at the P1, P1’ and P2’ positions, respectively. All four 
tynorphin fragments were assigned an occupancy of 0.5 and following refinement the 
model was observed to fit the electron density well, Figure 4.4. The peptide fragments 
bound in this way are referred to as being in “position 2”. 
 
                          
 
Figure 4.4: Placement of Tynorphin Residues in the Electron Density at the 
AnCE_Tyn_1 Active Site. (a) The original placement of two tynorphin fragments VVY 
(green) and PW (cyan) at “position 1” left residual difference density, most evident at 
the P2 position. The two fragments were placed in a second orientation, “position 2”, 
























In the position 2 arrangement the VVY tripeptide is located at the opposite end of the 
active site compared to in position 1, such that the residues occupy the S1, S1’ and S2’ 
subsites respectively. The C-terminal tyrosine forms similar, although not as extensive, 
interactions with the active site residues Gln265, Lys495 and Tyr504 as the tryptophan 
from the PW dipeptide in position 1. Additionally the hydroxyl oxygen of the tyrosine 
side chain forms water mediated interactions with the side chains of Gln265 and 
Gln266.  The hydrogen bonds formed by the carbonyl oxygen of proline in the dipeptide 
with the side chains of His367 and His371 are replicated by the P1’ valine here. 
 
The additional valine residue at P1, which completes the tripeptide, co-ordinates the 
catalytic zinc ion through its carbonyl oxygen, thus appearing to position the tripeptide 
for cleavage of the peptide bond between the two valine residues. 
 
In the position 2 arrangement the PW dipeptide now occupies the S3 and S2 subsites 
where, like the two valine residues in the tripeptide, it predominantly interacts with the 
active site through hydrophobic interactions. In particular the tryptophan forms stacking 
interactions with the side chain of His394, as illustrated in Figure 4.5. All of these 
interactions are summarised in Table 4.5 and Figure 4.5. 
 
 








P2’ Tyr OH Water 3.16 P2 Trp OXT Water 2.90 
P2’ Tyr O Gln265 NE2 3.06 P2 Trp O Ala340 N 3.16 
P2’ Tyr O Lys495 NZ 2.73 P2 Trp NE1 Water 2.83 
P2’ Tyr OXT Water 2.41 P2 Trp N Ala340 O 2.66 
P1’ Val O His337 NE2 2.64 P3 Pro O Water 3.26 
P1’ Val O His497 NE2 2.88 
P1‘ Val N Ala338 O 2.93 
P1 Val O Zn2+ 2.77 




Table 4.5: List of Interactions Formed by the VVY Tripeptide and PW Dipeptide 







                
 
            
 
 
Figure 4.5: Interactions Formed by the VVY Tripeptide and PW Dipeptide 
Fragments of Tynorphin at “Position 2” in the AnCE Active Site (AnCE_Tyn_1 
Data). (a) Representation of the hydrogen bond interactions formed by the VVY 
fragment of tynorphin at the S1, S1’ and S2’ subsites. Key water molecules are shown in 
orange and the active site zinc ion is in grey. The tripeptide and protein residues are 
shown as green and cyan sticks, respectively. (b) Representation of the interactions 
between the PW fragment of tynorphin and the S2 and S3 subsites. The colour scheme is 






































The second dataset collected for AnCE with tynorphin, AnCE_Tyn_2, consisted of 720 
images. All 720 images were used to process the data to 2.01 Å resolution. A complete 
summary of data processing statistics is presented in Table 4.2. 
 
As was the case for AnCE_Tyn_1, after placing the catalytic zinc ion in the active site 
some difference density remained. It was immediately apparent however that this 
density was far less extensive than that seen in AnCE_Tyn_1 and could not possibly 
accommodate all five tynorphin residues. Furthermore, the electron density was not 
continuous, with a clear break close to the catalytic zinc ion, Figure 4.6. 
 
The combination of reasonably high-resolution data (2.01 Å) and the relatively limited 
number of potential residues meant that a VY dipeptide was quickly and confidently 
placed in one half of the density. As illustrated in Figure 4.6, the bulky tyrosine side 
chain fits the density here very well.     
 
The position of the VY dipeptide is almost identical to that of the C-terminal valine and 
tyrosine residues of the VVY tripeptide bound in position 2 of the AnCE_Tyn_1 
structure. Valine occupies the S1’ subsite and tyrosine the S2’ subsite. This is shown in 
Figure 4.7 and a full list of interactions with active site residues is detailed in Table 4.6, 
for the most part these are identical to those in AnCE_Tyn_1.  
 
The main difference is that whereas in AnCE_Tyn_1 the catalytic zinc ion is co-
ordinated directly by the carbonyl oxygen of the additional valine residue at the P1 
position, the absence of a third peptide residue here means that the zinc co-ordination is 
completed by a water molecule. It is through this water molecule that the amide nitrogen 
of the P1’ valine interacts with the catalytic zinc ion, Figure 4.7.  
 
The second piece of active site electron density is quite clearly separated from the first; 
there was no possibility of placing a continuous peptide backbone here to include both 
regions. Instead a PW dipeptide was placed to occupy the S3 and S2 subsites in an almost 
identical manner to that seen in AnCE_Tyn_1 position 2 (Figures 4.6 and 4.7).   
 
A full list of hydrogen bonding interactions for this dipeptide with active site residues is 
included in Table 4.6, however direct contacts are minimal and those that are present are 
conserved in the AnCE_Tyn_1 position 2 structure. There are a number of additional 
water mediated interactions not present in AnCE_Tyn_1, likely due to increased active 
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site water content in the absence of residues at a second position. As in AnCE_Tyn_1, 
hydrophobic interactions play a key role in holding this dipeptide in place.  
 
 




Figure 4.6: Placement of Tynorphin Fragments in the AnCE_Tyn_2 Active Site. 
The Fo-Fc map is shown as a grey mesh, contoured at 3σ. The difference density 
observed here is not as extensive as for AnCE_Tyn_1. Two dipeptides, VY (magenta) 
and PW (purple), were fitted in the density in very similar locations to AnCE_Tyn_1 
position 2. A water molecule (blue sphere) is seen to co-ordinate the catalytic zinc ion 
(grey sphere). 
 








P2’ Tyr OH Water 3.01 P2 Trp OXT Water 2.99 
P2’ Tyr O Tyr504 OH 2.64 P2 Trp OXT Water 2.79 
P2’ Tyr O Gln265 NE2 3.19 P2 Trp OXT Water 2.40 
P2’ Tyr O Lys495 NZ 2.68 P2 Trp O Ala340 N 3.12 
P2’ Tyr OXT Water 2.66 P2 Trp NE1 Water 2.96 
P1’ Val O His337 NE2 2.69 P2 Trp N Ala340 O 2.73 
P1’ Val O His497 NE2 3.13 
P1’ Val N Glu368 OE2 2.69 
P1’ Val N Ala338 O 3.12 
P1’ Val N Water 2.95 
P1’ Val N Water 2.60 
 
Table 4.6: List of Interactions Formed by the VY and PW Dipeptides with AnCE 













         
 
               
 
 
Figure 4.7: Interactions Formed by the VY and PW Dipeptide Fragments of 
Tynorphin in the AnCE Active Site, Based on Interpretation of the Electron 
Density Map for AnCE_Tyn_2. (a) The hydrogen bonding interactions formed by the 
VY fragment of tynorphin at the S1’ and S2’ subsites. Key water molecules are shown in 
orange and the active site zinc ion in grey. The dipeptide and protein residues are shown 
as green and magenta sticks, respectively. (b) The interactions between the PW fragment 




































A total of 774 diffraction images were collected for AnCE_Tyn_3 covering 116.1o. Data 
were collected to 1.71 Å resolution and all 774 images were used for data processing. 
Data processing statistics are summarised in Table 4.2.  
 
Following molecular replacement using the native AnCE structure as a model there was 
once again additional electron density visible in the active site. However this density 
was far less extensive than that previously seen in AnCE_Tyn_1 and AnCE_Tyn_2, and 
it was only possible to fit a single dipeptide, occupying the S2’ and S1’ subsites. Based 
on interpretation of the visible density two valine residues were placed here, as 
illustrated in Figure 4.8. As was the case in the AnCE_Tyn_2 structure, a water 
molecule was placed in the difference density to co-ordinate the catalytic zinc ion. 
 
           
 
Figure 4.8: Placement of Tynorphin Fragments in the AnCE_Tyn_3 Active Site. 
Only a small amount of difference density is observed in the AnCE_Tyn_3 active site, 
illustrated by the Fo-Fc map contoured at 3 σ, shown as a grey mesh. A single VV 
dipeptide was placed in the same location as the VY dipeptide in AnCE_Tyn_2. As in 
AnCE_Tyn_2 a water molecule (blue sphere) is seen to co-ordinate the active site zinc 









A complete list of interactions between the VV dipeptide and active site residues is 
presented in Table 4.7 and summarised in Figure 4.9. The backbone of this dipeptide is 
positioned in an almost identical manner to the backbone of the VY dipeptide in the 
AnCE_Tyn_2 structure. Consequently, many of the interactions with active site residues 
are conserved. This includes the key interactions of the C-terminal carboxylate group 
with the side chains of Gln265 and Lys495, which anchor the peptide in the active site, 
and the water mediated interaction with the catalytic zinc ion formed by the amide 
nitrogen of the P1’ valine. 
 
               
Figure 4.9: Interactions Formed by the VV Dipeptide Fragment of Tynorphin in 
the AnCE Active Site, Based on Interpretation of the Electron Density Map for 
AnCE_Tyn_3. Interactions formed by the VV fragment of tynorphin at the S1’ and S2’ 
subsites. Key water molecules are shown in orange and the active site zinc ion in grey. 
Residues of the dipeptide and AnCE are shown as green and purple sticks, respectively. 
 
VV atom Interacting atom Distance (Å) 
P2’ Val O Tyr504 OH 2.62 
P2’ Val O Gln265 NE2 3.25 
P2’ Val O Lys495 NZ 2.77 
P1’ Val O His337 NE2 2.59 
P1’ Val O His497 NE2 3.01 
P1’ Val N Ala338 O 2.98 
P1’ Val N Glu368 OE2 2.92 
P1’ Val N Water 2.91 
P1’ Val N Water 2.50 
 
Table 4.7: List of Interactions Formed by the VV Dipeptide Fragment of 
















A total of 1800 diffraction images at 2.00 Å resolution were collected from the 
AnCE_Spin_4 crystal. Following initial processing using MOSFLM (Battye et al., 2011; 
Leslie and Powell, 2007) and Aimless (Evans, 2006; Evans, 2007) with all 1800 images, 
the Rmerge value was unacceptably high. Rather than imposing a limit on the resolution, 
the number of images used in the processing was reduced such that only images 1-1250 
were included. This greatly improved the Rmerge value (9.6 % overall and 68.4 % outer 
shell) without adversely affecting the completeness of the data, which remained at 99.5 
% overall.  Complete data processing statistics are shown in Table 4.3. 
 
Following molecular replacement using the native AnCE structure (Akif et al., 2010) as 
a search model, a significant amount of extra electron density was visible in the active 
site. Efforts were made to place the spinorphin peptide into this density, however it was 
immediately apparent that the density did not extend far enough along the catalytic 
channel to be able to accommodate the full-length peptide. 
 
Ultimately, the LVV tripeptide was modelled into the density. This equates to the first 
three residues of the spinorphin peptide. The residues were placed such that the S1, S1’ 
and S2’ subsites of the enzyme were occupied by leucine, valine and valine respectively. 
After placing these residues further rounds of refinement were performed using 
REFMAC (Murshudov et al., 2011). This confirmed that the residues fitted the density 
well, and also that there was definitely no further density in which it may have been 
possible to model other peptide residues. Figure 4.10 illustrates the fit of the tripeptide 
in the active site difference density. 
 
       
Figure 4.10: Placement of Spinorphin Fragments in Electron Density at the 
AnCE_Spin_4 Active Site. A tripeptide consisting of leucine, valine, and valine 
occupying the S1, S1’ and S2’ subsites, respectively is shown as cyan sticks in the 







Most of the interactions between the tripeptide and the ACE active site involve the 
peptide backbone. This is a common feature of peptide binding to ACE as it allows the 
enzyme to act on a wide range of peptide substrates.  
 
As is normally the case in structures of ACE homologues bound to peptides, a key point 
of contact with the enzyme is via the C-terminal carboxyl group of the tripeptide. Here 
the P2’ valine interacts through its carboxyl group directly with the side chains of 
Lys495 and Tyr504. There is also a water-mediated interaction with the side chain of 
Gln265. 
 
Further hydrogen bond interactions exist between the carbonyl oxygen of the P1’ valine 
and the side chains of His337 and His497. The amide nitrogen of this valine also 
interacts with the side chain of Glu369 and contacts the protein backbone at Ala338.  
 
The N-terminal residue of the tripeptide, the P1’ leucine, contacts the side chains of 
Tyr504 and Glu368. Interestingly, it also appears to co-ordinate the catalytic zinc ion via 
both its carbonyl oxygen and amide nitrogen, as illustrated in Figure 4.11. A complete 
list of interactions between the peptide and active site residues in presented in Table 4.8 
and summarised in Figure 4.11. 
 
LVV Atom Interacting atom Distance (Å) 
P2’ Val OXT Water 2.75 
P2’ Val O Lys495 NZ 2.64 
P2’ Val O Tyr504 OH 2.62 
P1’ Val O His337 NE2 2.70 
P1’ Val O His497 NE2 3.11 
P1’ Val N Ala338 O 3.34 
P1’ Val N Glu369 OE2 2.92 
P1 Leu O Zinc 2.28 
P1 Leu O Tyr504 OH 2.64 
P1 Leu N Zinc 2.55 
P1 Leu N Glu368 OE1 2.88 
P1 Leu N Water 2.75 
 
 
Table 4.8: List of Interactions Formed by the LVV Tripeptide Fragment of 









         
 
 
Figure 4.11: Interactions Formed by the LVV Tripeptide Fragment of Spinorphin 
in the AnCE Active Site Based on Interpretation of the Electron Density Map for 
AnCE_Spin_4. Interactions formed by the LVV fragment of spinorphin at the S1, S1’ 
and S2’ subsites. Key water molecules are shown in orange and the active site zinc ion in 





The AnCE_Spin_5 dataset comprised 900 diffraction images collected to 2.07 Å 
resolution. All 900 images were used for data processing, with statistics summarised in 
Table 4.3. 
 
Following molecular replacement and initial structure refinement it was clear that there 
was a significant portion of difference density in the active site of the structure, much 
more than was seen in AnCE_Spin_4. Four alanine residues were initially fitted into the 
density to build a tetrapeptide backbone. Following a round of restrained refinement it 
was then possible to build the appropriate side chains into the remaining density. This 
resulted in the peptide YPWT with the tyrosine, proline, tryptophan and threonine side 
chains adopting the P2, P1, P1’ and P2’ positions, respectively. As illustrated in Figure 
4.12, the tetrapeptide filled the difference density well and it was quite clear that no 
substantial further density was present, thus the peptide was not extended beyond these 
four residues. 
 















Figure 4.12: Placement of Spinorphin Fragments in Electron Density at the AnCE 
Active Site in the AnCE_Spin_5 Structure. A peptide consisting of four spinorphin 
residues: tyrosine, proline, tryptophan and threonine, is shown as magenta sticks in the 
AnCE_Spin_5 Fo-Fc density map, contoured at 3σ, occupying the S2, S1, S1’ and S2’ 
subsites. The peptide co-ordinates the catalytic zinc ion, grey sphere, via the proline and 
tyrosine carbonyl oxygen atoms. 
 
The position of the YPWT fragment of spinorphin in this way places the peptide bond 
between the tryptophan and proline above the catalytic zinc ion with the carbonyl 
oxygen atoms from both residues appearing to contact the zinc ion, Figure 4.13. 
 
The C-terminus of the YPWT peptide is held in place through interactions between the 
P2’ threonine carboxyl group and active site residues Gln265, Lys495, Tyr504. The 
tryptophan at the P1’ position interacts with the side chains of His337 and His497 
through it carbonyl oxygen atom, and with Glu368 and Ala338 via its amide nitrogen. 
There are fewer interactions between the N-terminus of the peptide and the active site; 
the amide nitrogen of the P2 tyrosine contacts the protein backbone at Ala340, whilst the 
hydroxyl group of its side chain interacts with the side chain of Thr387. 
 
As has previously been described for other spinorphin and tynorphin fragments, the 
hydrophobicity of this region of the AnCE active site also appears to play some role in 
YPWT binding.  Figure 4.13 and Table 4.9 illustrate the key interactions between 












            
 
 
Figure 4.13: Interactions Formed by the YPWT Tetrapeptide Fragment of 
Spinorphin in the AnCE Active Site, Based on Interpretation of the Electron 
Density Map for AnCE_Spin_5. Interactions formed by the YPWT fragment of 
spinorphin at the S2, S1, S1’ and S2’ subsites. Key water molecules are shown in orange 
and the active site zinc ion in grey. The peptide and protein residues are shown as green 




YPWT atom Interacting atom Distance (Å) 
P2’ Thr OXT Water 2.65 
P2’ Thr O Gln265 NE2 3.15 
P2’ Thr O Lys495 NZ 2.81 
P2’ Thr O Tyr504 OH 2.59 
P1’ Trp O His497 NE2 3.12 
P1’ Trp O His337 NE2 2.64 
P1’ Trp N Ala338 O 3.17 
P1’ Trp N Glu368 OE2 2.81 
P1 Pro O Tyr507 OH 2.86 
P1 Pro O Zinc 2.08 
P2 Tyr O Zinc 3.29 
P2 Tyr N Ala340 O 2.78 




Table 4.9: List of Interactions Formed by the YPWT Tetrapeptide Fragment of 






















The AnCE_Spin_6 dataset consisted of 920 images collected to 1.6 Å resolution. 
Attempts to process the data at such high resolution using all of the images resulted in 
unacceptably high values for Rmerge (>100 %). In an initial attempt to overcome this 
problem only the first 700 images were used. Although this reduced the Rmerge value 
significantly it was still too high. Whilst removing further images may have further 
improved the Rmerge this would have had an adverse effect on the completeness of the 
data.  
 
The data were therefore processed again, still using images 1-700, but imposing a high-
resolution limit of 1.90 Å. This resulted in an overall Rmerge of 11.8 % (66.3 % for outer 
shell data) and overall completeness of 95.8 % (95.0 % for the outer shell). Full data 
processing statistics are included in Table 4.3. 
 
Following molecular replacement and initial rounds of refinement, a relatively small 
amount of difference density was visible in the active site. The extent of this density was 
considerably less than seen for either AnCE_Spin_4 or AnCE_Spin_5 and was only able 
to accommodate a single dipeptide, Figure 4.14. 
 
Although the density was limited in terms of length, due to the high resolution of the 
data it was very clear which residues formed the dipeptide and proline and tyrosine were 
place at the P2’ and P1’ positions respectively, Figure 4.14. 
              
Figure 4.14: Placement of Spinorphin Fragments in Electron Density at the AnCE 
Active Site in the AnCE_Spin_6 Structure. A dipeptide fragment of spinorphin 
consisting of tyrosine and proline is shown as purple sticks in the Fo-Fc difference 
density map, contoured at 3σ, derived from the AnCE_Spin_6 data. The tyrosine and 
proline residues occupy the S1’ and S2’ subsites of the AnCE active site, respectively. 
The catalytic zinc ion does not interact directly with the dipeptide but is shown as a grey 





The majority of interactions between the YP dipeptide and the AnCE active site involve 
the carboxyl group of the P2’ proline, which interacts with the side chains of Gln265, 
Lys495 and Tyr504. Additionally, the carbonyl oxygen of the tyrosine residue forms 
hydrogen bond interactions with His337 and His497.  
 
The dipeptide does not appear to interact directly with the active site zinc ion. Instead, 
the dipeptide interacts with the zinc via a water molecule and the tyrosine carbonyl 
oxygen. This oxygen also interacts directly with active site residues Glu368 and Ala338. 
These interactions are illustrated in Figure 4.15 and detailed in Table 4.10. 
 
              
 
Figure 4.15: Interactions Formed by the YP Dipeptide Fragment of Spinorphin in 
the AnCE Active Site, Based on Interpretation of the Electron Density Map for 
AnCE_Spin_6. Interactions formed by the YP fragment of spinorphin at the S2’ and S1’ 
subsites. Key water molecules are shown in turquoise and the active site zinc ion in 
grey. The peptide and protein residues are shown as green and purple sticks, 
respectively. 
PY atom Interacting atom Distance (Å) 
P2’ Pro O Gln265 NE2 3.18 
P2’ Pro O Lys495 NZ 2.66 
P2’ Pro O Tyr504 OH 2.53 
P1’ Tyr O His337 NE2 2.73 
P1’ Tyr O His497 NE2 3.03 
P1’ Tyr N Water 2.38 
P1’ Tyr O Water 3.04 
P1’ Tyr O Ala338 O 3.27 
P1’ Tyr O Glu368 OE2 2.83 
 
Table 4.10: List of Interactions Formed by the YP Dipeptide Fragment of 














Following incubation with spinorphin and tynorphin, AnCE crystals were readily 
obtained from the “standard” crystallisation condition (1.2-1.3 M Na citrate, 0.1 M 
HEPES, pH 7.5). When taken to DLS for data collection, these crystals diffracted well 
and a number of complete datasets were collected to good, ~2 Å, resolution (Table 4.1). 
Although no cryo-protecting solutions were used there were no problems with ice, 
illustrated by the absence of ice rings on the diffraction image in Figure 4.2. The crystals 
appeared to be relatively stable during data collection. 
 
All data were processed in the space group h3. This is typical of AnCE crystals grown in 
this condition and indicates that there is unlikely to have been any significant 
conformational change occurring on spinorphin and tynorphin binding. This was 
confirmed both by visual inspection of the final structures and by calculating the RMSD 
compared to the native AnCE structure, PDB code 2X8Y, (Akif et al., 2010). RMSD 
values for all structures were in the range 0.115-0.228 Å. 
  
4.4.1 Structures of AnCE with Tynorphin 
All of the data collected for AnCE with tynorphin contained some active site difference 
density into which different fragments of the tynorphin peptide were modelled. However 
the extent of this density varied greatly across the three datasets. Furthermore, it was not 
possible to model the full-length tynorphin peptide into the active site electron density of 
any of the structures. 
 
4.4.1.1 AnCE_Tyn_1 
The greatest amount of difference density was visible in the AnCE_Tyn_1 structure and 
initially it seemed that the full-length tynorphin pentapeptide was bound here. However, 
following refinement, it was clear that there was insufficient difference density in the 
region around the peptide bond between the tyrosine and proline residues at the S1 and 
S1’ positions for this to be the case. Even after reducing the occupancy of the peptide 
quite significantly this issue remained; therefore tynorphin was placed in the active site 
as two fragments; VVY and PW. 
 
Further analysis of the density after placement of the VVY and PW peptides in what is 
referred to as “position 1” revealed residual difference density at a number of positions. 
This was indicative of tynorphin residues binding to the active site at multiple locations. 
Following careful analysis of the density and attempts at positioning residues in many 
different combinations, ultimately the same two fragments were placed in the active site 
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in a second orientation: position 2. Here the VVY tripeptide residues are now at the P1, 
P1’ and P2’ positions and the PW dipeptide residues at P3 and P2, respectively.  
 
These results suggest that the enzyme is cleaving the peptide bond between the tyrosine 
and proline residues. This at first does not seem surprising, given that angiotensin-
converting enzymes typically cleave the C-terminal dipeptide from their substrates. In 
this case however the penultimate peptide residue is a proline.  
 
As discussed in section 3.1.2, proline residues at the P1’ position have been identified as 
key features of the BPPs, which are natural ACE inhibitory peptides. The unique nature 
of the proline side chain is thought to protect the scissile bond from cleavage by 
restricting access to the amide nitrogen. Thus, it is very surprising to see the tynorphin 
peptide cleaved into these fragments. However in all three structures of AnCE with 
tynorphin the sequences of the fragments of peptide present in the active site indicate 
that this has occurred. This strongly suggests that this is a valid observation, rather than 
based on incorrect interpretation of the electron density maps. 
 
One possible explanation for this is that AnCE is acting as an aminopeptidase.  ACE has 
previously been shown to remove residues from the N-terminus of peptides if the C-
terminus is “protected”, a notable example being towards GnRH, which also has a 
proline residue at the penultimate, P1’ position (Jaspard et al., 1993; Skidgel et al., 
1985). The basis of aminopeptidase activity by ACE is not yet fully understood, 
however such activity could potentially explain the results seem here.  
 
An alternative, and perhaps more likely, explanation might be that AnCE is able to 
remove the C-terminal dipeptide from substrates with a P1’ proline, but that this occurs 
much more slowly than “normal” hydrolysis. On a biological scale, this activity may 
therefore not be relevant. In the crystal environment however, the peptides are exposed 
to AnCE at very high concentrations for extended periods of time and are quite possibly 
constrained to the active site for days or weeks.  
 
Although it is not possible to draw a definitive conclusion based on a single diffraction 
experiment using a single crystal, the positions and orientations of the different 
tynorphin fragments do indicate a probable sequence of events occurring in the AnCE 
active site.  
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It is likely that full-length tynorphin initially binds in the orientation that the peptide 
fragments adopt in position 1. That is to say that the C-terminal tryptophan residue 
occupies the S2’ subsite. This orientation is likely to be favourable, because in this 
position the C-terminal carboxyl group can form a number of key interactions with 
active site residues (namely Lys495, Tyr504 and Gln265) that anchor the peptide in 
place. This is a common feature of peptide interactions with angiotensin converting 
enzymes. Furthermore, this orientation places the aromatic side chains of tryptophan and 
proline in a hydrophobic pocket, with the proline residue effectively “sandwiched” 
between two histidine residues. 
 
Tynorphin binding in this way would position the peptide bond between the tyrosine and 
proline residues for cleavage, resulting in the two fragments: VVY and PW. If the PW 
dipeptide were then released, the VVY dipeptide could “slide” along the active site and 
now occupy the S1, S1’ and S2’ subsites, as seen in position 2. The newly generated 
carboxyl group would then form the same interactions with the S2’ subsite as the 
tryptophan residue had previously. This concept of “sliding” in the ACE active site has 
previously been observed with angiotensin (Masuyer et al., 2012). 
 
Following this movement the released PW dipeptide would then be free to occupy the S3 
and S2 subsites, as seen in position 2. It is likely that this is a weaker interaction, 
restricted mainly to hydrophobic and water mediated interactions. It should also be 
noted that the VVY tripeptide is now positioned ideally for cleavage of the peptide bond 




The difference density in the AnCE_Tyn_2 active site was considerably less ambiguous 
than that seen in AnCE_Tyn_1. As such, two dipeptides, PW and VY were quickly 
placed in the active site. The PW dipeptide adopts an almost identical position in the S3 
and S2 subsites as in position 2 of the AnCE_Tyn_1 structure. Similarly, the valine and 
tyrosine residues of the dipeptide are located at the P1’ and P2’ positions, respectively, as 
they were in the VVY tripeptide in position 2 of the AnCE_Tyn_1 structure. 
 
The most likely explanation for the arrangement seen here is that further cleavage of the 
tripeptide has occurred. The VVY tripeptide in AnCE_Tyn_1 position 2 was positioned 
ideally for cleavage of the peptide bond between the two valine residues. The alternative 
explanation is that the P1 valine residue is present but not visible in the structure due to 
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being mobile. The electron density around the valine residue of the dipeptide was 
examined carefully, however there was no evidence at all of it continuing past the P1’ 
position (Figure 4.6), hence it is highly likely that the VVY tripeptide has undergone 
further cleavage. An illustration of this process is shown in Figure 4.16 (b) and (c). 
 
The AnCE_Tyn_1 and AnCE_Tyn_2 datasets were collected three years apart from 
different crystals grown using different batches of AnCE. The consistency of the data is 
therefore an indication that this is an accurate representation of what is happening to 
tynorphin at the AnCE active site. If time had permitted, it would have been interesting 
to collect data from the crystals used for the AnCE_Tyn_1 data collection a few days or 
weeks after the initial collection. If the VVY tripeptide at position 2 were still intact, it 
would have been an indication that the additional cleavage seen in AnCE_Tyn_2 may 
have occurred prior to crystal growth. If however the tripeptide were observed to have 
undergone further cleavage it would illustrate that this may be occurring within the 
crystal itself.  
 
4.4.1.3 AnCE_Tyn_3 
The AnCE_Tyn_3 structure contained far less difference density in the active site than 
either of the previous two structures. Whereas in AnCE_Tyn_1 and AnCE_Tyn_2 there 
were two regions of density, in AnCE_Tyn_3 only a single dipeptide, VV, could be 
placed in the active site, occupying the S2’ and S1’ subsites. 
 
It is quite apparent from studying the electron density in Figure 4.8 that no further 
residues could have been added to the dipeptide, and that the two valine residues fit the 
density very well. However there is a small possibility that the VV dipeptide could 
actually be VY, as seen in AnCE_Tyn_2, but that the tyrosine side chain density is not 
entirely visible. 
 
Although the presence of a tyrosine residue cannot be ruled out entirely, the most 
probable explanation for the results seen in the AnCE_Tyn_3 structure is that AnCE has 
cleaved tynorphin into multiple fragments and individual residues. It is possible that the 
PW dipeptide present in AnCE_Tyn_1 and AnCE_Tyn_2 has been reduced to individual 
residues, which have either been released from the enzyme or are not bound in any 




               
Figure 4.16: Schematic Representation of Tynorphin Binding at the AnCE Active Site. In all figures the locations of the subsites of the enzymes are 
labelled as S3, S2, S1, S1’ and S2’. The location of the catalytic zinc ion between the S1 and S1’ subsites is also indicated. The tynorphin residues occupying 
each subsite are labelled. (a) In position 1 of the AnCE_Tyn_1 structure two peptide fragments, VVY (green) and PW (blue), are bound. It is likely that this is 
due to the enzyme cleaving the peptide bond between the tyrosine and proline residues of the full peptide, indicated by a black dotted line. (b) In position 2 of 
the AnCE_Tyn_1 structure the PW dipeptide has been released and re-bound at the S3 and S2 positions. The VVY fragment has moved along the active site 
and is now positioned for cleavage of the peptide bond between the two valine residues. (c) In the AnCE_Tyn_2 structure this cleavage has occurred with the 
release of a valine residue. (d) in the AnCE_Tyn_3 structure only a VV dipeptide is bound at the S1’ and S2’ positions, likely due to cleavage of the peptide 
bond between the valine and tyrosine residues in VVY or full length tynorphin. !
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The AnCE_Tyn_3 data is interesting because it was obtained from crystals grown at the 
same time as those used to collect the AnCE_Tyn_2 data. These two data sets were 
collected three weeks apart, meaning that the tynorphin in the AnCE_Tyn_3 data was 
incubated with the AnCE crystal for considerably longer. The results would appear to 
suggest that during this time further cleavage of the peptide has occurred. 
 
4.4.2 Stability of Tynorphin in the Presence of Angiotensin Converting Enzymes 
What is clear from the data presented here is that AnCE is cleaving the tynorphin 
peptide, apparently into multiple fragments. Tynorphin is a synthetic peptide, which was 
designed based on the haemorphin spinorphin with the aim of creating a better inhibitor 
of the enzyme DPPIII (Yamamoto et al., 2000). Like ACE, DPPIII is a zinc 
metalloprotease, but whereas ACE removes residues from the C-terminus of peptide 
substrates, DPPIII targets residues at the N-terminus (Bezerra et al., 2012). 
 
Whilst tynorphin is a more potent inhibitor of DPPIII than spinorphin, it is actually a 
weaker inhibitor of ACE. The percentage ACE inhibition by tynorphin is approximately 
50 % that seen at the same concentration of spinorphin (Yamamaoto et al., 2000). 
 
When the initial properties of tynorphin as an inhibitor were first reported by Yamamoto 
et al, the stability of this peptide in human serum was also measured. Tynorphin was 
incubated at 37 oC with human serum and after 2 and 4 hours the survival of the peptide 
was analysed using HPLC. After 2 hours very little full-length peptide remained, 
appearing to have been cleaved into VYP, YPW and VYPW. After a further 2 hours 
almost all of the peptide had been cleaved to a background level and only small amounts 
of VYP and individual amino acids were detected. 
 
Studying the sequences of the fragments detected after incubation with human serum 
suggests that a component in the serum is removing residues sequentially from either 
end of the peptide. This is somewhat different to the results of the AnCE crystallisation 
experiments, where it is the C-terminal dipeptide that appears to be removed. 
 
When leuhistin was added to the human serum and tynorphin mixture, tynorphin 
remained stable for at least 24 hours. Leuhistin is an inhibitor of aminopeptidases 
(Yoshida et al., 1991), indicating that it is aminopeptidases present in the human serum 
that are responsible for the observed rapid degradation of tynorphin. 
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There is no indication as to what the levels of ACE were in the serum, however it is not 
likely to have been present in very large quantities because ACE is predominantly 
located on endothelial cell membranes (Soubrier et al., 1988). There is therefore no 
strong evidence to contradict the observations made from the crystal structures of AnCE 
with tynorphin; that AnCE, and hence ACE, cleave tynorphin at multiple positions, and 
that this appears to begin with cleavage of the tyrosine-proline peptide bond. 
 
What is not clear is the time-scale on which these events occur. The proline residue at 
the P1’ position should protect the tyrosine-proline peptide bond from hydrolysis by 
AnCE in its role as a dipeptidyl carboxypeptidase, but the data presented here indicated 
that this may not be the case in the crystal environment. Further research is required to 
fully understand the stability of tynorphin towards angiotensin converting enzymes. A 
good starting point for this would be HPLC assays to understand what fragments AnCE 
cleaves tynorphin into and what the time frame is for these cleavage events, and hence 
whether they are biologically relevant.  
 
4.4.3 Structures of AnCE with Spinorphin 
All three datasets processed for AnCE with spinorphin displayed some difference 
density in the active site due to the presence of spinorphin fragments. As was the case 
with tynorphin, it was not possible to fit the full spinorphin heptapeptide (LVVYPWT) 




As illustrated in Figure 4.10, it was quite clear by studying the difference density in the 
AnCE_Spin_5 active site that the LVV tripeptide should be placed such that the residues 
occupied the S1, S1’ and S2’ subsites of the enzyme respectively. Placed in this way the 
catalytic zinc ion is co-ordinated by the carbonyl oxygen of the leucine and the amide 
nitrogen of the P1’ valine. This would appear to ideally position the tripeptide for 
cleavage of the leucine-valine peptide bond. Interestingly, this arrangement is very 
similar to the inhibition of MMPs (matrix metalloproteinases) by TIMPs (tissue 
inhibitors of metalloproteinases). Here there is bidentate chelation of the MMP zinc ion 
by the amino and carbonyl groups of the N-terminal TIMP residue (Brew et al., 2000). 
 
The electron density stops abruptly after the P2’ valine residue (Figure 4.10) and there 
was certainly no possibility of adding any additional spinorphin residues beyond this 
point. This strongly suggests that AnCE has cleaved spinorphin between the valine and 
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tyrosine residues, resulting in the LVV tripeptide. Further evidence for this is provided 
by the fact that a C-terminal carboxyl group that would have been introduced to the P2’ 
valine following peptide bond cleavage fits the difference density very well and forms 
conserved interactions with AnCE active site residues.  
 
Based on a single crystal structure, it is not possible to determine the sequence of events 
that led to the LVV tripeptide binding to the active site in this way. ACE homologues 
tend to remove the C-terminal dipeptide from their substrate, therefore it seems probable 
that the full spinorphin peptide may have bound to the active site with the C-terminal 
threonine residues at the P2’ position. The enzyme could then have removed the four C-
terminal residues by sequential cleavage of the WT and YP dipeptides. This would leave 
the LVV tripeptide able to slide along the active site to reach the position that it is in in 
the AnCE_Spin_4 structure. This is illustrated in Figure 4.17.!
 
4.4.3.2 AnCE_Spin_5 
The second structure of AnCE with spinorphin contains more extensive density in the 
active site than is seen in the AnCE_Spin_4 structure. As illustrated in Figure 4.12, the 
YPWT tetrapeptide was modelled in this density with the tyrosine, proline, tryptophan 
and threonine residues at the P2, P1, P1’ and P2’ positions, respectively. There was little 
ambiguity in the placement of these residues as the bulky side chains of tyrosine and 
tryptophan, the unique cyclic nature of proline and the terminal carboxyl group of 
threonine matched the density well, as shown in Figure 4.12. There was also no 
possibility of extending the N-terminus of the peptide beyond the tyrosine. The 
difference density stopped abruptly at this point, indicating that the peptide had been 
cleaved between the valine and tyrosine residues. 
 
This complements the AnCE_Spin_4 structure well, providing further evidence of the 
cleavage of the valine-tyrosine peptide bond by AnCE. It does however contradict the 
proposed sequence of events. Given that the YPWT peptide has remained intact here, 
the enzyme appears to be cleaving the valine-tyrosine bond in the full-length peptide, 
rather than following cleavage of the proline-tryptophan bond. Although angiotensin-
converting enzymes most commonly act as dipeptidyl carboxypeptidases, N-terminal 
tripeptidase activity has previously been reported not only for human ACE, but also for 
AnCE (Isaac et al., 2007; Lamango et al., 1996; Siviter et al., 2002) thus, this would not 





The AnCE_Spin_6 data shows much less difference density in the active site than in 
either of the other two spinorphin structures. In spite of this, it is very clear from the 
density that it is due to a dipeptide, consisting of tyrosine at the P1’ position and proline 
at the P2’ position. This is illustrated in Figure 4.14, where the YP dipeptide is shown in 
the electron density. 
 
The most likely explanation for the YP dipeptide at this position is that the YPWT 
peptide seen in AnCE_Spin_5 has had its C-terminal dipeptide (WT) removed by AnCE. 
The remaining two residues, tyrosine and proline, have then been able to slide along the 
active site and occupy the S1’ and S2’ positions. Here the newly introduced proline 
carboxyl group interacts with active site residues Gln265, Lys495 and Tyr504, 
stabilising the dipeptide in this position. This sequence of events is depicted in Figure 
4.17. 
 
Interestingly, the crystals used for AnCE_Spin_6 data collection were grown at the same 
time as those used for the AnCE_Spin_5 data. Hence, it seems reasonable to suggest, 
that during the intervening three weeks further peptide cleavage occurred within the 
crystal.  
 
This does not correspond quite so well with the interpretation of the AnCE_Spin_4 and 
AnCE_Spin_5 structures, where it was proposed that AnCE was cleaving the N-terminal 
tripeptide (LVV) from spinorphin. It is not possible to form a conclusion based only on 
the three structures presented here, however it is likely that AnCE is cleaving both the 
N-terminal tripeptide and the C-terminal dipeptide. It is not possible to ascertain from 
the structures alone the sequence or relative rates of these processes, although it is 
probable that the N-terminal tripeptide is removed first. It is also quite possible, based 
on the position of the LVV tripeptide in AnCE_Spin_4, that this fragment undergoes 
further cleavage to leucine and a dipeptide consisting of VV.  
 
Irrespective of the precise sequence of events, it is clear that AnCE is cleaving 
spinorphin at multiple sites and that the resulting peptide fragments are able to move and 
occupy different positions within the catalytic site. This is very similar to what was 
observed with tynorphin. Peptide hydrolysis at multiple sites is likely a consequence of 
the broad range of biological functions of ACE homologues. The majority of 
interactions formed between angiotensin converting enzymes and peptide substrates 
only involve the peptide backbone, resulting in relatively broad substrate specificity.!!
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Figure 4.17: Schematic Representation of Spinorphin Binding at the AnCE Active Site. In all figures the locations of the subsites of the enzymes are 
labelled as S3, S2, S1, S1’ and S2’. The location of the catalytic zinc ion between the S1 and S1’ subsites is also indicated. The spinorphin residues occupying 
each subsite are labelled. (a) In the AnCE_Spin_4 structure the tripeptide LVV, shown in green, occupies the S1, S1’ and S2’ subsites. (b) In the AnCE_Spin_5 
structure a four residue fragment of spinorphin, YPWT, occupies the S2, S1, S1’ and S2’ subsites. The peptide is positioned for cleavage of the peptide bond 
between the proline and tryptophan residues. (c) In the AnCE_Spin_6 structure a single dipeptide, YP (shown in purple), is found in the S1’ and S2’ subsites. 
This is likely to be the result of cleavage of the YPWT tetrapeptide shown in (b) and release of WT from the active site, enabling the YP dipeptide to move 
and occupy this position. (d) Schematic showing the full-length spinorphin peptide with residues colour coded as in (a), (b) and (c) to illustrate the different 
cleavage products. Arrows highlight sites where peptide cleavage has been observed to occur. !
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4.4.4 Stability of Spinorphin in the Presence of Angiotensin Converting Enzymes 
Two studies have previously investigated the stability of spinorphin in the presence of 
ACE. The first, performed by Lantz et al. in 1991, used a related haemorphin with the 
sequence LVVYPWTQR. This is identical to spinorphin with the addition of glutamine 
and arginine at the C-terminus. Following incubation with lung extract, a source of 
ACE, the C-terminal QR dipeptide was cleaved leaving LVVYPWT, i.e. spinorphin. 
Following further incubation the LVV tripeptide was released leaving YPWT. YPWT 
did not undergo further cleavage and remained stable for the 7 hours of the experiment.  
 
These results support the removal of the LVV N-terminal tripeptide seen here. However, 
the experiment was not performed with pure ACE. The lung extract would have 
contained many different membrane localised enzymes hence it is impossible to 
determine which enzymes were responsible for the cleavage. The fact that the YPWT 
peptide remained intact does appear to contradict the results from the crystal structures. 
 
The second time that this was investigated was by Zhao et al., in 1994. Here the same 
related haemorphin, LVVYPWTQR, was used and this time incubated directly with 
ACE. Here once again the peptide bond between threonine and glutamine was cleaved, 
resulting in the release of the QR dipeptide. Further incubation for 7 hours did not lead 
to further peptide cleavage, indicating that under these conditions ACE is neither acting 
as an N-terminal tripeptidase nor is it removing further residues from the C-terminus of 
the peptide. 
 
The results from the structural studies with AnCE are a direct contradiction of this, 
however there are a number of important points to consider. The first is that the nature 
of the two systems is exceedingly different. The stability experiments performed by 
Zhao et al., took place over 7 hours at 37 oC in a dilute solution. In contrast the 
crystallisation experiments were performed at 21 oC, the set-up is by its very nature 
highly concentrated, the components of the solution (buffer, salt and precipitant) were 
different and the peptide was incubated with the enzyme for 30 minutes prior to 
crystallisation and then in the crystals for up to 3 months. It is possible that ACE does 
display further activity towards spinorphin, but the rate of this reaction is so slow that it 
would not be detected under the conditions of the experiment performed by Zhao et al., 
it is also therefore unlikely to be physiologically relevant.  
 
The second consideration is that this work was performed using the D. melanogaster 
ACE homologue, AnCE, rather than the human enzyme. Although AnCE has been used 
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very successfully as a model for human ACE it is important not to overlook the 
limitations of this system. It is possible that whilst AnCE may cleave spinorphin, and 
indeed tynorphin, into multiple fragements, ACE may display much more limited 
peptidase activity towards these peptides. The only way to investigate this further would 
be to perform further experiments with both ACE and AnCE.  
 
4.4.5 Spinorphin and Tynorphin as ACE Inhibitors 
Spinorphin is a naturally occurring peptide formed by the cleavage of the β-chain of 
haemoglobin that was identified as an inhibitor of enkephalin degrading enzymes, 
including ACE (Nishimura et al., 1993). Tynorphin is a related peptide designed to be a 
better inhibitor of DPPIII and is a weaker inhibitor of ACE than spinorphin (Yamamoto 
et al., 2000).  
 
The sequences of spinorphin and tynorphin are closely related; spinorphin has an 
additional leucine residue at the N-terminus and an additional threonine at its C-
terminus. It is the additional leucine that is mainly thought to be responsible for the 
increased potency of spinorphin as an ACE inhibitor; a study performed using the 
closely related peptide VVYPWTQF showed that addition of an N-terminal leucine 
residue, as seen in spinorphin, decreased the IC50 for ACE inhibition from 10.2 µM to 
1.7 µM (Zhao et al., 1994; Zhao and Piot, 1997). 
 
Based on the structural data presented here it is not immediately apparent why the N-
terminal extension has such a profound effect on the inhibitory properties of these 
peptides. The most straightforward explanation would be that the additional residue 
allows the peptide to form more extensive interactions with the active site. However it is 
unlikely that the explanation is as simple as this. Primarily, this is because ACE tends to 
interact mainly with the peptide backbone of its substrates and the additional leucine 
residue has quite a small, non-polar side chain that is unlikely to form particularly 
extensive interactions with the active site.  
 
Beyond this, the mechanism by which spinorphin and tynorphin function as ACE 
inhibitors also remains unclear. Based on the data presented here they appear to be 
competitive inhibitors that bind to the active site through interactions that are well 





4.4.5.1 Comparison of Spinorphin and Tynorphin with the BPPs 
The BPPs are a group of natural ACE inhibitory peptides originally isolated from the 
venom of the pit viper B. jararaca. As detailed in Chapter 3, the properties of these 
peptides as ACE inhibitors have been studied quite extensively. The BPPs are all proline 
rich peptides and there is very little relationship between the sequences of these peptides 
and spinorphin and tynorphin. This raises the question as to how spinorphin and 
tynorphin function as ACE inhibitors. 
 
The P1’ proline is recognised as an important feature of the BPPs as it protects the 
scissile peptide bond from cleavage, allowing them to act as competitive inhibitors of 
ACE. Interestingly, a proline residue is conserved at this position in tynorphin, but not in 
spinorphin, which is a more potent ACE inhibitor. Furthermore the data obtained here 
indicate that whilst spinorphin is cleaved by AnCE into many fragments, this does not 
include removal of the C-terminal threonine residue, which would leave the proline at 
the P1’ positon. 
 
It is clear that much more work is required to understand the mechanisms by which 
spinorphin and tynorphin function as ACE inhibitors. This may involve further 
crystallisation experiments with ACE rather than AnCE and if possible with inactive 
AnCE or ACE mutants. The latter would allow the study of the binding mechanism of 
the full-length peptides, which would provide more information about any additional 
interactions formed by the N-terminus of spinorphin compared to tynorphin. 
 
It would also be very beneficial to obtain kinetic data for ACE and AnCE inhibition by 
both peptides, and to perform further analysis of their stability in the presence of ACE. 
This would likely involve the use of HPLC and it would be particularly important to 
look at stability over different timescales, in different solution conditions and at different 
temperatures.  
 
Based on the crystallographic data presented here, it is possible that small, two or three 
residue, fragments of spinorphin and tynorphin are acting as competitive ACE 
inhibitors. This is an interesting concept and suggests that it may be possible to create 
potent ACE inhibitors by focusing on maximising the interactions with a small area of 
the active site, likely the S1’ and S2’ pockets, rather than along the length of the substrate 




4.5 Conclusions and Further work 
The peptide spinorphin, which is produced by enzymatic cleavage of the β-chain of 
haemoglobin, and the closely related synthetic peptide tynorphin, were characterised as 
ACE inhibitors a number of years ago. Prior to this study there was very little data to 
indicate how these peptides acted as ACE inhibitors or to explain the observed 
differences in their ability to inhibit ACE. 
 
Here three structures are presented for each peptide in complex with the D. 
melanogaster ACE homologue, AnCE. The structures indicate that both peptides are 
being cleaved by AnCE into multiple fragments, some of which are being retained in the 
active site and presumably acting as competitive inhibitors of enzyme activity. 
 
The possible sequence of cleavage events is discussed but further experimental evidence 
is required to form a firm conclusion. From the data presented here it is also difficult to 
explain why spinorphin is a more potent ACE inhibitor than tynorphin and the further 
work that would be required to investigate this is outlined.  
 
The crystal structures indicate that small peptide fragments derived from enzymatic 
cleavage of longer peptides may be able to function as good ACE inhibitors. This is 
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In addition to the well-studied actions of certain naturally occurring peptides as ACE 
inhibitors, there is an increasing amount of evidence to suggest that much smaller 
dipeptide fragments can also have this effect (Lunow et al., 2013; Marczak et al., 2003; 
Martin et al., 2008). This is an important development, as small dipeptides are likely to 
be biologically available, for example as products of digestion, and could have an 
important role in the in vivo regulation of ACE activity. 
 
The work presented in Chapter 4 on the structural basis of ACE inhibition by the 
haemorphins spinorphin and tynorphin indicated that small peptide fragments, arising 
from hydrolysis by ACE, might be at least partly responsible for the inhibitory activity 
of these two peptides. 
 
In recent years the action of dipeptides as ACE inhibitors has begun to be characterised. 
In 2013 a study conducted by Lunow et al. reported that the dipeptides IW and AW 
were able to inhibit sACE activity with IC50 values of 0.7 µM and 20 µM, respectively 
(Lunow et al., 2013). In a further study, performed in 2015, the same group reported that 
some dipeptides displayed selective inhibition of the two domains of sACE (Lunow et 
al., 2015).  
 
Taken together with the potential bioavailability of such compounds, these 
developments indicate that research into the inhibitory actions of dipeptides could be an 
important area to pursue both in terms of understanding more about the in vivo activities 
of this enzyme, but also how it may be possible to use the way that these molecules 
interact with the two domains of sACE in the development of a new generation of 
domain specific inhibitors. 
 
In the work presented by Lunow et al. in 2015, a C-terminal tryptophan residue was 
implicated in selective inhibition of the C-domain by dipeptides. It has been suggested 
that this is as a result of the increased hydrophobicity of the S2’ pocket in the C-domain 
compared to the N-domain, a feature that has previously been exploited in the 
development of the C-domain selective inhibitors RXPA380 (Georgiadis et al., 2004) 
and kAW ((5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-tryptophan) 
(Almquist et al., 1980; Deddish et al., 1998; Nchinda et al., 2006; Redelinghuys et al., 
2006; Watermeyer et al., 2008). Similarly, an aliphatic residue at the P1’ position 
improved C-domain inhibition, with the dipeptides IW and VW being better inhibitors 
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than YW. Conversely, the data collected indicated that a C-terminal arginine residue 
might be associated with N-domain selectivity (Lunow et al., 2015). 
 
5.1.1 Aims 
The aim of the work presented in this chapter is to use the D. melanogaster ACE 
homologue AnCE as a model to study the structural basis of ACE inhibition by four 
dipeptides: WR, VW, IW and YW in order to learn more about how these molecules 
function as inhibitors and how this could be built upon in the design of future, domain 
specific inhibitors.  
 
AnCE is a good system to use as a model for this. The hydrophobicity of the S2’ pocket 
in the C-domain has been suggested as the cause of the observed domain selectivity seen 
with the tryptophan containing dipeptides. In the C-domain two valine residues, Val379 
and Val380 are primarily responsible for this. In the N-domain, Ser357 and Thr358 
replace these, respectively, reducing the hydrophobic nature of this site. Interestingly, in 
AnCE, Phe363 and Thr364 replace Val379 and Val380, respectively. This indicates that 
the S2’ pocket in AnCE shares some features with that of the N-domain, whilst also 
retaining some of the hydrophobicity present in the C-domain. It should therefore be 
possible to use AnCE to provide an insight into how these dipeptides interact with both 




5.2.1 AnCE Expression, Purification and Crystallisation 
Expression and purification of AnCE was performed as outlined in 2.7. Recombinant 
AnCE was expressed using the methylotropic yeast P. pastoris and purified by 
hydrophobic interaction chromatography followed by size exclusion chromatography. 
The identity and purity of the protein were confirmed by SDS-PAGE analysis. 
 
Co-crystallisation experiments with the dipeptides WR, VW, IW and YW were 
performed using the hanging drop vapour diffusion technique following the general 
protocol for AnCE crystallisation that is detailed in section 2.7.4. The four dipeptides 
were all purchased from GL Biochem (Shanghai) Ltd.  
 
Immediately prior to crystallisation, AnCE at a concentration of 17.5 mg ml-1 was 
incubated with 20 mM of each dipeptide in a 1:4 ratio of dipeptide:protein at 4 oC for 
approximately 30 minutes. 1 µl of the protein and dipeptide mixture was then mixed 
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with 1 µl of reservoir solution to form a 2 µl drop. Each drop was suspended on a 
coverslip over 500 µl of the appropriate reservoir solution (1.2-1.3 M sodium citrate, 0.1 
M HEPES pH 7.5) and the wells sealed with high vacuum grease. The crystallisation 
experiments were incubated at 21 oC and observed regularly for any signs of crystal 
formation.  
 
5.2.2 X-ray Diffraction Data Collection 
Previous experiments with AnCE have shown that the high sodium citrate concentration 
(1.2-1.3 M) used during crystallisation provides sufficient cryo-protection, negating the 
need for additional cryo-protectants (Akif et al., 2010). Based on this, prior to crystal 
mounting an additional 1 µl of the reservoir solution was added to the drop so as to 
maximise the sodium citrate concentration and to help to stop the drop from becoming 
too dry.  
 
Crystals were mounted directly into litholoops (Molecular Dimensions Ltd., 
Newmarket, UK) and rapidly frozen in liquid nitrogen for transportation to the 
synchrotron.  
 
All diffraction data were collected at DLS using beamline i04. Data were captured using 
a Pilatus3 6M detector and all diffraction experiments were performed at 100 K.  A 
summary of key data collection parameters is presented in Table 5.1. 
 
5.2.3 Data Processing and Structure Solution 
All datasets collected were initially processed using the xia2 pipeline (Winter, 2010) at 
DLS. Following this the “best” dataset collected for each dipeptide was identified based 
on the resolution and completeness of the data. These four datasets were then used for 
further processing and structure solution. 
 
Integration for the four best datasets was performed using MOSFLM (Battye et al., 
2011; Leslie and Powell, 2007) followed by scaling using Aimless (Evans, 2006; Evans, 
2007). Initial phases were calculated by molecular replacement using Phaser (McCoy et 
al., 2007) with the native AnCE structure, PDB code 2X8Y (Akif et al., 2010), as the 
search model. 
 
Following production of the initial models, iterative rounds of model building in Coot 
(Emsley et al., 2011) and refinement using REFMAC (Murshudov et al., 1997; 
Murshudov et al., 2011) were performed. A key part of this was modelling dipeptide 
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residues into active site difference density. Water molecules were added where Fo-Fc 
peaks in electron density exceeded 3σ and where potential hydrogen bonds could be 
made.  
 
Molprobity (Chen et al., 2010) was used to validate the quality of the final structures 
and LigPlot+ (Laskowski and Swindells, 2011) to study interactions between the 
dipeptides and the active site. The molecular graphics program Pymol (The PyMOL 
Molecular Graphics System, Version 1.7.4, Schrödinger, LLC) was used to perform 
RMSD calculations and to prepare the figures. 
 
5.3 Results 
5.3.1 Co-crystallisation of AnCE with IW, VW, YW and WR 
Following co-crystallisation with the four dipeptides, crystals appeared in every drop 
(1.2-1.3 M sodium citrate, 0.1 M HEPES, pH 7.5) within 10 days of incubation at 21 oC. 
These crystals had the same appearance as those that are normally obtained for AnCE in 
this condition and some examples are shown in Figure 5.1. 
 
 




Figure 5.1: Examples of AnCE Crystals Obtained Following Co-crystallisation with 
the Dipeptides IW, VW, YW and WR. Crystals are shown in a 2 µl drop and were 






5.3.2 X-ray Diffraction Data Collection 
X-ray diffraction data for AnCE in complex with each of the dipeptides were collected 
at DLS using beamline i04 on 16th April 2015. Following this, a further two datasets 
were collected for AnCE with IW and WR, also using beamline i04 at DLS, on 2nd July 
2015. All data were collected using a Pilatus3 6M detector. An example of the 
diffraction images obtained is shown in Figure 5.2. 
 
        
Figure 5.2: Example of a Diffraction Image Obtained from a Crystal of AnCE with 
IW. Resolution rings are shown in yellow and labelled. Diffraction beyond 2.6 Å is 
clearly visible on the inset image.!!
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Dataset name Collection date Beamlline Detector Number of images Phi range (o) Resolution range (Å) Overall completeness (%) 
AnCE_IW_1 16th April 2015 i04 Pilatus3 6M 1800 0-180 28.80-1.95 81.8 
AnCE_VW_1 16th April 2015 i04 Pilatus3 6M 900 0-180 86.54-1.90 99.6 
AnCE_YW_1 16th April 2015 i04 Pilatus3 6M 900 0-180 86.33-1.72 98.4 
AnCE_WR_1 16th April 2015 i04 Pilatus3 6M 900 0-180 86.25-1.72 98.9 
AnCE_IW_2 2nd July 2015 i04 Pilatus3 6M 1200 63-243 86.69-2.15 99.5 
AnCE_WR_2 2nd July 2015 i04 Pilatus3 6M 900 123-303 86.66-1.71 99.9 
 
 
Table 5.1: Summary of Data Collection and Initial Processing Statistics for AnCE with the Dipeptides IW, VW, YW and WR. Where more than one 
dataset was collected for the same dipeptide the data used in downstream processing is highlighted in yellow.  !
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The six datasets collected were all successfully processed in the first instance using the 
xia2 pipeline at DLS (Winter, 2010) in the space group h3. The statistics obtained from 
this are included in Table 5.1.  
 
Where two datasets were collected for the same dipeptide, namely IR and WR, the 
“best” dataset was identified and used in further processing steps. For WR this selection 
was straightforward and the second dataset collected (AnCE_WR_2) was chosen 
because it was collected to a higher resolution than the first. 
 
In the case of IW the resolution of the first dataset, AnCE_IW_1, was slightly higher 
than that of AnCE_IW_2, 1.90 Å and 2.15 Å, respectively. However during data 
processing the maximum completeness that could be achieved for the AnCE_IW_1 data 
was 81 %. Attempts were made to improve this value by imposing a resolution limit, but 
even when this reached 2.15 Å, the resolution of AnCE_IW_2, the overall completeness 
was still less than 85 %. In contrast, the overall completeness for the AnCE_IW_2 data 
at this resolution was 100 % hence this dataset was used for further processing and 
structure solution. 
 
5.3.3 Data Processing and Structure Solution 
The four datasets, one for AnCE with each dipeptide, were processed using MOSFLM 
(Battye et al., 2011; Leslie and Powell, 2007) and Aimless (Evans, 2006; Evans, 2007) 
in the space group h3, which is the space group normally seen for AnCE crystals grown 
in this condition (Akif et al., 2010). Phases were calculated by molecular replacement 
using Phaser (McCoy et al., 2007) with the native AnCE structure, PDB code 2X8Y 
(Akif et al., 2010), as the search model. In each case there was one molecule per 
asymmetric unit in the crystal. 
 
Following an initial round of rigid body refinement, performed using REFMAC 
(Murshudov et al., 1997; Murshudov et al., 2011), there was clear difference density at 
each of the three N-linked glycosylation sites that are present in the native AnCE 
structure, hence N-linked glycan chains were added to the models at Asn53, Asn196 and 
Asn311. The catalytic zinc ion was modelled into the active site difference density, co-
ordinated by His367, His371 and Glu395. Following these adjustments a portion of 
difference density remained in the active site of each of the four structures. Dipeptide 
residues were fitted to this density as appropriate and this is discussed in the subsequent 
sections. Further rounds of refinement followed prior to structure validation using 
Molprobity (Chen et al., 2010). Data processing statistics are detailed in Table 5.2.
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 AnCE_IW AnCE_VW AnCE_YW AnCE_WR 
Beamline at DLS i04 i04 i04 i04 
Detector Pilatus3 6M Pilatus3 6M Pilatus3 6M Pilatus3 6M 
Wavelength (Å) 0.980 0.980 0.980 0.980 
Space group h3 h3 h3 h3 





































1 1 1 1 
Resolution range (Å) 86.69-2.15 86.54-2.20 86.33-1.72 86.64-1.71 
♯Rmerge (%) 9.5 (64.1) 8.2 (48.8) 5.7 (49.8) 6.1 (71.4) 
+Rpim (%) 7.3 (48.8) 5.5 (32.4) 5.2 (46.0) 4.7 (46.2) 
Mean I/σ(I) 1.0 (0.8) 9.4 (2.8) 7.9 (1.6) 11.2 (1.7) 




























Multiplicity 4.8 (4.6) 3.6 (3.7) 2.6 (2.2) 4.7 (3.9) 
Wilson B factor (Å2) 34.47 35.11 25.72 28.15 



































§Rcryst/♯♯Rfree (%) 16.45/19.92 17.93/22.13 17.25/19.61 16.81/18.57 
R.M.S deviation 
from ideal values 
Bond lengths (Å) 





































#!!!"#$" = !Σ!!"Σ! !!! ℎ!" − ! ! ℎ!" /Σ!!"Σ!!!(ℎ!"), where Ii(hkl) is the intensity of 
ith measurement and <I(hkl)> is the average of symmetry-related observations of a 
unique reflection. 
+!!"# = !Σ!!" !!!! Σ!!!! !! ℎ!" − ! ℎ!" /Σ!!"Σ!!!(ℎ!") 
§!!"#$% = !Σ! !!!!! /Σ!!!, where Fo and Fc are observed and calculated structure factor 
amplitudes of reflection h, respectively. 
##Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections. 
 
Table 5.2: X-ray Diffraction Data Collection, Processing and Refinement Statistics 
for AnCE with IW, VW, YW and WR. Outer shell values are shown in parentheses. 
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5.3.4 Crystal Structures of AnCE in Complex with the Dipeptides 
Analysis of the overall topology of each structure indicates that there has been no large-
scale movement of secondary structure elements compared to the native AnCE structure. 
This is confirmed by calculated RMSD values in the range 0.094 to 0.139 for each 
structure compared to native AnCE. Key features of AnCE seen in the structures include 
the long substrate binding channel that extends the length of the molecule and that is 
capped by an “N-terminal lid” formed by helices α1, α2 and α3. The active site is 
located at the centre of this channel, marked by the location of the catalytic zinc ion. It is 
here that difference density was observed in each of the dipeptide structures.  
 
5.3.4.1 AnCE and IW 
A total of 1200 diffraction images were collected from the crystal of AnCE with the 
dipeptide IW, which covered 180o. All 1200 of these images were used to process the 
data to a final resolution of 2.15 Å. Data processing statistics are summarised in Table 
5.2. 
 
Following initial rounds of model building and refinement, a quantity of difference 
density was visible in the AnCE active site. The IW peptide was placed into this density 
such that the isoleucine and tryptophan residues were occupying the S1’ and S2’ pockets 
respectively. As shown in Figure 5.3, all atoms of the dipeptide are well accommodated 
by the electron density at this position.   
 
                               
 
 
Figure 5.3: Fo-Fc Density Map Contoured at 3σ to Illustrate Binding of the IW 
Dipeptide to the AnCE Active Site. The IW residues are shown as green sticks and the 
Fo-Fc map as a grey mesh. Both residues are well accommodated by the density. 
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The mode of binding of the dipeptide is such that the C-terminal tryptophan side chain 
resides in a “hydrophobic pocket” that is formed primarily by Phe441, Phe551 and 
Phe363 (Figure 5.4). Further to this, the P2’ tryptophan residue also forms a number of 
interactions with the S2’ pocket that are well conserved in peptide binding to ACE 
homologues. The C-terminal carboxylate group interacts with the side chains of residues 
of Gln265, Lys495 and Tyr504. Additionally, the indole ring of the tryptophan side 
chain interacts with the side chain of Gln266. 
 
Further contacts with the active site are made by the P1’ isoleucine. This residue contacts 
the side chains of His337 and His497 through its carbonyl oxygen, and the protein 
backbone at Ala338 via its amide nitrogen. 
 
The dipeptide does not appear to interact directly with the catalytic zinc ion, rather it 
forms a water-mediated interaction from the P1’ amide nitrogen. Interestingly this 
nitrogen forms a direct interaction with Glu368, which has been implicated in the 
catalytic mechanism, where it is thought to have a role in activating the catalytic water 
molecule for nucleophilic attack (section 1.6.4) (Zhang et al., 2013). The binding of IW 
to the active site is illustrated in Figure 5.4 and the interactions that occur between the 
dipeptide and the enzyme are listed in Table 5.3. 
 
An important observation is that the position adopted by the tryptophan residue in the 
structure of AnCE with IW is almost identical to that of the tryptophan moiety of the C-
domain selective inhibitor RXPA380 in the crystal structure with both AnCE and the C-
domain of sACE (Akif et al., 2010; Corradi et al., 2007). This indicates that the IW 
dipeptide is likely to bind to the C-domain in the same manner as observed here for 
AnCE. 
 
IW atom Interacting atom Distance (Å) 
P2’ Trp OXT Water 2.79 
P2’ Trp O Lys495 NZ 2.60 
P2’ Trp O Tyr504 OH 2.68 
P2’ Trp NE2 Gln266 OE1 3.34 
P1’ Ile O His497 NE2 3.11 
P1’ Ile O His337 NE2 2.75 
P1’ Ile N Ala338 O 3.18 
P1’ Ile N Glu368 OE2 2.71 
P1’ Ile N Water 2.65 
 
Table 5.3: List of Interactions Formed by the IW Dipeptide in the AnCE Active 
Site.  
! 137 
               
 
         
 
Figure 5.4: Binding of the Dipeptide IW to the AnCE Active Site. (a) The isoleucine 
and tryptophan residues occupying the S1’ and S2’ subsites, respectively, are shown as 
green sticks, with interacting protein residues shown as cyan sticks. This includes 
residues Thr364, Phe441 and Phe511, which make a critical contribution to the 
hydrophobic nature of the binding pocket. Water molecules involved in binding are 
shown as orange spheres and the catalytic zinc ion is a grey sphere. (b) Schematic 
representation of (a). Colouring as in (a) with the exception of water molecules, which 
























5.3.4.2 AnCE and VW 
A total of 900 diffraction images were collected from the crystal of AnCE with the 
dipeptide VW. These covered a total of 180o and reached a resolution of 1.90 Å. 
Following integration of all images performed using MOSFLM, attempts were made to 
scale the data using Aimless, but this resulted in exceedingly high Rmerge values. 
 
Visual inspection of the diffraction images indicated that for a subset, images 501-700, 
there were very few Bragg peaks at greater than 2 Å resolution. These images were 
therefore removed and further attempts made to scale the data.  
 
Removing this subset of images did improve the Rmerge value to some degree but not to 
an acceptable value. Ultimately, a resolution limit of 2.2 Å was imposed and this, 
combined with removing images 501-700, resulted in an overall Rmerge value of 48.8 %. 
Importantly, the overall completeness remained at 99.3 %, indicating that removing the 
subset of images had not adversely affected the results. Full data processing statistics are 
detailed in Table 5.2. 
 
Following initial refinement of the structure of AnCE with VW some difference density 
was clearly visible in the active site. As shown in Figure 5.5, this density was somewhat 
ambiguous. Although more extensive than that seen for IW (Figure 5.3), it was not so 
well defined, making placement of the dipeptide residues more difficult.  
 
                      
 
 
Figure 5.5: Fo-Fc Density Map Contoured at 3σ to Illustrate Binding of the VW 
Dipeptide to the AnCE Active Site. The IW residues are shown as green sticks and the 
Fo-Fc map as a grey mesh. 
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Initially, two alanine residues were placed into the density to occupy the S2’ and S1’ 
subsites. After refinement there was very clear density for the valine side chain at the P1’ 
position and some remaining density at the P2’ position. The valine and tryptophan side 
chains were therefore added to the residues at P1’ and P2’ respectively. As shown in 
Figure 5.5, the difference density very well accommodates the peptide backbone and the 
valine side chain and the large, bulky tryptophan side chain also fits reasonably well. 
 
Although VW binds in approximately the same location as reported for IW, the P1’ 
residue adopts a slightly different position. The most obvious manifestation of this is 
that the valine nitrogen is able to interact directly with the catalytic zinc ion, rather than 
doing so through a water molecule, as seen in IW. This subtle movement means that the 
interaction with Glu368 that is seen with IW is not replicated here, as the isoleucine 
nitrogen is now more than 4 Å from the glutamate side chain.  The interactions formed 





VW atom Interacting atom Distance Å 
P2’ Trp OXT Water 2.74 
P2’ Trp O Lys495 NZ 2.65 
P2’ Trp O Gln265 NE2 3.23 
P2’ Trp O Tyr504 OH 2.45 
P2’ Trp NE2 Gln266 OE1 3.05 
P1’ Val O His497 NE2 2.58 
P1’ Val O His337 NE2 2.84 















          
 
            
 
 
Figure 5.6: Binding of the Dipeptide VW to the AnCE Active Site. (a) The valine and 
tryptophan residues occupying the S1’ and S2’ subsites, respectively, are shown as green 
sticks, with interacting protein residues shown as magenta sticks. This includes residues 
Thr364, Phe441 and Phe511, which make a critical contribution to the hydrophobic 
nature of the binding pocket. Water molecules involved in binding are shown as orange 
spheres and the catalytic zinc ion is a grey sphere. (b) Schematic representation of 
binding. Colouring as in (a) with the exception of water molecules, which are shown in 






















After placement of the dipeptide in the S2’ and S1’ subsites, some residual density was 
visible, extending past the zinc ion towards the S1 pocket, Figure 5.5. This is quite a 
significant piece of density; furthermore it appears to be continuous with the portion of 
density that has been attributed to the VW dipeptide. In spite of this the density is not 
particularly well defined, hence it was challenging to build the model into it. 
 
Based on the fact that the active site difference density is continuous, it is most likely 
due to the dipeptide in some way. With this in mind, an attempt was made to place the 
VW dipeptide in a second position in the active site, such that the valine residue 
remained in the S1’ site, but the tryptophan residue now resided in the S1 pocket. This is 
illustrated in Figure 5.7, which shows that whilst this model does not provide a “perfect 
fit” for the residual density, it is the best interpretation of the data available. It is 
therefore possible that in some molecules the VW dipeptide may have bound in this 
alternative location.!
 
Binding in this manner would mean that the C-terminal carboxylate of the tryptophan 
residue could interact with the catalytic zinc ion. Furthermore, the tryptophan nitrogen 
may be close enough to interact with the side chain of Glu368, a residue that has been 
implicated in catalysis. In AnCE Trp341 and Phe375 may play a role in providing a 
hydrophobic environment for the large tryptophan side chain. 
 
              
 
Figure 5.7: Placement of a Second VW Molecule at a Second Position in the AnCE 
Active to Fill the Remaining Difference Density. The VW molecule is shown as 
orange sticks, with the valine and tryptophan residues adopting the P1’ and P1 positions 
respectively. The difference density is displayed as a Fo-Fc map contoured at 3σ, shown 
as a grey mesh.  
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5.3.4.3 AnCE and YW 
900 diffraction images were collected from the crystal of AnCE with YW, covering 
180o. The maximum resolution of the data was 1.72 Å. In order to achieve good 
statistics for data processing at this resolution a subset of images, 51-250, were 
excluded. This resulted in an overall Rmerge value of 5.7 % and an overall completeness 
of 98.4 %. Full data processing statistics are presented in Table 5.2. 
 
Following initial rounds of model building and refinement, some difference density was 
visible in the active site. This was located in a very similar position to that seen for the 
dipeptides IW and VW (sections 5.3.4.1 and 5.3.4.2, respectively). The YW dipeptide 
was modelled into this difference density such that the tryptophan and tyrosine residues 
occupied the S2’ and S1’ subsites, respectively. As illustrated in Figure 5.8, this density 
very well accommodates the dipeptide backbone, whilst the large tryptophan and 
tyrosine side chains fit adequately. Unlike in the structure with VW, there is no evidence 
of any further difference density in the active site channel, indicating that YW binds at a 
single location. 
 
                     
 
 
Figure 5.8: Fo-Fc Density Map Contoured at 3σ to Illustrate Binding of YW to the 
AnCE Active Site. The YW dipeptide is shown as green sticks in the Fo-Fc map, 
displayed as a grey mesh. The tryptophan and tyrosine residues adopt the P2’ and P1’ 




The YW dipeptide binds in such a way as to form very similar interactions with the 
active site residues as previously described for IW and VW. The C-terminus is held in 
place via conserved interactions between the P2’ tryptophan carboxylate group and the 
side chains of Gln265, Lys495 and Tyr504. The P1’ carbonyl group also contacts the 
side chains of His337 and His497.  
 
Based on the interpretation of the active site difference density, the P1’ tyrosine nitrogen 
is not close enough to the active site zinc ion to interact with it directly, the interaction is 
instead mediated by a water molecule. This nitrogen does directly contact the protein 
backbone at Ala338 and also appears to interact with the side chain of Glu368, which 
has a proposed role in the catalytic mechanism (Zhang et al., 2013). The interactions 





YW atom Interacting atom Distance (Å) 
P2’ Trp OXT Water 2.76 
P2’ Trp O Lys495 NZ 2.89 
P2’ Trp O Gln265 NE2 3.12 
P2’ Trp O Tyr504 OH 2.59 
P2’ Trp NE1 Gln266 OE1 3.23 
P1’ Tyr O His337NE2 2.65 
P1’ Tyr O His497 NE2 2.95 
P1’ Tyr N Water 2.26 
P1’ Tyr N Glu368 OE2 2.71 
















             
 
 
             
 
Figure 5.9: Binding of the YW Dipeptide to the AnCE Active Site. (a) The dipeptide 
is shown as green sticks with the tryptophan and tyrosine residues occupying the S2’ and 
S1’ subsites, respectively. The catalytic zinc ion is shown as a grey sphere and key water 
molecules involved in binding as orange spheres. Interacting AnCE residues are shown 
as purple sticks and this includes those that contribute to the hydrophobic nature of the 
binding site, such as Thr364, Phe441 and Phe551. (b) Schematic representation of 
dipeptide binding. The colour scheme is as described for (a), but with water molecules 




















5.3.4.4 AnCE and WR 
900 diffraction images were collected for AnCE with WR, all of which were used to 
process the data to 1.71 Å resolution. Data processing statistics are detailed in Table 5.2. 
 
Following initial cycles of refinement, some difference density remained in the active 
site. It was immediately clear however that this was far less extensive than that seen for 
AnCE with IW, VW and YW (Figures 5.3, 5.5 and 5.8) and that it could not 
accommodate the WR dipeptide. 
The conclusion was hence drawn that the WR dipeptide had not bound to AnCE. A 
citrate ion from the crystallisation condition was placed in the active site density, Figure 
5.10, as is seen in the native AnCE structure, PDB code 2X8Y (Akif et al., 2010) when 





Figure 5.10: Fo-Fc Density Map Contoured at 3σ, Illustrating Binding of a Citrate 
Ion to the AnCE Active Site Following Co-crystallisation with the Dipeptide WR. 
The citrate ion is shown as green sticks in the difference density, which is displayed as a 
grey mesh. The active site zinc ion is shown as a grey sphere for reference. The citrate 
ion fits the observed density well and there is quite clearly insufficient difference density 
to accommodate the WR dipeptide. 
 
5.4 Discussion 
5.4.1 General Features of Dipeptide Binding to AnCE 
The results obtained here illustrate that dipeptides with a C-terminal tryptophan residue 
function as competitive inhibitors of ACE by binding to the enzyme’s active site. This is 
in accordance with kinetic data previously published by Lunow et al., 2015. 
 
The three dipeptides with a C-terminal tryptophan residue that were studied (IW, VW 
and YW) all bind to the AnCE active site in the same location, such that the tryptophan 





manner, the C-terminal carboxylate group is able to form interactions with conserved 
residues Gln265, Lys495 and Tyr504. Additionally, the carbonyl oxygen of the P1’ 
residue contacts the side chains of His337 and His497. These interactions are all 
commonly seen in peptide binding to angiotensin converting enzymes, as detailed in 
Chapters 3 and 4, and would be conserved in both the C- and N-domains of sACE. 
 
Adopting this position also means that the indole nitrogen of the C-terminal tryptophan 
residue forms an interaction with Gln266, which is conserved in the structures of AnCE 
with IW, VW and YW. The importance of this interaction to dipeptide binding is 
highlighted by the fact that the Gln266 side chain in the VW structure exists in a 
different conformation to that in the structures with YW and IW. This is so that it can 
maintain this interaction with the tryptophan side chain, which is in a slightly different 
orientation, as illustrated in Figure 5.11. 
!!!!!!!!!!!!!!! !
 
Figure 5.11: Interaction Between the Side Chain of Gln266 and the P2’ Dipeptide 
Tryptophan Residue. The Gln266 oxygen contacts the tryptophan indole nitrogen in 
the structures of AnCE with IW, VW and YW. The significance of this interaction is 
highlighted by the movement of the Gln266 side chain to accommodate the small 
variations in position of the tryptophan in the three structures. Here Gln266 is shown as 
cyan sticks interacting with the dipeptide IW, cyan sticks, and as magenta sticks, in a 




Interestingly, Gln266 is conserved in neither the C-domain nor the N-domain, where 
Thr282 and Ser260 replace it, respectively. Neither threonine nor serine would be able 
to replicate this direct interaction with the tryptophan residue, although it is possible that 
a water-mediated interaction could occur. 
 
Whilst this means that this interaction is not relevant in terms of understanding the 
domain selectivity displayed by these dipeptides, it is a good example of how subtle 
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changes in active site residues can impact on substrate and inhibitor binding. It would be 
interesting to investigate the effect of this interaction further by mutating the C-domain 
Thr282 to glutamine and observing the effect that this has on inhibition. Small changes 
such as this are also important when considering the potential for designing inhibitors to 
specifically target insect ACE homologues, as discussed in section 1.10. !
5.4.2 Role of the C-terminal Tryptophan 
A C-terminal tryptophan moiety has previously been identified as an important 
determinant of selective inhibition of the C-domain, and this has been exploited in the 
development of inhibitors such as RXPA380 and kAW (Georgiadis et al., 2004; 
Redelinghuys et al., 2006;). 
 
Dipeptides with a C-terminal tryptophan moiety have also been shown to be potent and 
selective inhibitors of the C-domain of ACE (Lunow et al., 2013). Much of the 
hydrophobic nature of the C-domain is conserved in AnCE; thus, the structural data 
obtained here can be used to understand the basis of this selectivity. 
 
Comparison of the structures of AnCE with IW, VW and YW with those of AnCE with 
RXPA380 and the C-domain with kAW indicates that the C-terminal tryptophan moiety 




Figure 5.12: Comparison of Binding of the C-domain Selective Inhibitors IW, kAW 
and RXPA380 to ACE. The IW dipeptide from the structure with AnCE presented here 
is shown as cyan sticks with the zinc ion as a grey sphere for reference. Superposed onto 
this is RXPA380 from the structure with AnCE (PDB code 2X96 (Akif et al., 2010), 
which is shown as green sticks, and kAW from the structure with the C-domain (PDB 
code 3BKL (Watermeyer et al., 2008)), which is shown as pink sticks. The C-terminal 
P2’ tryptophan moiety is observed to bind at the same location in all three structures, 






This indicates that this is a conserved mode of binding and that the same factors that 
cause RXPA380 and kAW to be selective inhibitors of the C-domain are also 
responsible for this property of IW, VW and YW. The hydrophobic effect appears to be 
the principal driving force for tryptophan binding at this position, with AnCE residues 
Phe441, Phe511 and Phe363 contributing to a hydrophobic “pocket” for the tryptophan 
side chain. 
 
Phe441 and Phe511 are both conserved in the N- and C-domains of ACE. Previous work 
has implicated two valine residues, Val379 and Val380, in the C-domain as being key 
determinants of selectivity. These are not conserved in the N-domain, being replaced by 
serine and threonine respectively.  
 
In AnCE Val380 is, as in the N-domain, replaced by a threonine residue. Val379 is also 
not conserved, but the hydrophobic nature at this position is maintained because it is 
replaced by Phe363. This, combined with the structural data, suggests that Val379 
perhaps has a more significant role than Val380 in tryptophan binding, because the 
presence of a threonine at the equivalent position to that of Val380 does not appear to 
have negatively impacted IW, VW or YW binding to AnCE. 
 
It is important to take into consideration however that no kinetic data have yet been 
obtained for AnCE inhibition by these dipeptides. Although structural data indicate that 
IW, VW and YW are likely to be good AnCE inhibitors it is impossible to determine 
this from the structure alone. Furthermore, an additional interaction between the 
tryptophan side chain and Gln266 has been identified in AnCE that is likely to enhance 
binding, whilst the substitution of Val379 by Phe363 may increase the influence of 
hydrophobic interactions. These factors may well be sufficient to counter the negative 
effect of the Val380 threonine substitution, which may therefore have a much greater 
negative influence on binding to the N-domain. !
5.4.3 Importance of the P1’ Residue 
5.4.3.1 Role of an Aliphatic P1’ Residue in C-domain Inhibition 
The data presented by Lunow et al., 2015 indicate that whilst the C-terminal residue 
appears to be the key determinant of dipeptide domain selectivity, the P1’ residue does 
also have a role in this. An aliphatic residue at the P1’ position was observed to result in 
more effective inhibition of the C-domain, with IW and VW being more potent 




Two C-domain valine residues that are not conserved in the N-domain have been 
established as key determinants of C-domain selectivity. One of these residues, Val380, 
is located in very close proximity to the position adopted by the P1’ residues of the 
dipeptides in the structures that are presented here.  
 
In the N-domain, a threonine residue replaces Val380, and this is also the case in AnCE 
(Thr364), thus making this protein an ideal model for studying the role of this residue. 
 
As illustrated in Figure 5.13, the P1’ isoleucine residue in the IW structure comes to 
within ~4 Å of Thr364. Assuming that the dipeptides bind in a similar position in the C-
domain active site, then the hydrophobic interaction between Val380 and isoleucine or 
valine of the dipeptide is likely to be an important stabilising force for binding. The loss 
of this in the N-domain, combined with the previously outlined changes affecting the S2’ 






Figure 5.13: The Role of the P1’ Residue in Dipeptide Binding. The IW dipeptide 
from the structure with AnCE is shown as green sticks and the active site zinc ion as a 
grey sphere for reference. Val380 from the C-domain is shown as grey sticks. This 
residue is within 4 Å of the P1’ isoleucine residue, explaining the preference for an 
aliphatic P1’ residue for C-domain binding. In AnCE and the N-domain Val380 is 
replaced by threonine and AnCE Thr364 is shown as cyan sticks. Hence, the stabilising 









5.4.3.2 Effect of P1’ Tyrosine on YW Binding and Inhibition 
The dipeptide YW is much less selective for the C-domain than either IW or VW. It is 
both a weaker inhibitor of the C-domain and a much stronger inhibitor of the N-domain 
than these two dipeptides (Lunow et al., 2013). 
 
Analysis of the structure of AnCE with YW indicates that the hydroxyl group of the P1’ 
tyrosine is ~3 Å from the side chain of Asp360, hence, there is the potential for a 
hydrogen bond interaction between these two residues, stabilising YW binding at this 
position. This is supported by the observation that the side chain of Asp360 exists in a 
different conformation in the structure with YW compared to with IW and VW, in order 
to facilitate this interaction, Figure 5.14. 
 
!!!!!!!!!!!!!!!!!!!! !!
Figure 5.14: Interaction Between YW P1’ Tyrosine and AnCE Residue Asp360. The 
YW dipeptide from the structure with AnCE is shown as green sticks and the catalytic 
zinc ion as a grey sphere. The Asp360 side chain from the YW structure, purple sticks, 
adopts a different conformation to the equivalent residue in the structure with IW, cyan 
sticks, in order to form an interaction with the tyrosine side chain. 
 
 
Asp360 is replaced by Glu376 in the C-domain. This means that the charge at this 
position is conserved, but the longer Glu376 side chain is likely to clash with the 
tyrosine residue, potentially explaining the decreased potency of YW as a C-domain 
inhibitor. 
 






In contrast, Asp360 is conserved in the N-domain as Asp354, meaning that this 
interaction could be replicated, helping to explain why YW is a much better inhibitor of 
the N-domain than either IW or AW.   
 
These observations indicate that, in addition to the well-characterised role of the P2’ 
moiety, the interactions formed by the P1’ inhibitor residue can also have an important 
role in binding to the active site and hence the potency of the inhibitor. This is an area 
that should be explored further, to investigate how these interactions might be further 
exploited in inhibitor design. 
 
5.4.4 The Structure of AnCE with VW 
The difference density found in the catalytic channels of both the YW and IW structures 
was very clear, particularly for IW, and placement of the dipeptides was quite 
straightforward. This was not the case for VW, where more extensive density was seen. 
 
Initially the VW dipeptide was placed in the same position as YW and IW had been, 
meaning that all of the conserved interactions made by the C-terminus could be formed. 
These interactions, combined with the fact that the density for the valine side chain at 
P1’ is very well defined (Figure 5.5), mean that there is very little uncertainty 
surrounding this placement. 
 
Positioned in this way, the peptide backbone at the P1’ position has moved by ~ 1 Å 
compared to the YW and IW structures. This brings the valine side chain very close to 
Glu368, conserved in both the N- and C-domains. Consequently, the side chain of this 
residue has rotated relative to the YW and IW structures, presumably to minimise any 
contacts, as illustrated in Figure 5.15. This also means that the VW dipeptide is able to 
directly contact the catalytic zinc ion, whereas YW and IW do so through a water 
molecule. 
 
It is not immediately apparent by studying the structures why the VW dipeptide binds in 
a slightly different manner but it is clear from the difference density that this is the 
position that it is adopting. It might be the case that this is not the case in the C-domain, 







Figure 5.15: Positions of the Dipeptides VW and IW in the AnCE Active Site. The 
VW dipeptide is shown as magenta sticks and the IW dipeptide as cyan sticks. The P2’ 
tryptophan residues are found at the same position in both structures, but the peptide 
backbone at the P1’ position has moved by approximately 1 Å between the two 
structures. The side chain of Glu368 has also moved slightly between the two structures 
in order to avoid a clash with the valine side chain of VW. The Glu368 side chain from 
the structures with VW and IW are shown as cyan and magenta sticks, respectively. 
 
 
What is perhaps more surprising than this movement is the residual density beyond the 
P1’ valine. This is a significant portion of density, indicating that it is likely to be due in 
someway to the dipeptide. It also appears to be continuous with the VW portion of the 
density, with no visible break.  
 
Based on these observations, attempts were made to place the dipeptide in a second 
position. In Chapter 4, two of the datasets collected for AnCE with the inhibitor 
tynorphin (VVYPW) appear to show the PW dipeptide fragment bound at the P2 and P3 
positions. Given the similarity between PW and VW, an attempt was made to place VW 
at the position occupied by PW in the tynorphin structures. However analysis of the 
difference density seen in this structure is not indicative of the dipeptide binding at the 
same position. The density is located much closer to the catalytic zinc ion and in fact 
appears continuous with the C-terminal portion. !
Ultimately, the VW dipeptide was placed in the active site density in a second 
orientation. The valine remained in the S1’ position and the tryptophan was now 
occupying the S1 site. The different density adequately accommodates this arrangement, 
as shown in Figure 5.7. 
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Binding in this manner, the VW dipeptide might co-ordinate the catalytic zinc ion 
through its carboxylate group. The tryptophan moiety may then be in a similar position 
to the phenylalanine moieties of ACE inhibitors captopril, lisinopril, enalprilat and 
RXPA380, stabilised by hydrophobic interactions with Trp341 and Val502. Although 
this would provide an explanation for the density seen in the active site, it is not clear 
why VW would bind in this manner, but not IW, which is so very similar. It would 
therefore be prudent to collect more data for this complex before drawing a firm 
conclusion. 
 
5.4.5 AnCE and WR 
In spite of the ambiguity surrounding the VW structure, it remains clear that the 
dipeptides IW, VW and YW are all present, in some manner, in the AnCE structures. 
This does not appear to be the case for WR.  This is not entirely surprising, as WR is the 
only one of the dipeptides without a C-terminal tryptophan residue, and, analysis of the 
structures of IW, VW and YW has indicated that the bulky tryptophan side chain has a 
critical role in dipeptide binding to AnCE through the hydrophobic effect. 
 
The data presented by Lunow et al., 2015 indicate that WR is a very poor inhibitor of 
the C-domain, and the absence of WR in the AnCE structure strongly suggests that this 
is due to it having a very poor affinity for the active site. Considering the structures of 
the other dipeptides bound to AnCE provides some insight into the reasons for this. 
 
Interactions between the C-terminus of peptides and the S2’ subsite have been shown to 
be important conserved features of binding. It is therefore highly likely that WR would 
bind to the ACE active site with the C-terminal arginine residue at the P2’ position and 
the tryptophan residue at P1’. This would result in the large, positively charged arginine 
side chain projecting into a very hydrophobic pocket. Specifically, the arginine side 
chain is likely to be within 4 Å of two conserved phenylalanine residues: Phe441 and 
Phe511 (using AnCE numbering). 
!
In the AnCE active site, the presence of the large, hydrophobic, Phe363 residue is likely 
to further impede binding. In the C-domain the valine residue at this position is also 
likely to have a similar, although possibly less pronounced effect. 
 
WR is a slightly better inhibitor of the N-domain than the C-domain. This is likely a 
result of Phe363 being replaced by Ser357, which would help to reduce the 
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hydrophobicity of the S2’ subsite somewhat. However the fact that WR is not a very 
potent N-domain inhibitor indicates that this region of the active site remains 
sufficiently hydrophobic such that insertion of a large polar side chain is not entropically 
favourable. This means that whereas addition of a hydrophobic moiety at the P2’ 
position of potential inhibitors can help to enhance C-domain inhibition, large polar P2’ 
groups are unlikely to be a feature of successful N-domain inhibitors.  
 
5.5 Conclusions 
The data presented here provide, for the first time, an insight into the structural basis of 
ACE inhibition by dipeptides. The tryptophan containing dipeptides IW, VW and YW 
are all confirmed to be competitive inhibitors that bind to the active site of the enzyme. 
 
Key binding features include interactions formed by the C-terminal carboxylate group 
with Gln265, Lys495 and Tyr504, which are conserved features of peptide binding to 
angiotensin converting enzymes. Only one of the dipeptides, VW, appears to directly 
interact with the catalytic zinc ion, indicating that this is not a pre-requisite.  
 
A C-terminal tryptophan moiety has been shown to result in selective inhibition of the 
C-domain by these dipeptides. The data obtained here indicate that this is likely to be 
due to the increased hydrophobicity of the S2’ pocket of the C-domain compared to the 
N-domain, with the dipeptide tryptophan residues adopting the same positions on 
binding as the C-terminal tryptophan moieties of the inhibitors RXPA380 and kAW. 
Furthermore, an additional interaction with AnCE Gln266 was identified, that is 
conserved neither in the N- nor the C-domain. This highlights the importance of small 
substitutions in the active site pockets.  
 
In addition to the role of the P2’ position, the importance of the P1’ residue has also been 
identified. An aliphatic residue at P1’ improves C-domain inhibition and the structural 
data here indicate that this is due to the presence of a valine residue that is not conserved 
in the N-domain.  
 
An interaction has also been identified between a P1’ tyrosine and AnCE residue 
Glu368. This is conserved in the N-domain, but not in the C-domain. This feature should 
be the subject of further study, as it may be possible to exploit it in the design of N-















Chapter 6: A New Structure of AnCE in a 


















6.1.1 Existing AnCE Crystal Structures 
AnCE, an angiotensin converting enzyme homologue from D. melanogaster, has been 
used extensively as a model to study substrate and inhibitor binding to ACE. This 
includes the work presented in Chapters 3, 4 and 5 of this thesis.  
 
The crystal structure of AnCE was first reported by Kim et al., in 2003 (Kim et al., 
2003). This structure, referred to as the “form I” structure was determined at 2.40  Å 
resolution using crystals in the P21 space group. In 2010 a second, higher resolution 
(1.90 Å), AnCE structure was reported. This is referred to as the “form II” structure and 
was obtained from crystals in the h3 space group (Akif et al., 2010). It is the form II 
structure that has been used in all of the ensuing complex structures  (Akif et al., 2010; 
Akif et al., 2011; Akif et al., 2012; Masuyer et al., 2014) and in the work presented in 
Chapters 3, 4 and 5.  
 
Crystals for the form II structure are typically grown using the hanging drop vapour 
diffusion technique in a condition that contains 1.2-1.3 M sodium citrate, 0.1 M HEPES, 
pH 7.5. The condition gives rise to reproducible, diffraction quality crystals that 
consistently appear within 7-10 days of incubation at 21 oC. A comprehensive 
description of the AnCE crystallisation process, including pictures of crystals and an 
example diffraction image is given in section 2.7.4. 
 
6.1.2 Requirement for a New AnCE Crystallisation Condition 
The form II crystal structure has been used with great success to study binding of a wide 
range of inhibitors to AnCE. However it has recently become apparent that crystals 
grown using this condition may not always be ideal. 
 
All of the ACE inhibitors studied thus far have been competitive inhibitors, which form 
strong interactions with the active site, frequently through co-ordination of the catalytic 
zinc ion. As part of the process of developing a new generation of inhibitors, the need 
for which is discussed in some detail in section 1.5.1, attention has moved towards novel 
compounds, which bear very little resemblance to current inhibitors. 
 
Flavonoids are one example of this. These are low molecular weight polyphenol 
compounds isolated from plant extracts, which have been observed to display some 
ACE inhibitory activity (Guerrero et al., 2012; Loizzo et al., 2007; Nyman et al., 1998; 
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Park et al., 2003). These are particularly interesting, because their presence in plant 
extracts means that they are bioavailable through diet. 
 
Luteolin, Figure 6.1, is the most potent flavonoid ACE inhibitor identified thus far, with 
an IC50 value of 23 µM reported (Guerrero et al., 2012). Attempts to co-crystallise AnCE 
with luteolin in order to understand more about its inhibitory actions have so far proved 
unsuccessful. In each case crystals appear in the standard condition but the inhibitor is 
not present in the active site. 
 
                                     
 
Figure 6.1: Chemical Structure of the Flavonoid Luteolin, which Inhibits ACE with 
an IC50 of 23 µM (Guerrero et al., 2012). 
 
The condition used for AnCE crystallisation contains a high concentration of sodium 
citrate (1.2-1.3 M) and in the absence of luteolin, or any other inhibitor, a citrate ion is 
seen co-ordinating the catalytic zinc ion. It is possible that the affinity of luteolin, and 
other flavonoids, for the AnCE active site is insufficient to displace the citrate ion, hence 
why co-crystals have not formed. It would therefore be beneficial to obtain AnCE 
crystals from a condition that does not contain citrate, as this may be more suitable for 
co-crystallisation with new, weaker, inhibitors. 
 
In addition to this, as discussed in Chapter 3, it has not so far been possible to obtain 
crystals for AnCE with some of the BPPs using the current condition. The hypothesis is 
that binding of these peptides is causing a movement of secondary structure elements, 
similar to that seen in the structure of tACE with BPPb (Masuyer et al., 2012), and that 
this is having an effect on the crystal contacts that form between the protein molecules. 
In any new crystallisation condition that is identified it is probable that different crystal 





The aim of the work presented in this chapter is to identify a new condition in which 
AnCE can crystallise and to use these crystals to determine the structure of AnCE in a 
new crystal form. Ultimately, the aim is then to use this new condition to obtain crystals 
of AnCE with new inhibitors that have not co-crystallised in the standard condition. By 
studying the mechanisms of binding of these compounds it may then be possible to learn 




6.2.1 AnCE Expression and Purification 
Recombinant AnCE was expressed by the methylotropic yeast P. pastoris and purified 
using a two step protocol consisting of HIC followed by SEC, as described in section 
2.7. Purity of the protein was confirmed by SDS PAGE analysis.  
 
6.2.2 AnCE Crystallisation 
Following purification AnCE was dialysed to completeness into 5 mM HEPES pH 7.5, 
0.1 mM PMSF. Dialysis was performed at 4 oC using 12-14 kDA MWCO visking tubing 
(Medicell Membranes Ltd, London). The dialysed sample was then concentrated to 15 
mg ml-1 by centrifugation at 3000 g using 30 kDa molecular weight cut-off Amicon 
Ultra-15 Centrifugal Filter Units (Merck Millipore) and a Heraeus centrifuge (Thermo 
Fisher Scientific).  
 
Crystallisation experiments were performed using a Phoenix crystallisation robot (Art 
Robbins Instruments). Experiments were prepared in Intelli-plate 96 crystallisation 
plates (Hampton Research) using the sitting drop vapour diffusion method (described in 
section 2.6.2.3). 50 µl of the appropriate reservoir solutions were transferred, using the 
crystallisation robot, into each of the 96 wells of the crystallisation plates. 300 nl sitting 
drops were then assembled containing a 1:1 ratio of AnCE:reservoir solution. Plates 
were sealed using ClearVue sheets (Molecular Dimensions Ltd., Newmarket, UK) and 
incubated at 21 oC. All crystallisation experiments were observed regularly for any signs 
of crystal formation.  
 
In excess of one thousand different crystallisation conditions were screened using the 
following commercially available, pre-prepared screens: Clear StrategyTM Screen I HT-
96, Clear StrategyTM Screen II HT-96, Heavy + Light HT-96, JCSG-plusTM HT-96, 
MemGoldTM HT-96, MIDASTM HT-96, Morpheus® HT-96, PACT premierTM HT-96, 
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The PGA ScreenTM HT-96, ProPlexTM HT-96, Structure Screen 1 + 2 HT-96 and Stura 
FootPrint Combination HT-96 (all purchased from Molecular Dimensions Ltd., 
Newmarket, UK). 
 
6.2.3 Crystal Harvesting and X-ray Diffraction Data Collection 
Crystals grown in a drop containing 0.1 M MMT (Malic acid, MES monohydrate, Tris) 
buffer pH 4.0, 25 % w/v PEG 1500 were mounted directly from the drop into litholoops 
(Molecular Dimensions Ltd., Newmarket, UK) and flash frozen in liquid nitrogen for 
transportation to the synchrotron.  
 
All X-ray diffraction data were collected at 100 K on beamline I24 at DLS and captured 
using a Pilatus3 6M detector. 
 
6.2.4 Diffraction Data Processing 
Raw diffraction images were processed using MOSFLM (Battye et al., 2011; Leslie and 
Powell, 2007) prior to scaling using Aimless Evans, 2006; Evans, 2007), part of the 
CCP4 suite (Winn et al., 2011). Initial phases were calculated by molecular replacement 
using Phaser (McCoy et al., 2007) with the form II AnCE structure, PDB code 2X8Y 
(Akif et al., 2010) as the search model.  
 
The resulting model was subjected to an initial round of rigid body refinement using 
REFMAC (Murshudov et al., 1997; Murshudov et al., 2011). Following this, iterative 
rounds of model building and refinement were performed using Coot (Emsley et al., 
2011) and REFMAC, respectively, with a subset of 5 % of reflections separated for use 
as the Rfree set for cross-validation. 
 
Model building included adding water molecules to the structure where Fo-Fc peaks in 
electron density exceeded 3σ and where potential hydrogen bonds could be formed. 
Ligands were added to the active site as appropriate based on interpretation of the 
difference density.  
 
Validation of the final model was performed using Molprobity (Chen et al., 2010). 
LigPlot+ (Laskowski and Swindells, 2011) was used to study interactions of ligands with 
the AnCE active site and PDBePISA (Krissinel and Henrick, 2007; Krissinel, 2010) to 
probe crystal contacts between molecules. The molecular graphics program PyMol (The 
PyMOL Molecular Graphics System, Version 1.7.4, Schrödinger, LLC) was used to 
produce all of the structural figures. 
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6.3 Results and Discussion 
6.3.1 AnCE Crystallisation 
Following incubation at 21 oC for approximately 3 months, crystals were observed in a 
condition containing 0.1 MMT buffer pH 4.0 and 25 % w/v PEG 1500. An example of 
these crystals is shown in Figure 6.2. 
 
 
                                      
 
 
Figure 6.2: Crystals of AnCE Grown in a Condition Containing 0.1 M MMT 




6.3.2 X-ray Diffraction Data Collection 
Crystals grown in the “new” condition were mounted directly into litholoops for data 
collection at DLS. A total of 250 diffraction images were collected to 1.85 Å resolution, 
an example of a diffraction image is shown in Figure 6.3. 
 
Although diffraction experiments were performed at 100 K, no cryoprotecting solutions 
were used. This is because the crystallisation condition contains 25 % w/v PEG and 
PEGs have been reported to act as a cryoprotectant in some cases (Berejnov et al., 
2006).  
 
The crystal was largely stable during data collection, however there was some evidence 
of radiation damage occurring towards the end of the experiment. The quality of later 
diffraction images was visibly worse than earlier images, with a clear reduction in 
resolution. For this reason, only images 1-200 (inclusive) were used in data processing.  
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There is also some evidence of ice rings on the diffraction images at approximately 3.7 
Å, 2.2 Å and 1.9 Å (Chapman and Somasundaram, 2010; Dowell and Rinfret, 1960) 









Figure 6.3: X-ray Diffraction Image Collected from an AnCE Crystal Grown in the 
New Condition. Ice rings are visible 3.7 Å, 2.2 Å and 1.9 Å. Diffraction beyond 1.9 Å 











6.3.3 Data Processing and Structure Solution 
Integration and scaling of diffraction images 1-200 using MOSFLM and Aimless 
indicated that the crystals used for the data collection belonged to the space group 
P212121. This is in contrast to both the form I and form II AnCE structures, which were 
determined using crystals from the P21 and h3 space groups, respectively (Akif et al., 
2010; Kim et al., 2003). There was one molecule per asymmetric unit in the crystal. 
Data processing statistics are detailed in Table 6.2. 
 
Phases were calculated by molecular replacement performed using Phaser. The form II 
AnCE structure, PDB code 2X8Y (Akif et al., 2010) was used as the search model. A 
single phaser solution was found and the molecular replacement statistics, detailed in 
Table 6.1, indicate that this is almost certainly the correct solution. In particular, the 
TFZ score (translation function z-score) of 11.3 is significantly higher than 8, which is 
normally indicative of a correct solution (Oeffner et al., 2013). 
 
 
Parameter RFZ TFZ PAK LLG 
Value 6.4 11.3 0 15, 534 
 
 
Table 6.1: Molecular Replacement Statistics for the Form III AnCE Structure. 
Statistics obtained following molecular replacement performed using Phaser with the 
form II AnCE structure (PDB code 2X8Y) as the search model. RFZ = rotation function 





After molecular replacement, clear electron density was visible for AnCE residues 18-
614 (20-614 in the form II structure), the highly conserved catalytic zinc ion (co-
ordinated by His367, His371 and Glu395) and for N-linked glycans, which were added 
to the model at Asn53 and Asn311.  
 
Following initial rounds of model building and refinement clear difference density was 
visible in the catalytic channel and this was filled by a malate ion from the 
crystallisation solution. Final rounds of refinement were then performed, the statistics 
from which are shown in Table 6.2. The Rcryst value (16.31 %) is acceptable for a 
structure of this resolution (1.85 Å) and indicates that the model corresponds well to the 
diffraction data. Similarly, the difference between the Rcryst and Rfree values is 2.3 %, 
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which indicates that overfitting of the model has not occurred during refinement (section 
2.6.3.4.1) (Kleywegt and Brünger, 1996). This model is now referred to as the “form 
III” AnCE structure. 
 
Beamline at DLS i24 
Detector Pilatus3 6M 
Wavelength (Å) 1.000 
Space group P212121 
Unit cell parameters: 
a, b, c (Å) 
α, β, γ (o) 
 
86.12, 94.90, 99.03 
90.00, 90.00, 90.00 
Molecules per asymmetric unit 1 
Resolution range (Å) 68.62-1.85 
♯Rmerge (%) 6.1 (58.8) 
+Rpim (%) 5.0 (49.2) 
Mean I/σ(I) 10.6 (2.2) 
Completeness (%) 97.8 (89.5) 






Multiplicity 3.2 (2.2) 
Wilson B factor (Å2) 25.0 














§Rcryst/♯♯Rfree (%) 16.31/18.56 
R.M.S deviation from ideal 
values 
Bond lengths (Å) 













PDB code 5A2R 
#!!!"#$" = !Σ!!"Σ! !!! ℎ!" − ! ! ℎ!" /Σ!!"Σ!!!(ℎ!"), where Ii(hkl) is the intensity of 
ith measurement and <I(hkl)> is the average of symmetry-related observations of a 
unique reflection. 
+!!"# = !Σ!!" !!!! Σ!!!! !! ℎ!" − ! ℎ!" /Σ!!"Σ!!!(ℎ!") 
§!!"#$% = !Σ! !!!!! /Σ!!!, where Fo and Fc are observed and calculated structure factor 
amplitudes of reflection h, respectively. 
##Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections. 
 
Table 6.2: X-ray Diffraction Data Collection, Processing and Refinement Statistics 




6.3.4 Analysis of the Form III Structure 
6.3.4.1 Overall Structure 
The overall fold of the form III AnCE structure is illustrated in Figure 6.4. It adopts the 
characteristic, predominantly helical fold found in structures of angiotensin converting 
enzymes, consisting of twenty-one α-helices, nine short 310 helices and only two anti-
parallel β-strands. Key ACE structural features are conserved, including the long, central 
substrate binding channel with the active site at its centre, and the lid that controls 
access to this, which is formed by helices α1, α2 and α3.  
 
Visual inspection of the structure indicates that the overall topology is identical to that 
of both the form I and form II AnCE structures, with no gross movement of structural 
elements. This is confirmed by RMSD values of 0.27 Å and 0.33 Å for the form I and 
form II structures, respectively. 
                               
Figure 6.4: The Overall Appearance of the Form III AnCE Structure (PDB code 
5A2R). Cartoon representation of secondary structure elements highlights the 
dominance of α-helices, which are labelled α1-21. There are only two short β-strands. 
The overall topology is identical to that of the form I and form II structures. Key 
features include the long substrate binding channel with the active site at its centre, 
highlighted by the location of the catalytic zinc ion, grey sphere, and a malate ion from 
the crystallisation condition, green sticks. This channel is capped by a lid formed by 






Given that it is the form II structure that has been used in all of the inhibitor binding 
studies reported in the last five years, this will be the main focus of comparisons made 
during the analysis of the new AnCE structure.  
 
6.3.4.2 The Active Site 
Following initial rounds of refinement there remained a small portion of difference 
density in the active site. Based on the size and shape of the density and the components 
of the purification buffers and crystallisation solutions, a malate ion, presumably arising 
from the MMT buffer, was modelled into this density. As illustrated in Figure 6.5 the 
malate ion fits the density well and there was no residual density remaining following 
further refinement. 
 
         
 
Figure 6.5: Electron Density Map for Malate Binding to the AnCE Active Site. 
Electron density map is shown as a grey mesh contoured at 1σ around key active site 
residues (pink sticks), the catalytic zinc ion (grey sphere) and the malate ion from the 
crystallisation condition (cyan sticks). The malate ion fits the observed density well and 




The manner in which the malate ion binds to the active site is not dissimilar to that 
displayed by the C-terminal portion of the peptide and dipeptide inhibitors considered in 
Chapters 3, 4 and 5. One of the carboxylate groups interacts with the side chains of 
active site residues Gln265, Lys495 and Tyr504, whilst the other contacts the nitrogen 
atoms of His337 and His497. This is illustrated in Figures 6.5 and 6.6. 
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6.3.4.2.1 Comparison with the Form II Active Site 
As outlined in section 6.1.2, in the form II AnCE structure, in the absence of a ligand, a 
citrate ion is observed to co-ordinate the catalytic zinc ion. This has been identified as a 
problem in terms of studying the binding of new, weaker inhibitors, which are unable to 
displace this ion.  
 
Analysis of the form III structure indicates that the malate ion binds to the AnCE active 
site in a very similar manner to the citrate ion in the form II structure. Consequently, 
there is no observable movement of active site residues. 
 
Both ions interact with Gln265, Lys495 and Tyr504 through a carboxylate group. 
However whereas the second malate carboxylate contacts His337 and His497, the two 
remaining citrate carboxylate groups partake in water-mediated interactions with 
Tyr507, Asp399 and Glu395, the latter of which is also involved in zinc ion co-
ordination.   
 
Crucially, the citrate ion is also observed to interact with the catalytic zinc ion via a 
water molecule. Whilst this water molecule is conserved in the new AnCE structure, the 
position of the malate ion indicates that it would be unable to replicate this interaction. 
This suggests that the malate ion is not held so strongly in the active site and hence 
might be more easily displaced by weaker inhibitors. A summary of these interactions in 
both the form II and form III structures is presented in Figure 6.6 and summarised in 
Tables 6.3. 
Citrate atom Interacting atoms Distance (Å) 
OA1 Water 2.61 
OA2 Y504 OH 2.87 
OA2 Q265 NE2 3.28 
OA2 K495 NZ 3.22 
OHB Water 2.86 
OG2 Water 3.20 
OB1 Water 2.96 
Malate atom Interacting atoms Distance (Å) 
O1 Y504 OH 2.52 
O1 Q265 NE2 3.02 
O1 K495 NZ 2.70 
O2 Water 2.79 
O4 H497 NE2 2.95 
O4 H337 NE2 2.67 
 
Table 6.3: List of Interactions Formed by the Citrate and Malate Ions in the Active 
Sites of the Form II and III AnCE Structures. 
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Figure 6.6: Binding of Citrate and Malate Ions to the Form II (PDB code 2X8Y) 
and Form III AnCE Structures (5A2R). (a) Key active site residues from the form II 
AnCE structure that interact with the citrate ion are shown as cyan sticks with the citrate 
ion as green sticks. The catalytic zinc ion is shown as a grey sphere and a water 
molecule that mediates an interaction between the citrate and zinc ions as an orange 
sphere. (b) The same active site residues are shown for the form III structure this time in 
magenta, with the malate ion in green. The catalytic zinc ion is a grey sphere. The water 
molecule from (a) is conserved and shown as an orange sphere, but the orientation of the 
malate ion means that there is no water-mediated interaction between the malate and the 
zinc.  
 
6.3.4.3 Glycosylation Profiles of the Form II and Form III Structures 
Glycosylation is a common feature of angiotensin converting enzyme structures, and has 
been shown to be essential for the stability and function of human sACE (Gordon et al., 
2003). 
 
Whilst no glycosylation was reported for the form I AnCE structure, three N-linked 
glycosylation sites, at Asn53, Asn196 and Asn311, are clearly visible on the form II 
structure. Interestingly, although there is very clear difference density for N-linked 
glycans at Asn53 and Asn311 on the form III structure, there is no evidence of N-linked 
glycosylation at Asn196. This is in spite of the fact that both the form II and form III 
structures were obtained from protein expressed using P. pastoris. Analysis of the two 





























    
 
 
Figure 6.7: Crystal Contacts in the Form II (PDB code 2X8Y) and Form III (PDB 
code 5A2R) AnCE Structures.  (a) In the form II AnCE structure that there are two 
different interfaces between symmetry molecules. To illustrate this, three AnCE 
molecules are shown as cartoon and surface representations. The central molecule is 
shown in cyan and the two symmetry molecules in grey. The two interfaces are labelled 
as interface 1 and interface 2. The N-linked glycosylation at Asn196 is shown as cyan 
sticks and is an integral part of interface 2. (b) The three different interfaces between 
symmetry molecules in the new structure. The interfaces are labelled 1-3. The molecules 
are shown as surface and cartoons with the central molecule in magenta and the three 
symmetry molecules in grey. For all interfaces the buried surface area (BSA) was 
















In the form II structure, each molecule contacts four symmetry related molecules, 
meaning that there are two different types of interface in the crystal, as shown in Figure 
6.7. The first of these, interface one, involves the N-terminal lid of one molecule 
(helices α1 and α2) and a region of the second molecule containing parts of α10, α11, 
α14 and α18. Interface two is considerably larger, and involves α3, α6 and α8 of the first 
molecule and α5, α8 and α12 of the second. 
 
Each molecule in the form III structure contacts six symmetry related molecules, which 
results in three different interfaces, as shown in Figure 6.7. The first interface involves 
helices α5, α8 and α9 of one molecule and helices α3, α8, α18 and α20 of the 
neighbouring molecule. The second interface involves the N-terminal lid of one 
molecule and helices α5 and α8 of a second molecule. As illustrated in Figure 6.7, this 
interface is quite similar to interface one of the form II structure. The final interface in 
the form III structure is much smaller than the other interfaces; Lys20 of α1 of one 
molecule contacts four residues of α18 belonging to a second molecule. 
 
                            
 
Figure 6.8: Stabilisation of N-linked Glycosylation at Asn196 by Crystal Contacts 
in the Form II AnCE Structure. The glycosylation is shown as blue sticks with 
hydrogen bonding residues from the symmetry molecule in grey. Hydrogen bonds are 
shown as black dashes. 
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Importantly, this results in the N-linked glycosylation at Asn196 being an integral 
component of interface two in the form II structure. Hydrogen bonds are formed 
between the glycan chains and residues Arg147, Arg238, Lys241 and His242 of the 
symmetry-related molecule, Figure 6.8. The extent of these interactions with the 
symmetry related molecule means that the large glycan chain should be held in a single 
conformation; hence, it is visible in the crystal structure.  
 
In contrast, none of the interfaces between symmetry molecules in the form III structure 
include the region surrounding Asn196. The large glycan chain is therefore likely to be 
highly mobile and exist in many different conformations throughout the molecule, 
explaining why no electron density is visible for it in the new structure. 
 
6.3.4.4 Further Differences Between the Form II and Form III AnCE Structures 
Relating to Crystal Contacts 
There are some additional, albeit more subtle, differences between the two structures in 
the region surrounding Asn196. As shown in Figure 6.9, the region encompassing the 
tops of helices α2 and α3 has moved by approximately 1.3 Å between the two structures.  
 
 
Figure 6.9: Movement of α2 due to Differences in Crystal Contacts in the Form II 
(PDB code 2X8Y) and form III (PDB code 5A2R) AnCE structures. Surface 
representation of interface 2 in the form II structure shows one molecule in cyan and the 
symmetry molecule in grey. Close-up view of the interface shows the interacting 
residues from each molecule of the interface in cyan and grey respectively. Additionally, 
corresponding residues from the form III structures have been superposed and are shown 
in magenta to illustrate the movement of the protein backbone in this region.  Hydrogen 
bonding interactions with Asn601, Asp245 and Lys241 of the symmetry molecule in the 
form II structure pull part of α2 and the loop between α2 and α3 towards the symmetry 
molecule, resulting in movement of the peptide backbone by up to 1.3 Å compared to 
the new structure. 
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In the form II structure, this region has been pulled closer to the symmetry related 
molecule by hydrogen bonding interactions between the main chains of Tyr88 and 
Gln89 and the side chain of Asn601 from the symmetry molecule, and between the side 
chains of Gln84 and Arg86 and the side chains of Lys241 and Asp245, respectively, of 
the related molecule. 
 
 
Figure 6.10: Comparison of Positions Adopted by Side-Chains at Interface 2 in the 
Form II Structure and Interface I in the New Structure. (a) Surface representation of 
interface 2 of the form II structure with AnCE shown in cyan and the symmetry 
molecule in grey. Key interacting residues at this interface are shown as sticks with a 
close-up view in (c). For comparison, equivalent residues from the new structure are 
shown in (c) as magenta sticks. The Lys38 side chain moves by approximately 5 Å in 
the two structures to hydrogen bond with Asp305 of the symmetry molecule in the form 
II structure and Glu35 of the same molecule in the new structure. (b) Surface 
representation of interface 1 in the new structure, which overlaps significantly with 
interface 2 in the form II structure. The AnCE surface is shown in cyan with the 
symmetry molecule in coral. Key interacting residues are shown as sticks with a close-
up view in (d), where symmetry molecule residues are in coral and AnCE residues from 
the new structure in magenta with residues from the original structure shown in cyan for 
comparison. To avoid a clash with Asn610 of the symmetry molecule, Glu64 in the new 
structure adopts a different conformation to in the form II structure where it forms a 
hydrogen bond with Lys291 of the symmetry molecule. Similarly, to avoid a clash with 
Val484 of the symmetry molecule Ile65 exists as a different rotamer in the two 
structures. 
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Figure 6.7 illustrates that there is quite a significant overlap between interface 1 of the 
form II structure and interface 2 of the form III structure. In the latter, residue Lys38 
forms a hydrogen bond with neighbouring residue Glu35, Figure 6.10. In the form II 
structure, Lys38 has moved by approximately 5 Å so as to interact with Asp305 of the 
symmetry related molecule. Consequently, the side chain of Glu35 adopts a slightly 
different conformation and forms an additional, second interaction with Arg39, within 
the molecule (Figure 6.10). 
 
Remaining at this interface, Glu64 of the form II structure is observed to form hydrogen 
bonds with two lysine residues: Lys60 from within the molecule and Lys291 of the 
symmetry molecule. In the new structure, the proximity of the symmetry molecule in 
this region means that Glu64 has adopted a different conformation so that it avoids a 
clash with Asn610. Consequently, the interaction with Lys60 is lost, Figure 6.10. 
Furthermore, Ile65 is observed to exist as different rotamers in the two structures, most 
probably to avoid a clash with Val484 in the form III structure, Figure 6.10. 
 
6.4 Conclusions and Future Directions 
In this chapter a new crystallisation condition has been identified that gives rise to 
diffraction quality crystals of the D. melanogaster ACE homologue, AnCE. The new 
structure of AnCE, the form III structure is reported in a different space group to the two 
previous structures. Some minor differences compared to previous AnCE structures 
have been identified, including the absence of one of the three N-linked glycosylation 
sites, which are the result of differences in crystal contacts between symmetry related 
molecules. 
 
The overall fold of the structure is otherwise identical to that reported previously, and 
the positions of active site residues are unchanged. This indicates that this is a valid 
structure and that this condition could be used to produce crystals for future structural 
studies. 
 
Crucially, the citrate ion found to co-ordinate the active site zinc ion in the form II 
structure is absent from the new structure. There is a malate ion, originating from the 
crystallisation condition, in the active site, however it does not appear to interact with 
the zinc ion and hence may not be so tightly bound.  
 
The presence of the active site citrate ion has been identified as a problem in studying 
the structural basis of inhibition by new, potential inhibitor precursors such as 
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flavonoids, which may not have sufficient affinity for the active site to displace the 
citrate. The data presented here indicate that the new condition may be more suitable for 
this role. 
 
Future work will now involve co-crystallisation experiments with a range of potential 
inhibitors, including luteolin (Figure 6.1) and other flavonoids, as well as some of the 
BPPs for which crystals were not obtained from the original condition (Chapter 3).!!
 
 

















Chapter 7: Recombinant Expression of an 



























Due to its role as a key vector in the transmission of the Plasmodium falciparum 
parasite, a major causative agent in malaria, the mosquito Anopheles gambiae is an 
exceedingly important organism to study.  
 
More recently, it has also become apparent that A. gambiae may be an important tool for 
studying angiotensin converting enzymes. Whilst the existence of insect ACE 
homologues has been known for two decades (Lamango and Isaac, 1994) the A. 
gambiae genome codes for ten ACE-like enzymes (AnoACEs). This is the highest 
number seen in any insect genome to date and may be indicative of the gene products 
having a wide range of important roles in mosquito physiology. Studying these enzymes 
could therefore help to elucidate some of the roles of ACE-like enzymes not only in 
insects but also in mammals, outside of blood pressure regulation.  
 
Given the significant evidence that exists for insect ACE homologues having a role in 
reproduction (section 1.9.1.1) (Ekbote et al., 2003a; Ekbote et al., 2003b; Hurst et al., 
2003; Macours and Hens, 2004; Vercruysse et al., 2004; Wijffels et al., 1996), and the 
role of A. gambiae as a vector for transmission of P. falciparum, there is also the long-
term possibility of using AnoACE inhibition in insecticides as a method for controlling 
the transmission of malaria.  
 
A complete introduction to the A. gambiae ACE homologues is presented in section 
1.10. Currently, work on these enzymes has been limited to a single genomics study and 
some analysis of gene expression patterns (Burnham et al., 2005). Whilst this has 
provided a good foundation, a lot more work is required in order to understand the 
functions and physiological roles of these enzymes. 
 
7.1.1 Aims and Approaches 
As discussed in section 1.10, the aim of this work is to begin by focusing on a single one 
of these enzymes: AnoACE3, and to work towards protein expression and purification. 
The longer-term goal would then be to produce sufficient quantities of pure protein to 
enter crystallisation trials and ultimately to produce a crystal structure. As has been the 
case for ACE homologues from humans and D. melanogaster this could then be used to 
study the structural basis of substrate and inhibitor binding. Pure protein could also be 




Due to their extensive glycosylation, recombinant expression of both the human and D. 
melanogaster ACE homologues has only been achieved using eukaryotic systems; 
human ACE is expressed using Chinese hamster ovary (CHO) cells and D. 
melanogaster AnCE using P. pastoris.  
 
The sequence alignment for AnoACE3 and AnCE presented in section 1.10 indicates 
that the three N-linked glycosylation sites present in the AnCE crystal structure are 
likely to be conserved in AnoACE3. This, combined with the high degree of overall 
sequence similarity shared by AnoACE3 with AnCE (65 %) and each domain of human 
sACE (52 %) indicates that AnoACE3 is likely to undergo quite extensive post-
translational modification and that this will be important for its function and stability. 
 
Given that AnCE is routinely expressed using P. pastoris producing high yields of 
active protein, this system was chosen as the starting point for AnoACE3 expression 
work. The primary advantage of using P. pastoris over higher eukaryotic systems such 
as the CHO cells used for expression of human ACE is that it is much more cost 
effective. It requires no specialist equipment, as the yeast can be grown in shake flasks 
in much the same way as E. coli. Genetic manipulation is also much more 
straightforward and there is the potential to achieve high protein yields in a much shorter 
time frame.  
 
7.2 Methods 
The AnoACE3 coding sequence cloned into the pPICZα vector was kindly provided by 
Prof. Elywn Isaac, University of Leeds and, prior to this work beginning, was 
transformed into the GS115 P. pastoris expression strain by Dr Akif Mohd. Key features 
of the pPICZα vector are outlined in section 2.3.1 and a vector map is included in 
Appendix A. 
 
7.2.1 Mut Phenotype Determination 
To determine the methanol utilisation (Mut) phenotype of the transformants, cells were 
streaked onto minimal dextrose medium plus histidine (MDH: 1.34 % YNB, 4 × 10-5 % 
biotin, 2 % dextrose, 4 × 10-2 % histidine) and minimal methanol medium plus histidine 
(MMH: 1.34 % YNB, 4 × 10-5 % biotin, 0.5 % dextrose, 4 × 10-2 % histidine) agar 
plates. Plates were incubated at 30 oC for 48 hours. After 48 hours growth on each plate 
was observed. Transformants observed to have grown equally well on both plates are 
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determined to be of the Mut+ phenotype whilst those that show significantly poorer 
growth on the MMH plates are of the MutS phenotype. 
 
7.2.2 Mut+ Expression Protocol 
GS115 cells transformed with the pPICZα/AnoACE3 construct previously confirmed to 
be of the Mut+ phenotype were grown on YPD agar plates at 30 oC for 48 hours so that 
discreet colonies appeared.  
 
20 ml BMGY media prepared in a 250 ml baffled flash was inoculated with a single one 
of these colonies and grown at 30 oC with orbital shaking at 250 rpm until log-phase 
growth was reached. This was determined by measuring the optical density at 600 nm 
and typically took 16-8 hours. At this point the culture was harvested by centrifugation 
at 3000 g, 18 oC for 5 minutes using the Beckman CoulterTM Avanti J-25 centrifuge with 
the 16.250 rotor. The supernatant was discarded and the cell pellet resuspended in 200 
ml BMMY media for induction. The 200 ml culture was returned to the incubator at 30 
oC, 250 rpm for 48-72 hours, exact time dependent on the aim of the experiment. Every 
24 hours HPLC grade methanol was added to a final concentration of 0.5 % to maintain 
the concentration required for induction, compensating for losses through evaporation 
and consumption.   
 
At the end of the expression period the culture was harvested by centrifugation at 3000 g 
as described above. Samples of the supernatant and cell pellets were analysed by SDS 
PAGE following the general protocol outlined in section 2.5.2 to detect any secreted or 
intracellular expression. 
 
7.2.3 MutS Expression Protocol 
Where there was ambiguity in the results of the Mut phenotype testing expression trials 
were also conducted following the protocol for cells with the MutS phenotype. As for 
Mut+ expression, this protocol begins with growing individual colonies on YPD agar 
plates. 
 
50 ml BMGY media prepared in a 500 ml flask was inoculated with an individual 
colony of GS115 cells transformed with the pPICZα/AnoACE3 construct and incubated 
at 30 oC with orbital shaking at 250 rpm until log phase was reached. This was 
determined by measuring the optical density at 600 nm and typically took 16-18 hours. 
At this point cells were harvested by spinning at 3000 g, 18 oC as detailed above. The 
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supernatant was discarded and the cell pellet resuspended in 10 ml BMMY media in a 
100 ml baffled flask. 
 
The 100 ml culture was incubated at 30 oC, 250 rpm for a further 48-96 hours. The 
length of induction was varied between experiments in order to investigate the optimal 
time period. Every 24 hours 100 % HPLC grade methanol was added to the culture to a 
final concentration of 0.5 % in order to maintain the concentration required for 
induction, compensating for losses through evaporation and consumption.  
 
At the end of the expression the culture was harvested by centrifugation at 3000 g, 18 oC 
as described previously.  Samples of the cell pellet and expression supernatant were 
analysed by SDS PAGE to identify any intracellular or secreted expression of 
AnoACE3. 
 
7.2.4 Optimisation of Expression 
Following the Mut+ and MutS expression protocols outlined above failed to yield any 
detectable AnoACE3, as discussed in sections 7.3.2 and 7.3.3. To try and overcome this 
problem the protocols were altered and expression trials were performed following the 
general methodology outlined above but varying methanol concentration (0.5 - 3 %), 
growth temperature (28 - 30 oC), induction time (24 - 96 hours) and media type 
(BMGY/BMMY and MMH/MM). 
 
7.2.5 Ammonium Sulphate Precipitation of Expression Samples 
Owing to the continued lack of detectable AnoACE3 expression, ammonium sulphate 
precipitation was performed on expression supernatants prior to SDS PAGE analysis. 
Supernatants were treated with an equal volume of 3 M ammonium sulphate, 20 mM 
Tris pH 8.0 and incubated for 10 minutes at room temperature. Ammonium sulphate 
treated samples were spun down at 4000 g, 4 oC for 10 minutes using the Beckman 
CoulterTM Avanti J-25 centrifuge and the 16.250 rotor. Both the pellet and supernatant 
were subsequently analysed by SDS PAGE to detect any AnoACE3. 
 
7.3 Results and Discussion 
7.3.1 Mut Phenotype Determination 
The preliminary work completed by Dr Akif Mohd had produced four positive 
transformants of GS115 cells with the pPICZα/AnoACE3 construct. All four of these 
were screened to determine the Mut phenotype by comparing growth on MMH and 
MDH agar plates. Although this is very much a subjective analysis it was very clear that 
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one of the transformants had grown equally well on both plates and was hence of the 
Mut+ phenotype. This result indicates that the AOX1 gene remains intact so these cells 
should grow well using methanol as a metabolite.  
 
The results for the other three transformants were not quite so clear, but appeared to 
indicate poorer growth on the MMH compared to the MDH agar plate. This indicates 
that the AOX1 gene has been lost and the cells are not able to use methanol as a 
metabolite as efficiently. They are of the MutS phenotype. 
 
The Mut+ expression protocol facilitates the growth of larger expression cultures much 
more easily than the MutS protocol. Expression trials were therefore initiated using the 
Mut+ transformant in the first instance. 
 
7.3.2 Expression of AnoACE3 
Due to the presence of the α-factor in the pPICZα vector, any AnoACE3 that is 
expressed should be secreted from the cells into the culture medium. However, upon 
analysis by SDS PAGE there was no evidence of any protein expression close to the 
expected molecular weight of AnoACE3 (73.6 kDa). An example of a typical expression 
gel is shown in Figure 7.1. This gel contains samples of the culture media taken before 
induction and at regular intervals up to 50 hours post-induction. At no point is a protein 
close to the expected molecular weight of AnoACE3 visible. There are trace amounts of 
some smaller species, however if anything AnoACE3 should appear larger than 
expected due to its probable glycosylation. 
                          
Figure 7.1: Analysis of AnoACE3 Expression by SDS-PAGE. Samples of the 
supernatant taken at 0 hours (pre-induction), +5, +23, +26, +30, +47 and +50 hours 
following induction were analysed. At no point on the gel is there any evidence of a 
species close to the expected molecular weight, 73.6 kDa, of AnoACE3. There are only 
trace amounts of some much smaller species at +23 and +26 hours. 
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It is possible that AnoACE3 was being expressed, but poorly. The large culture volume 
would have compounded this problem by diluting the protein, potentially to a point that 
it was not visible on the gel. To overcome this samples were concentrated prior to 
analysis, however no expression was detected.  
 
As detailed in the section 7.2.4, many attempts were made to achieve AnoACE3 
expression including altering the growth temperature from 30 oC to 28 oC, varying the 
concentration of methanol used for induction between 0.5 and 3 %, testing for 
expression at time points up to 96 hours and changing the expression medium from 
BMGY/BMMY to MMH/MM. The reason for the change in medium is that unlike 
BMGY/BMMY, MMH/MM media is not buffered. It is possible that AnoACE3 was 
being expressed but degraded by proteases active at the neutral pH maintained by the 
buffered media. Removing this buffering may have inactivated the proteases so that any 
AnoACE3 was no longer being degraded. Unfortunately none of the above approaches 
proved successful. 
 
Another possibility for the lack of detectable AnoACE3 is that the protein is being 
produced but retained in the cells rather than being secreted. To check for this cell 
pellets from the various expression trials were routinely subjected to SDS PAGE 
analysis but there was never any evidence of AnoACE3 within the cells. 
 
Expression trials were also performed using the transformants deemed to be of the MutS 
phenotype. The variations outlined above were also applied to the MutS expression 
protocol however again there was no evidence of AnoACE3 expression. 
 
As a final attempt to concentrate the sample so as to detect any weak AnoACE3 
expression, the expression media was treated with ammonium sulphate. Both the 
supernatant and pellet from this treatment were analysed by SDS PAGE but no 
AnoACE3 was detected. 
 
At this stage the decision was taken to cease attempts to express AnoACE3 using P. 
pastoris and move to alternative expression systems. This is the basis of the work 





7.3.3 Possible Reasons for the Failure to Express AnoACE3 
There is always the possibility with recombinant protein expression that the target 
protein will prove to be toxic to the cells in some way. This seems very unlikely in the 
case of AnoACE3 however, given that the closely related homologue, AnCE, is 
expressed well by P. pastoris. Furthermore the expression protocols that were trialled all 
involved the cultures reaching high optical density values prior to the induction of 
expression. This technique can often enable P. pastoris to produce proteins that are toxic 
to it (Ahmad et al., 2014); hence it is very unlikely that this was the problem here. 
 
It can also be the case that the target protein is being expressed, but is either itself 
unstable or being degraded by yeast proteases present in the culture. To try and 
determine whether this was the problem with AnoACE3, expression trials were 
performed using a non-buffered media. The rationale for this being that in the absence of 
a buffer to maintain the neutral pH, culture conditions may be such that some of the 
yeast proteases are no longer active and so unable to act on any AnoACE3. 
Unfortunately this change did not have any impact on detectable expression levels. 
Another possibility would have been to add a protease inhibitor such as PMSF to the 
culture, but given that AnoACE3 is itself a protease this would have been somewhat 
counter-productive.   
 
In some ways the lack of detectable AnoACE3 expression is surprising, given that the 
closely related homologue, AnCE, has been successfully expressed using this system. 
Taking this into consideration, perhaps the most likely explanation for the lack of 
expression is due to incorrect post-translational processing. 
 
As explained in section 1.10, whilst the core peptidase domain is very well conserved 
between AnCE and AnoACE3, AnoACE3 also has an additional N-terminal sequence of 
unknown function not found in AnCE. Furthermore, although both proteins have a 
conserved N-terminal signal sequence, this is omitted from the AnCE expression 
construct but still present in the AnoACE3 construct. 
 
It is quite possible that these differences in the N-terminal region may in some way be 
responsible for the lack of AnoACE3 expression in P. pastoris. For example, further 
glycosylation sites might be present that are essential for protein stability. Although P. 
pastoris is able to glycosylate proteins the nature of the glycans added is not the same as 
in the native system. In P. pastoris these glycans have a very high mannose content, 
which may not be ideal.  
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Furthermore, the human ACE enzymes also have O-linked glycosylation sites. Whilst 
this has not been an issue with AnCE it is possible that the additional N-terminal region 
of AnoACE displays O-linked glycosylation. To investigate this further a glycosylation 
prediction was performed on the full AnoACE3 sequence and this did identify a 
potential additional N-linked glycosylation site and also an O-linked glycosyation site in 
the N-terminal region (Gupta and Brunak, 2004). 
 
Another issue that may arise due to the different nature of the N-termini of AnoACE3 
and AnCE again relates to post-translational processing of the expressed protein. Both 
constructs contain the α-factor signal sequence at their N-termini, which should target 
them for secreted expression.  
 
As part of the secretion pathway the α-factor signal sequence is cleaved from the target 
protein by the enzyme Kex2. Cleavage of this sequence then allows the protein to move 
from the Golgi apparatus to vesicles for secretion. There is increasing evidence to 
suggest that the nature of the N-terminus of the target protein can have a profound effect 
on the ability of Kex2 to remove the α-factor, thus impacting on the secretion of the 
target protein (Yang et al., 2013). It is quite possible that the differing nature of the N-
termini of AnCE and AnoACE3 has therefore affected this process, resulting in the lack 
of detectable AnoACE3 expression. 
 
7.4 Conclusions 
AnoACE3 is an ACE homologue from A. gambiae that shares 54 % sequence similarity 
with the D. melanogaster enzyme AnCE. Given that AnCE has been successfully 
expressed using the methylotropic yeast P. pastoris, recombinant expression of 
AnoACE3 using the same system was attempted. 
 
In spite of significant efforts no AnoACE3 expression by P. pastoris was detected. The 
reasons for this are unknown, however it is possible that it may be related to the unique 
nature of the N-terminus of the AnoACE3 construct, which may impact the post-
translational processing of the protein.  
 
As a result of this, work towards the expression of AnoACE3 in higher eukaryotic 
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Due to the lack of success seen when trying to express AnoACE3 using the Pichia 
pastoris expression system, the decision was made to begin creating new constructs for 
expression in mammalian and insect systems using HEK293T and Sf9 cells respectively. 
This work was completed with support from the group of Prof. Ray Owens at the 
Oxford Protein Production Facility (OPPF), Harwell Science and Innovation Campus, 
Didcot, Oxon, UK.  
 
All work with AnoACE3 was carried out concurrently with the two Drosophila 
melanogaster ACE homologues: AnCE and ACER (introduced in section 1.9). Previous 
efforts to express ACER using Pichia pastoris have also proved unsuccessful hence 
moving to mammalian and insect systems at the same time as for AnoACE3 was a 
logical step. The reasons for also attempting this with AnCE were twofold. Primarily as 
a positive control but also because producing AnCE in an insect system when it is itself 
an insect protein may in the longer term be interesting for comparison with the protein 
produced from yeast. 
 
8.2 Methods 
8.2.1 Construct Design 
Graphical illustrations of the predicted domain structures of AnoACE3 and ACER are 
shown in Figure 8.1. ACER and AnoACE3 are both predicted to be secreted proteins as 
illustrated by the predicted signal sequences at their N-termini. This is in contrast to 
mammalian ACE which is membrane bound, but comparable to AnCE which has a 17 
residue secretion signal sequence at its N-terminus, also illustrated in Figure 8.1. Like 
AnCE, the ACER signal sequence appears to be located at the N-terminus of the protein 
and is comprised of the first 22 residues. 
 
AnoACE3 appears to be slightly different. The signal sequence is predicted to be located 
directly upstream of the conserved peptidase domain, consisting of residues 60-87. 
There is then an “undefined” 60 residue sequence at the very N-terminus of the protein 
which is conserved in neither AnCE nor ACER. At this point the function of this region 
is unknown. 
 
In order to maximise the likelihood of successfully expressing AnoACE3 a series of 
constructs, AnoACE_1 to AnoACE_6, was created. These contained either the full 
sequence (residues 1-698), the 17 residue signal sequence onwards (61-698) or only the 
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conserved peptidase domain (88-698). The constructs and their key features are 




Figure 8.1: Domain Organisation of tACE, AnCE, ACER and AnoACE3. All four 
proteins share a conserved peptidase domain shown in blue. tACE and sACE (not shown 
in this picture) both have a membrane binding domain, shown in green, at their C-
termini, which is present in neither AnCE, ACER nor AnoACE3. Instead AnCE and 
AnoACE3 both have a 17 residue signal sequence and ACER has a 22 residue signal 
sequence, shown in purple, at their N-termini, meaning that they are secreted rather than 
membrane bound. AnoACE3 also has an additional 60 residue region at the N-terminus 
of unknown function. This is displayed in orange. 
 
 
All 6 constructs were designed to be cloned into the pOPIN vector suite using the “In-
Fusion®” technique (Clontech Laboratories, Inc.). This requires the insert to have 15 
base pair sequences at the 5’ and 3’ ends that are complementary to the vector sequence. 
These additional residues are indicated in green on the primer sequences in Tables 8.1, 
8.2 and 8.3. 
 
AnoACE_1 and AnoACE_2, both containing the predicted signal sequence, were 
designed for cloning into the pOPINEneo vector. Their native signal sequences will be 
used to drive secreted expression in both Sf9 and HEK293T cells. The synthesised 
proteins will also contain a C-terminal eight-residue histidine tag to aid purification and 
detection by western blot. For all constructs the decision was made to locate the poly-
histidine tags at the C-termini due to the variable nature of the N-terminus in different 
constructs and due to the presence of the N-terminal lid in other ACE homologues. The 








Vector Forward primer Reverse primer 
AnoACE_1 “Unknown” region 
Native signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
1-698 2090/81 pOPINEneo AGGAGATATACCATG
CGATTTGGAATCA 
Tm = 64.2 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
AnoACE_2 Native signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
60-698 1913/75 pOPINEneo AGGAGATATACCATG
ATGGCAAGTAATA 
Tm = 65.3 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
AnoACE_3 µ-phosphatase signal 
sequence 
Conserved peptidase domain 
C-terminal His-tag 
87-698 1835/72 pOPINTTGneo GCGTAGCTGAAACCG
GCCGTCGTTCAA 
Tm = 71.8 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
AnoACE_4 HBM signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
87-698 1835/72 pOPIN-HBM TCTTACATCTATGCGC
GTCGTTCAACGG 
Tm = 68.2 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
AnoACE_5 HA signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
87-698 1835/72 pOPIN-HA TGCCTGGTGTTCGCGC
GTCGTTCAACGG 
Tm = 72.5 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
AnoACE_6 Ac64 signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
87-698 1835/72 pOPIN-Ac64 CATTCTGCCTTTGCGC
GTCGTTCAACGG 
Tm = 70.1 oC 
GTGATGGTGATGTTT
GGCCGCCATAAAAT 
Tm = 67.8 oC 
 
Table 8.1: AnoACE Construct and Primer Details. The regions of the primers shown in green indicate the 15 bp sequences complementary to the vector 









Vector Forward primer Reverse primer 
ACER_1 µ-phosphatase signal 
sequence 
Conserved peptidase domain 
C-terminal His-tag 
31-602 1799/71 pOPINTTGneo GCGTAGCTGAAACCG
GCGTGCTGGAGG 
Tm = 72.8 oC 
GTGATGGTGATGTTT
GGTGCTAAACGTT 
Tm = 67.7 oC 
ACER_2 HBM signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
31-602 1799/71 pOPIN-HBM TCTTACATCTATGCGG
TGCTGGAGCGC 
Tm = 68.0 oC 
GTGATGGTGATGTTT
GGTGCTAAACGTT 
Tm = 67.7 oC 
ACER_3 HA signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
31-602 1799/71 pOPIN-HA TGCCTGGTGTTCGCGG
TGCTGGAGGCG 
Tm = 73.6 oC 
GTGATGGTGATGTTT
GGTGCTAAACGTT 
Tm = 67.7 oC 
ACER_4 Ac64 signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
31-602 1799/71 pOPIN-Ac64 CATTCTGCCTTTGCGG
TGCTGGAGGCG 
Tm = 73.1 oC 
GTGATGGTGATGTTT
GGTGCTAAACGTT 
Tm = 67.7 oC 
 
 
Table 8.2: ACER Construct and Primer Details. The regions of the primers shown in green indicate the 15 bp sequences complementary to the vector 















Vector Forward primer Reverse primer 
AnCE_1 µ-phosphatase signal 
sequence 
Conserved peptidase domain 
C-terminal His-tag 
18-614 1796/70 pOPINTTGneo GCGTAGCTGAAACCG
GCGCGCTGGTCA 
Tm = 73.1 oC 
GTGATGGTGATGTTT
TGATGAGACGCAT 
Tm = 65.4 oC 
AnCE_2 HBM signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
18-614 1796/70 pOPIN-HBM TCTTACATCTATGCGG
CGCTGGTCAAGG 
Tm = 69.2oC 
GTGATGGTGATGTTT
TGATGAGACGCAT 
Tm = 65.4 oC 
AnCE_3 HA signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
18-614 1796/70 pOPIN-HA TGCCTGGTGTTCGCGG
CGCTGGTCAAGG 
Tm = 73.9 oC 
GTGATGGTGATGTTT
TGATGAGACGCAT 
Tm = 65.4 oC 
AnCE_4 Ac64 signal sequence 
Conserved peptidase domain 
C-terminal His-tag 
18-614 1796/70 pOPIN-Ac64 CATTCTGCCTTTGCGG
CGCTGGTCAAGG 
Tm = 71.3 oC 
GTGATGGTGATGTTT
TGATGAGACGCAT 
Tm = 65.4 oC 
 
 
Table 8.3: AnCE Construct and Primer Details. The regions of the primers shown in green indicate the 15 bp sequences complementary to the vector 
required for In-Fusion® cloning. The molecular weights given in kDa are for the mature proteins so do not include the signal sequences. 
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Constructs AnoACE_3, AnoACE_4, AnoACE_5 and AnoACE_6 were designed for 
cloning into the pOPINTTGneo, pOPIN-HBM, pOPIN-HA and pOPIN-Ac64 vectors 
respectively.  Due to the fact that these four constructs only contain the conserved 
peptidase domain, these vectors were chosen to provide the proteins with the µ-
phosphatase, HBM, HA and Ac64 signal sequences respectively. These four constructs 
all include a C-terminal histidine tag. Vector maps are included in Appendix A. 
 
The AnCE and ACER constructs that have previously been used for P. pastoris 
expression do not contain the native signal sequences, hence the AnCE and ACER 
constructs created for the insect and mammalian work also only contain the conserved 
peptidase domain. Four constructs were designed for each protein: AnCE_1, AnCE_2, 
AnCE_3 and AnCE_4 and ACER_1, ACER_2, ACER_3 and ACER_4, for cloning into 
the pOPINTTGneo, pOPIN-HBM, pOPIN-HA and pOPIN-Ac64 vectors respectively. 
Construct details are summarised in Tables 8.2 (ACER) and 8.3 (AnCE). 
 
8.2.2 PCR Amplification of AnoACE3, ACER and AnCE Coding Sequences 
The inserts for the new AnoACE, AnCE and ACER constructs were created by PCR 
amplification using the P. pastoris vector DNA as the template. Successful PCR 
amplification was confirmed by analysis of products on an agarose gel following the 
method outlined in section 2.5.1. 
 
8.2.2.1 AnoACE3 
The PCR amplification of the AnoACE constructs was performed as outlined in Tables 
8.4 and 8.5, which detail the components of the reaction mixture and the thermal cycling 
parameters respectively. All PCR reactions were performed using KOD hot start DNA 
polymerase (Merck Millipore) using a PTC-100 Thermal Cycler (MJ Research). The 
components of the reaction mixture and the thermal cycling parameters were based upon 
the manufacturer’s instructions. In particular the annealing temperature of 64 oC was 
chosen as it is the lowest primer Tm and the extension time of 40 seconds was selected 
based on the rate of 20 seconds per kilobase (quoted by the manufacturer) and product 
sizes ranging from 1835 to 2090 bp. 
 
8.2.2.2 ACER 
The general protocol for amplification of the ACER coding sequences was as described 
for AnoACE3 with slight alterations to the parameters to suit the specific properties of 
the ACER primers, as detailed in Tables 8.4 and 8.5. 
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Component Volume per reaction (µl) 
10 × buffer for KOD hot start polymerase 5 
MgSO4 (25 mM) 3 
dNTPs (2 mM each) 5 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
Template DNA (15 ng µl-1) 3 
KOD hot start DNA polymerase (1 U µl-1) 1 
HPLC grade water 5 
 
 
Table 8.4: Components of the AnoACE3 and ACER Polymerase Chain Reaction. 
 
Step Temperature and time 
(AnoACE3) 
Temperature and time 
(ACER) 
Polymerase activation 95 oC for 2 minutes 95 oC for 2 minutes 
Denaturation 95 oC for 20 seconds 95 oC for 20 seconds 
Annealing 64 oC for 10 seconds 68 oC for 10 seconds 
Extension 70 oC for 40 seconds 70 oC for 40 seconds 
Repeat denaturation to extension for a total of 30 cycles. 
Final extension 72 oC for 2 minutes 72 oC for 2 minutes 
 
 









Due to the fact that the original AnCE constructs were received from our collaborator 
(Prof. Elwyn Isaac) the only available starting material was the GS115 transformant 
used for AnCE expression as detailed in section 2.7.  
 
In order to obtain template DNA for the PCR amplifications a total genomic DNA 
extraction was performed based on the protocol presented by Lõoke et al., 2011.  
 
2 ml of YPD media were inoculated with a single colony of GS115 cells transformed 
with the pPIC9/AnCE construct and grown for 24 hours at 30 oC with orbital agitation at 
250 rpm. The culture was harvested by centrifugation at 4600 g, 4 oC for 10 minutes 
using a Heraeus centrifuge (Thermo Fisher Scientific, MA, USA) and the supernatant 
discarded. The cell pellet was resuspended in 100 µl of 200 mM lithium acetate, 1 % 
SDS and incubated for 5 minutes at 70 oC. 300 µl of 70 % ethanol were added to the 
lysate and the suspension resuspended vigorously before spinning down at 15, 000g for 
3 minutes at room temperature using a microcentrifuge (Centrifuge 5415 D, Eppendorf). 
The resulting pellet was washed with 70 % ethanol prior to resuspension in 100 µl of 
HPLC grade water and a final centrifugation step at 15, 000 g for 3 minutes. The 
supernatant was used as the PCR template. 
 
PCR parameters for the AnCE constructs were determined in the same way as for 
AnoACE and ACER. Here the annealing temperature was increased slightly to 65 oC to 
match the lowest primer Tm. Additionally, betaine was included in the reaction mixture 
to improve specificity given that genomic DNA was being used as the template. 
Similarly, an additional 5 cycles were performed, bringing the total to 35. Full details of 
reaction components and thermal cycling parameters are included in Tables 8.6 and 8.7 
respectively. 
 
8.2.3 DpnI Treatment of PCR Products 
In order to remove any remaining template DNA all of the AnoACE3, AnCE and ACER 
PCR products were treated with the restriction enzyme DpnI (Promega, WI, USA). The 
reaction components listed in Table 8.8 were added directly to the PCR mixtures after 
thermal cycling and then incubated at 37 oC for 5 hours. A “PCR clean-up” was then 
performed on each reaction using the Wizard® SV gel and PCR clean-up system 
(Promega, WI, USA) in accordance with the manufacturer’s instructions. The 
concentration of the purified DNA was determined by measuring the absorbance at 260 
nm using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, MA, USA). 
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Component Volume per reaction (µl) 
10 × buffer for KOD hot start polymerase 5 
MgSO4 (25 mM) 3 
dNTPs (2 mM each) 5 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
Template DNA 3 
Betaine (3 M) 3 
KOD hot start DNA polymerase (1 U µl-1) 1 
HPLC grade water 5 
 
 






Step Temperature and time 
Polymerase activation 95 oC for 2 minutes 
Denaturation 95 oC for 20 seconds 
Annealing 65 oC for 10 seconds 
Extension 70 oC for 40 seconds 
Repeat denaturation to extension for a total of 35 cycles. 
Final extension 72 oC for 2 minutes 
 
 









Component Volume (µl) 
DpnI (10 u µl-1) 0.5 
Acetylated BSA (10 µg µl-1) 0.2 
10 × Promega buffer B 2.5 
HPLC grade water 2.8 
PCR product 19 
 
Table 8.8: Preparation of the Reaction Mixture for the DpnI Treatment of the 
AnoACE3, ACER and AnCE PCR Products. 
 
8.2.4 In-Fusion® Reactions 
All In-Fusion® reactions were performed using In-Fusion® HD EcoDryTM Cloning kits 
(Clontech Laboratories, Inc.). These consist of lyophilised pellets of the In-Fusion® HD 
enzyme premix. 250 ng of each purified PCR product was added to the pellets in a 96-
well PCR plate. HPLC grade water was added to each well to a final volume of 10 µl. 
The plate was sealed and incubated at 42 oC for 30 minutes in a Veriti® Thermal Cycler. 




8.2.5 Transformation of E. coli 
Products of the In-Fusion® reactions were immediately transformed into One Shot® 
OmniMAXTM 2 T1R chemically competent E. coli (Life Technologies) using a heat 
shock method.  
 
The competent cells were purchased in pre-prepared 50 µl aliquots. 4 µl of the diluted 
In-Fusion® reactions were each added to an aliquot and incubated on ice for 30 minutes. 
The cells were then “heat shocked” at 42 oC for 30 seconds and incubated on ice for a 
further 2 minutes. 300 µl SOC media were added to each aliquot prior to incubation at 
37 oC for 1 hour.  
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After incubation 25 µl of each transformation was plated onto 1 ml LB-agar 
supplemented with 50 µg ml-1 carbenicillin, 0.02 % X-Gal (5-bromo-4-chloro-3-indolyl-
beta-D-galacto-pyranoside) (in DMF) and 1 mM IPTG (isopropyl β-D-1-
thiogalactopyranoside). The addition of X-Gal and IPTG is to enable “blue-white 
screening” of colonies. 
 
8.2.6 Plasmid DNA Preparation 
Individual white colonies were picked for each transformation and incubated overnight 
at 37 oC with orbital agitation at 600 rpm in 1.2 ml power broth supplemented with 50 
µg ml-1 carbenicillin. 
 
Plasmid DNA was extracted from each culture using a QIAprep Spin Miniprep Kit 
(Qiagen) in accordance with the manufacturer’s protocol. Plasmid DNA concentrations 
were determined by measuring the absorbance at 260 nm using a NanoDrop 8000 
spectrophotometer (Thermo Fisher Scientific, MA, USA). 
 
8.2.7 PCR Verification of Constructs 
The presence of the appropriate insert in the purified plasmid DNA was determined 
using PCR. The reactions were prepared as detailed in Table 8.9 and the thermal cycling 
parameters are listed in Table 8.10. The primers used are the same as those that were 
used for the original PCR amplification (8.2.2). PCR products were analysed on an 
agarose gel to confirm presence of the correct insert following the general protocol 
given in section 2.5.1. 
Component Volume per reaction 
(µl) 
Phusion Flash® High Fidelity PCR 
Mix (Thermo Fisher Scientific) 
12.5 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
Template DNA 1.5 
HPLC grade water 8 
 
Table 8.9: List of Components for the Polymerase Chain Reaction to Confirm the 




Step Temperature and time 
Polymerase activation 94 oC for 2 minutes 
Denaturation 94 oC for 30 seconds 
Annealing 60 oC for 30 seconds 
Extension 68 oC for 2 minutes 
Repeat denaturation to extension for a total of 30 cycles. 
Final extension 68 oC for 4 minutes 
 
Table 8.10: Thermal Cycling Parameters for the Polymerase Reaction to Confirm 
the Presence of the AnoACE3, ACER and AnCE Inserts in the pOPIN Vectors 
After InFusion® Reactions. 
 
8.2.8 Trial Transfections of HEK293T and Sf9 Cells Performed at OPPF, UK 
8.2.8.1 Transient Transfection of HEK293T Cells 
24 hours prior to transfection, 1 ml of HEK293T cells was plated at a density of 1.5-2.0 
× 105 cells ml-1 in individual wells of a 24-well tissue culture plate. Cells were incubated 
for 24 hours at 37 oC in a 5 % CO2/95 % air environment. 
 
2 µl 1.33 mg ml-1 GeneJuice® transfection reagent (Merck Millipore) and 1 µg purified 
plasmid DNA were added to 60 µl serum free DMEM, mixed thoroughly and incubated 
at room temperature for 10 minutes. During this time the medium was removed from 
each well of the 24-well plate and replaced with 1 ml of DMEM supplemented with 2 % 
FBS. After incubation the DNA/GeneJuice cocktails were added to the appropriate wells 
and incubated at 37 oC in 5 % CO2/95 % air for 3 days. 
 
After 3 days secreted protein expression was assessed by analysis of the media by 
western blot following the general protocol outlined in section 2.5.3. A His Tag 
peroxidase conjugated antibody (R & D Systems, Oxon, UK) was used to detect the 
presence of proteins with a polyhistidine tag. 
 
8.2.8.2 Transfection of Sf9 Cells 
500 µl aliquots of Sf9 cells at a density of 5 × 105 cells ml-1 in Sf-900™ ii SFM (serum 
free media) (Invitrogen) were prepared in a 24-well plate and incubated at room 
temperature for 30 minutes in order to attach to the plate surface. 
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250 ng Ian Jones bacmid, 50 µl Sf-900™ ii SFM and 0.75 µl FuGeneHD transfection 
reagent (Promega) were combined with 250 ng of plasmid DNA and incubated for 30 
minutes at room temperature. 
 
After the incubation periods the transfection mixtures were added to the appropriate 
cells and incubated for 5 days at 27 oC. After 5 days expression was assessed by western 
blot performed by Dr Joanne Nettleship at the OPPF. 
 
8.2.9 Trial Transfections of HEK293T Cells Performed at University of Bath 
Having seen some evidence of expression when working at the OPPF, the aim was now 
to try and express two of these constructs: AnoACE_2 and ACER_3 using HEK293T 
cells at the University of Bath. This was attempted using two different transfection 
reagents: GeneJuice® (Merck Millipore) and FuGeneHD (Promega). 
 
8.2.9.1 Transfections using GeneJuice® 
Cells were plated at a density of 1 × 105 cells ml-1 in 1 ml of DMEM supplemented with 
10 % FBS in a 24 –well tissue culture plate and incubated for 24 hours at 37 oC in a 5 % 
CO2/95 % air environment. 
 
1 µg purified plasmid DNA and 2 µl 1.33 mg ml-1 GeneJuice® transfection reagent 
(Merck Millipore) were added to 60 µl serum free DMEM, mixed thoroughly and 
incubated at room temperature for 10 minutes.  
 
The media on the previously prepared cells was removed and replaced with 1 ml 
DMEM supplemented with 2 % FBS. The transfection mixture was added to the 
appropriate well of the plate and incubated at 37 oC in 5 % CO2/95 % air for 72 hours. 
 
Expression was detected by western blots performed on media samples following the 
protocol outlined in section 2.5.3 using a His Tag peroxidase conjugated antibody (R & 
D Systems, Oxon, UK) to detect proteins with polyhistidine tags. 
 
8.2.9.2 Transfections using FuGeneHD 
Cells were plated at a density of 5 × 105 cells ml-1 in 1 ml of DMEM supplemented with 
10 % FBS in a 24 –well tissue culture plate and incubated for 24 hours at 37 oC in a 5 % 
CO2/95 % air environment.  
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After 24 hours the media on the cells was removed and replaced with 1 ml of fresh 
DMEM supplemented with 10 % FBS. 
 
45 µl of serum free DMEM and 1 µg of the appropriate plasmid DNA were mixed 
together and 3 µl FuGeneHD (Promega) transfection reagent added. The transfection 
mixture was incubated at room temperature for 10 minutes before being added to the 
appropriate cells. Transfected cells were incubated at 37 oC in a 5 % CO2/95 % air 
environment for 72 hours. After this time expression was detected by western blot 
following the protocol outlined in section 2.5.3 using a His Tag peroxidase conjugated 
antibody (R & D Systems) to detect proteins with polyhistidine tags. 
 
8.3 Results 
8.3.1 PCR Amplification of AnoACE, AnCE and ACER Coding Sequences 
Successful amplification of the AnoACE, ACER and AnCE coding sequences for the 
new constructs was confirmed by agarose gel electrophoresis. Gel images are shown in 
Figure 8.2 and clearly indicate products at the expected sizes as detailed in Tables 8.1, 
8.2 and 8.3. 
 
8.3.2 Transformation into E. coli and PCR Verification 
Following the In-Fusion® reactions to introduce the PCR products into the appropriate 
pOPIN vector, the constructs were transformed into One Shot® OmniMAXTM 2 T1R 
chemically competent E. coli using a heat shock method. Successful transformations 
were identified by the growth of white colonies on LB-agar plates supplemented with 
carbenicillin, X-Gal and IPTG. There were multiple white colonies for each of the 
constructs, indicating that all of the In-Fusion® reactions and transformations had been 
successful.  
 
This was further verified by PCR using isolated plasmid DNA as the template and the 
original cloning primers for each construct. Analysis of the PCR products by gel 
electrophoresis indicated products at the expected size for each of the constructs, 



















Figure 8.2: Analysis of the AnoACE3 (a), ACER (b) and AnCE (c) PCR Products 
by Agarose Gel Electrophoresis. Figure illustrates that all of the PCR amplifications 
for the new constructs were successful, with products visible at the expected sizes for 




8.3.3 Trial Transfections Performed at OPPF, UK 
Expression of the ACE homologues by the HEK293T and Sf9 cells was detected by 
western blotting using an antibody recognising the polyhistidine tags included in all of 
the constructs. The two western blots are shown in Figures 8.3 and 8.4 and a summary 




Figure 8.3: Analysis of Secreted AnoACE3, ACER and AnCE Expression by 





Figure 8.4: Analysis of Secreted AnoACE3, ACER and AnCE Expression by Sf9 































Table 8.11: Initial Results of Expression Trials in HEK293T and Sf9 Cells. 
Expression levels (where present) are graded as strong, moderate or weak. “In well” 
refers to the samples that have stayed at the top of the gel in Figure 8.4. 
 
 
Western blot analysis of the HEK293T media 72 hours after transfection indicates that 
all but one of the constructs, AnCE_4, was successfully expressed. The level of 
expression seen varies between the different constructs. AnoACE_1, AnoACE_2, 
AnoACE_3 and AnoACE_4 appear to have expressed particularly well, whilst only 
trace expression is seen for ACER_2, ACER_4 and AnCE_1. 
 
The histidine tagged proteins all appear at around the 120 kDa marker on the western 
blot. This is considerably larger than the expected molecular weights listed in Tables 
8.1, 8.2 and 8.3 (~ 70 kDa) and is likely due to the extensive glycosylation that is a 
characteristic of ACE homologues.The western blot results indicate that expression of 
the different constructs was much more variable in the Sf9 cells compared to the 
HEK293T cells. There are high levels of AnoACE_2, AnoACE_3, AnoACE_6, 
ACER_3, ACER_4 and AnCE_4 whilst a moderate amount of AnCE_1 has been 
detected. The remaining samples give very little, if any, signal at the expected molecular 
Construct Expression in 
HEK293T Cells 
Expression in Sf9 
Cells 
AnoACE_1 Strong In well 
AnoACE_2 Strong Strong 
AnoACE_3 Strong Strong 
AnoACE_4 Strong Weak/in well 
AnoACE_5 Moderate Weak/in well 
AnoACE_6 Moderate Strong 
ACER_1 Strong Weak/in well 
ACER_2 Weak Weak/in well 
ACER_3 Strong Strong 
ACER_4 Weak Strong 
AnCE_1 Weak Moderate 
AnCE_2 Moderate In well 
AnCE_3 Moderate In well 
AnCE_4 None Strong 
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weight. In a number of cases there is quite a clear band right at the very top of the gel. 
This may indicate aggregation of some description that has prevented the protein from 
migrating through the gel. The blot was repeated to rule out any problems with sample 
preparation and the same result was achieved. 
 
Interestingly, whilst the products of the HEK293T cells migrated with much larger 
apparent molecular weights than expected, the proteins produced by the Sf9 cells appear 
close to the predicted size of 70 kDa.  
 
8.3.4 Trial Transfections Performed at the University of Bath 
Following the successful results achieved with the support of Prof. Ray Owen’s group at 
the OPPF, work towards the expression of some of these constructs at the University of 
Bath was initiated. To begin with two constructs were selected: AnoACE_2 and 
ACER_3 and transfection and expression trials using HEK293T cells were performed 
using two transfection reagents: GeneJuice® (Merck Millipore) and FuGeneHD 
(Promega). Transfections were also performed simultaneously with a control protein 
known to show good secreted expression from HEK293T cells.  
 
Expression of target proteins was detected by western blot using an antibody 
recognising the polyhistidine tag. These blots are shown in Figures 8.5 and 8.6.  
 
 
                           
Figure 8.5: Analysis of Secreted ACER_3 and AnoACE_2 Expression by HEK293T 




                                      
 
Figure 8.6: Analysis of Secreted ACER_3 and AnoACE_2 Expression by HEK293T 
Cells Following Transfection. Transfection Performed using FuGeneHD 
Transfection Reagent. 
 
The western blots indicate that, as expected, the control protein was expressed well with 
both transfection reagents. There was also some expression of AnoACE_2 with both 
reagents, but ACER_3 expression is only seen when FuGeneHD is used.  
 
Both AnoACE_2 and ACER_3 appear on the western blots to be 100-130 kDa in size. 
This is significantly larger than their predicted molecular weights (~70 kDa) but is 




8.4.1 Trials Transfections Performed at the OPPF 
Overall the transfections and subsequent expression trials performed at the OPPF were 
very successful. All 14 constructs showed some expression in either the HEK293T of 
Sf9 cells and many were expressed well in both systems. Whilst AnCE and ACER have 
previously been expressed using recombinant techniques in P. pastoris, this is the first 
time that expression of AnoACE3, or any of the Anopheles gambiae ACE homologues, 
has been achieved. 
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8.4.1.1 Comparison of Expression in HEK293T and Sf9 Cells 
Based on the western blot in Figure 8.3, the best expression in HEK293T cells was seen 
for AnoACE_1, AnoACE_2, AnoACE_3 and AnoACE_4. Moderate expression of the 
other constructs was detected with the exception of AnCE_4, which did not appear to 
show any expression. 
 
Apart from the signal sequence, AnCE_4 is identical to the other three AnCE constructs. 
Given that these did all show some level of expression in HEK293T cells the lack of 
AnCE_4 expression is not indicative of expression being incompatible with the 
HEK293T system, for example due to incorrect post-translational processing or the 
absence of key chaperones. Furthermore, the AnCE_4 construct displayed very good 
expression in Sf9 cells (Figure 8.4). This indicates that there were no undetected 
problems with the cloning as the same vector preparations were used for both 
transfections. 
 
The most probable reason for the lack of detectable expression of the AnCE_4 construct 
in HEK293T cells is the signal sequence. The AnCE_4 construct uses the Ac64 signal 
sequence. Interestingly, this is also used for the ACER_4 and AnoACE_6 constructs, 
both of which show considerably weaker expression in HEK293T cells compared to the 
other constructs. The Ac64 signal sequence is derived from the gp64 protein of a nuclear 
polyhedrosis virus infecting Autographa californica, a type of moth. This signal 
sequence is therefore most suitable for use with the Baculovirus expression system in 
insect cells; hence the absence of AnCE_4 expression in HEK293T cells is neither 
unexpected nor a cause for concern. 
 
It follows then that the AnoACE_6, ACER_4 and AnCE_4 constructs were amongst 
those that showed the best expression in the Sf9 cells. Many of the other constructs did 
not show such good expression in the Sf9 cells, but again this is most likely due to the 
signal sequences not being ideal for use in insect systems. 
 
8.4.1.2 Comparison of Expression of the Different AnoACE Constructs 
The most interesting expression profiles in many ways are those of AnoACE_1 and 
AnoACE_2. Neither of these constructs has an additional signal sequence introduced 
during cloning. The AnoACE_2 construct has the N-terminal signal sequence that is 
conserved in other secreted ACE homologues, including AnCE and ACER. Perhaps 
unsurprisingly given that it is an insect protein, the AnoACE_2 construct shows very 
good secreted expression in the Sf9 cells. The AnoACE_2 expression detected in the 
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HEK293T cells is also amongst the strongest of all of the constructs, indicating that this 
signal sequence is able to target the protein for secretion in the HEK293T cells. 
 
The AnoACE_1 construct contains an additional sequence at its N-terminus, upstream 
of the signal sequence, which is not conserved in other ACE homologues. The function 
of this sequence is entirely unknown. Interestingly, whilst the AnoACE_1 construct 
shows good expression in the HEK293T cells, the only evidence of AnoACE_1 
expression in the Sf9 cells is a small amount of protein that has remained in the wells of 
the gel in Figure 8.4. The fact that the sample has not been able to migrate down the gel 
suggests that it has aggregated. Even taking this into consideration, the amount of 
protein present is small compared to AnoACE_2. 
 
Given that the Sf9 cells are probably more representative of the A. gambiae system than 
the HEK293T cells, this raises very interesting questions as to the biological role of the 
N-terminal region. The very limited data available at the moment make it impossible to 
speculate as to what this may be but it is certainly an area that should be investigated 
further.  
 
The most important next step in future work though would be to repeat the Sf9 
expression trials, which, unfortunately time did not permit in this work. It is important to 
remember that these are the results of a single experiment and any number of factors 
could have caused anomalous results. It may ultimately transpire that the AnoACE_1 
construct does in fact express very well in Sf9 cells. 
 
8.4.1.3 Glycosylation Profiles of the Expressed Proteins 
The western blots in Figures 8.3 and 8.4 show that the products of the HEK293T 
expression trials are much larger than those from the Sf9 cells. Whilst the Sf9 products 
migrate close to the expected molecular weight of approximately 70 kDa, the HEK293T 
products appear at close to double the expected size. This is almost certainly due to 
differences in the glycosylation profiles of the two systems. 
 
This is not unexpected, as the differences in the N-glycosylation pathways in insect and 
mammalian systems have been well documented. Although insect cells are able to add 
N-linked glycans to proteins these are not processed beyond the initial high mannose 
and paucimannose structures. In contrast mammalian systems are able to add much 
larger, more complex glycan structures terminating in galactose or sialic acid residues 
(Harrison and Jarvis, 2006; Kost et al., 2005; Nettleship et al., 2010).  
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The different glycosylation profiles produced by the two systems may prove to be 
important for future work. The glycosylation profile could affect the activity of the 
enzymes, which would be an important consideration in any biochemical 
characterisation. It would also almost certainly have an impact on the crystallisation 
process. Generally speaking extensive glycosylation makes crystallisation very difficult 
as it increases heterogeneity. Based on these results it would perhaps be sensible to 
begin work on this using protein expressed in Sf9 cells, where the glycosylation appears 
to be less extensive. This is also likely to more closely resemble the glycosylation 
profile that the enzymes would have when expressed in their native systems.  
 
Ultimately, whichever system is chosen, it may well still prove necessary to use 
glycosidases to reduce some of the glycan chains or even to express mutant forms of the 
protein with any non-essential glycosylation sites removed. 
 
8.4.2 Trial Transfections Performed at the University of Bath 
The long-term aim of this work is to establish conditions under which useful quantities 
of AnoACE, ACER and AnCE can be expressed for use in crystallisation trials and other 
experimental work. Given that good expression has been seen in both the mammalian 
and insect system, the expression system of choice for this aim would probably be Sf9 
cells, as the potential protein yields are higher than for the HEK293T cells. However 
due to time constraints, the decision was made to begin work in Bath towards expression 
in HEK293T cells, as the transfection process is considerably faster.  
 
Two constructs were initially chosen for this: AnoACE_2 and ACER_3. This decision 
was based on the yields seen in the expression trials performed using HEK293T cells at 
the OPPF.  
 
This work is still in its early stages, thus the results are only preliminary. As shown in 
Figures 8.5 and 8.6 there is evidence that expression of both of these proteins in 
HEK293T cells has been achieved.  Based on the western blots the yield is very low, 
however these are small-scale trials (culture volume 1 ml). Furthermore, the expressed 
proteins are being secreted from the cells into the media, thus being greatly diluted.  
 
The western blots in Figures 8.5 and 8.6 indicate that whilst some level of AnoACE_2 
expression was achieved with both of the transfection reagents tested, ACER_3 
expression was only detectable using FuGeneHD. These results were only based on a 
single experiment, so it would be premature to conclude that FuGeneHD is the most 
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suitable transfection reagent, but it will be important to consider this observation as the 
work progresses. 
 
Having established some level of expression the next stages of this work will be to 
scale-up and perform the transfections on a larger scale. This will most likely involve 
some work to optimise the transfection process so as to obtain the best possible yields. 




Expression of three insect ACE homologues: AnCE and ACER from D. melanogaster 
and AnoACE3 from A. gambiae has been achieved using both mammalian HEK293T 
and insect Sf9 cells. Although AnCE expression has previously been achieved using the 
yeast P. pastoris, this is the first time that expression of an ACE homologue from A. 
gambiae has been achieved in any system. It is therefore an important step forward. 
 
Work has now been initiated to optimise and scale-up the expression process in 
HEK293T cells with the aim of producing enough protein to begin crystallisation trials. 
It would also be desirable to begin this process in Sf9 cells. This is because this cell line 
should ultimately be able to produce higher yields of the target proteins. Furthermore the 
glycosylation of the proteins produced by the Sf9 cells appears to be less extensive than 
of those from the HEK293T cells, meaning that proteins produced in this system may be 










































9.1 Angiotensin Converting Enzymes and ACE Inhibitors 
The role of angiotensin converting enzyme in mammalian blood pressure regulation has 
been the subject of extensive study for over 60 years, since the initial discovery of the 
enzyme in 1954 (Skeggs et al., 1954; Acharya et al., 2003). As an integral component of 
the renin-angiotensin aldosterone system, ACE functions to increase blood pressure, 
and, as such, has been the target of anti-hypertensive agents, ACE inhibitors, since the 
1980s (Patchett et al., 1980). 
 
Surprisingly, the development of ACE inhibitors took place long before the first ACE 
structure was reported, thus, these drugs were designed with no structural information. 
Currently ACE inhibitors are amongst the most widely prescribed drugs in the World, 
and are an effective treatment for hypertension and other cardiovascular ailments. In 
spite of this however many patients suffer from adverse side effects that range from a 
persistent dry cough to angioedema, which can be fatal (Bas et al., 2007). 
 
It is now widely accepted that ACE has a whole host of physiological functions outside 
of blood pressure homeostasis. It is the inhibition of the function of ACE in these other 
processes that appears to be the cause of many of the adverse effects pertaining from 
ACE inhibition. 
 
The domain organisation of ACE appears to be central to these additional roles. ACE 
consists of two homologous domains, arranged in tandem, each of which possesses a 
functional peptidase active site (Soubrier et al., 1988). These two domains, known as the 
N- and C-domains, display different substrate specificity. The C-domain has been shown 
to be primarily responsible for blood pressure homeostasis in vivo, whilst the N-domain 
is able to hydrolyse novel substrates such as GnRH and AcSDKP more efficiently 
(Georgiadis et al., 2003). 
 
With this in mind, significant efforts are currently being made to develop new inhibitors 
that specifically target only one of the two domains of ACE. Selective inhibition of the 
C-domain could target the hypertensive function of ACE, whilst leaving the role of the 
N-domain in other physiological processes uninhibited, thus reducing or eliminating 
many of the common side effects arising from treatment with ACE inhibitors.  
 
Similarly, selectively targeting the role of the N-domain outside of the RAAS might be 
an equally exciting prospect.  For example, inhibiting hydrolysis of AcSDKP by the N-
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domain has been identified as a potential method for protecting haematopoietic stem 
cells during some aggressive chemotherapy regimes (Bogden et al., 1991). 
 
The aim of much of the work presented in this thesis was to investigate the structural 
basis of ACE inhibition and how the interaction of different inhibitors with the active 
site could be exploited in the design of new, domain selective, ACE inhibitors.  
 
The enzyme AnCE from D. melanogaster was the primary tool for doing this. AnCE is a 
close homologue of ACE, sharing 60 % sequence identity with each of the two catalytic 
domains. It has previously been used successfully as a model for studying the structural 
basis of inhibitor binding (Akif et al., 2010). 
 
The main reason for using AnCE is that it is much more amenable to X-ray 
crystallography studies than human ACE. The challenges associated with working with 
ACE are highlighted by the fact that almost fifty years elapsed between the initial 
discovery of this enzyme in 1954 (Skeggs et al., 1954) and the report of the first crystal 
structure in 2003 (Natesh et al., 2003).  The primary reason for this is the extensive 
glycosylation that is required for the correct processing and function of this enzyme. 
This makes ACE unsuitable for recombinant expression using traditional prokaryotic 
systems such as E. coli, and makes crystallisation challenging due to the heterogeneity 
introduced by the glycan chains.  
 
In contrast, whilst AnCE still undergoes some post-translational processing, it can be 
expressed using the methylotropic yeast P. pastoris and appears much more amenable to 
crystallisation; a condition has been identified which typically yields diffraction quality 
crystals within 7-10 days. (Akif et al., 2010). 
 
9.2 Bradykinin Potentiating Peptides 
Bradykinin potentiating peptides (BPPs), isolated from the venom of the pit viper B. 
jararaca, are potent inhibitors of ACE that formed the basis for the development of the 
very first inhibitors (Cushman and Ondetti, 1999).  
 
These peptides are characterised by a C-terminal IPP motif that is thought to be central 
to ACE inhibition; the proline residue at the penultimate position protects the scissile 
peptide bond from cleavage. 
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More recently, a number of BPPs have been characterised as selective inhibitors of the 
C-domain (Cotton et al., 2002) and interactions between the P2 residue of the peptide 
and the S2 subsite have been implicated in this.  
 
In Chapter 3, the crystal structures of AnCE with two BPPs, BPP9a and BPPn, are 
presented. BPP9a is a selective inhibitor of the C-domain, and the structure with AnCE 
re-enforces the proposed role of the P2 residue in this. The P2 glutamine of BPP9a comes 
into close proximity of the side chain of AnCE residue Thr387. In the N-domain this is 
replaced by Arg381, the long, positively charged, side chain of which is highly likely to 
clash with the P2 moiety (Figure 3.9).  
 
The structural data presented in Chapter 3 indicate that the P6 position of the peptide 
may also have an important role in ACE inhibition. The previously reported structure of 
tACE with BPPb (Masuyer et al. 2012) suggests that there is an interaction between the 
P6 proline of BPPb and tACE residue Trp59. In the structure of AnCE with BPP9a 
(Chapter 3) only the C-terminal portion of the peptide is visible, and this is thought to be 
due to a lack of stabilising interactions with the active site to hold the N-terminal portion 
of the peptide in a single conformation. 
 
Comparison of the tACE and AnCE structures indicates that Thr40 in AnCE replaces 
Trp59 in tACE. This substitution means that the interaction with the P6 tryptophan 
would not be conserved, which could lead to increased flexibility of this portion of the 
peptide, resulting in it not being visible in the crystal structure.  
 
Based solely on the structural data presented in this thesis it is not possible to quantify 
the importance of any interaction between the protein and peptides at the P6 position, 
however it would be interesting to expand this study to consider the effects of this 
interaction on the potency of BPPs as ACE inhibitors. This could include synthesis of 
new peptides, identical to BPP9a save for the P6 position, and investigating their potency 
as inhibitors of both the N- and C-domains.  
 
The second structure presented in Chapter 3 is of AnCE in complex with a novel 
peptide, BPPn. BPPn was designed to investigate the importance of the conserved P3 
proline residue, which has been mutated to arginine. 
 
Only the conserved IPP motif is visible in the active site of the structure with BPPn 
(Figure 3.6). It is possible that this is due to cleavage of the peptide by AnCE, however 
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the fact that there is some residual density beyond the P1 isoleucine indicates that it is 
perhaps more likely that the remainder of the peptide is not visible due to its flexibility.  
 
With this in mind, an interaction between the conserved P3 proline residue, mutated to 
arginine in BPPn, and a conserved tryptophan residue found in both domains of ACE 
and in AnCE has been proposed as having an important role in stabilising the peptide in 
the active site (Figure 3.10).  
 
The structural data alone however are insufficient to determine whether this has an 
effect on the potency of the peptide as an ACE inhibitor. Further work should now be 
carried out to quantify the inhibitory activity of BPPn.  
 
If it does transpire that this mutation has had a deleterious effect on inhibitor potency, 
then maintaining and indeed improving this interaction, for example by addition of a P3 
tryptophan moiety, would be an important factor to consider in future inhibitor design. 
 
9.3 Spinorphin and Tynorphin 
Spinorphin and tynorphin are both peptides that have been identified as ACE inhibitors. 
Spinorphin is a natural peptide derived from the enzymatic cleavage of the β-chain of 
haemoglobin whilst tynorphin is a related, truncated peptide that is not such a potent 
ACE inhibitor (Nishimura and Hazato, 1993; Yamamoto et al., 2000). 
 
Interestingly, the sequences of spinorphin and tynorphin bear very little resemblance to 
the BPPs, thus the basis of their action as ACE inhibitors has not been clear.  
 
The aim of the work presented in Chapter 4 was to use AnCE as a model to study the 
binding of spinorphin and tynorphin to ACE and hence to learn more about their actions 
as ACE inhibitors.  
 
To this end a number of sets of diffraction data were collected for the two complexes, 
which were used to produce six crystal structures, three for AnCE with each peptide. 
 
As discussed in section 4.4, interpretation of the electron density maps for these 
structures was not always straightforward. In all cases clear residual difference density 
was visible in the active site that was thought to be due to peptide binding, but it was not 
possible to model the full-length peptides into the active sites of any of the structures. 
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The conclusion was drawn that AnCE was cleaving both spinorphin and tynorphin into 
multiple fragments, and it was these that were present in the active site of the crystal 
structures. 
 
What is not clear from this study alone is whether this cleavage is occurring on a 
timescale that is biologically relevant, or whether it is an artefact from crystallisation, 
where AnCE and the inhibitors are held at high concentrations in a constrained 
conformation for an extended period of time.  
 
This needs to be investigated further. The most appropriate method for this is likely to 
be incubating spinorphin and tynorphin with ACE for different time periods and using a 
combination of HPLC and mass spectrometry to monitor the persistence of the full-
length peptides and to identify any smaller fragments that are produced.  
 
9.4 Dipeptide Inhibitors 
The structures obtained of AnCE with spinorphin and tynorphin indicate that much 
smaller peptide fragments might be responsible for the observed inhibitory activity of 
these peptides. This correlates well with recent reports of the inhibitory actions of small 
dipeptides towards ACE. 
 
Tryptophan-containing dipeptides have recently been characterised as ACE inhibitors 
and, perhaps more importantly, dipeptides with a C-terminal tryptophan residue have 
been shown to be selective inhibitors of the C-domain (Lunow et al., 2013; Lunow et 
al., 2015). 
 
In Chapter 5, the crystal structures of AnCE bound to three such inhibitory dipeptides 
are presented. The data indicate that these dipeptides all bind to the AnCE active site and 
as such are expected to behave as competitive inhibitors. The mode of binding is the 
same as seen with other peptide inhibitors such that conserved interactions between the 
C-terminus of the dipeptide and the active site are made. 
 
The C-terminal tryptophan residue occupies the S2’ hydrophobic pocket and this is likely 
to be the main driving force for domain selectivity, as the hydrophobicity of this 
environment is not retained to such an extent in the N-domain. Interestingly, an 
additional interaction was identified between the tryptophan and AnCE residue Gln266 
that would neither be conserved in the N- nor the C-domain.  
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The importance of the P2’ residue in domain selectivity has been reported previously. 
Based on the structures presented in Chapter 5, it appears that the P1’ residue may also 
have an important role. An aliphatic residue at this position favours C-domain inhibition 
due to a stabilising interaction with a valine residue that is not conserved in the N-
domain. Conversely, an interaction was identified between the side chain of the P1’ 
tyrosine residue and a glutamate reside in AnCE. This interaction would not be 
conserved in the C-domain but could be in the N-domain. This is an important feature 
that could potentially be used in the development of N-domain selective inhibitors.  
 
Overall the work with the dipeptides and AnCE illustrates how very subtle differences 
confined to a relatively small area of the active site can have a profound effect on 
inhibitor potency. It is important to consider this alongside the other interactions along 
the catalytic channel that have been identified through the studies on BPPs when 
considering the design and development of new inhibitors.  
 
9.5 A New AnCE Crystal Structure 
All of the structural data presented in Chapters 3, 4 and 5 were obtained using AnCE 
crystals grown from the same condition: 1.2-1.3 M sodium citrate, 0.1 M HEPES, 
pH7.5. Whilst this crystallisation condition has been used very successfully on these 
occasions, a number of circumstances have arisen where it has not been ideal. 
 
Part of the focus on developing new ACE inhibitors is to consider natural compounds 
that display some inhibitory activity and to consider how features of these could be used 
in inhibitor design. Structural studies are therefore essential to understand the basis of 
their interaction with ACE. 
 
In some cases this has proved to be very challenging, and crystallisation experiments 
have repeatedly failed to yield co-crystals of AnCE and the inhibitor. In all cases only a 
citrate ion, arising from the crystallisation condition, is present in the active site. It is 
thought that the weaker inhibitors are unable to displace the citrate ion, hampering 
attempts at structure-based studies. 
 
In an attempt to overcome this a new crystallisation condition has been identified and 
using crystals grown in this condition a new structure of AnCE in a different crystal 
form has been elucidated. Careful analysis of this structure, presented in Chapter 6, 
indicates that it is largely identical to existing AnCE structures and as such crystals 
obtained from this condition can confidently be used in future experiments. 
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Whilst there is no citrate ion in the active site of the new structure, a malate ion, also 
thought to arise from the crystallisation condition, is present. Unlike the citrate ion, the 
malate ion does not appear to interact with the catalytic zinc ion (Figure 6.6). This 
suggests that it may not be so tightly bound and hence could be more easily displaced by 
weaker inhibitors. This could make this condition more suitable for studying the binding 
of novel inhibitors, and work has already been initiated to try and achieve this.  
 
9.6 ACE Homologues from A. gambiae 
In addition to AnCE, many other insect ACE homologues have been identified. ACE 
homologues have been identified in every insect genome sequenced to date, indicating 
that they must have important biological roles (Isaac et al., 2007). Given that insects do 
not have a circulatory system resembling that found in mammals, studying the roles of 
insect ACE-like enzymes could help to better our understanding of the roles of ACE 
outside of the RAAS. 
 
Furthermore, there is a significant amount of evidence to suggest that insect ACE-like 
enzymes have an important conserved role in reproduction. With this in mind, the 
prospect of developing ACE inhibitors that specifically target insect enzymes and using 
these in insecticides has been considered.  
 
The ACE homologues from the mosquito A. gambiae (AnoACEs) are particularly 
interesting for a number of reasons. Firstly, the genome appears to code for ten different 
ACE-like enzymes, the highest number found in any organism thus far. In addition to 
this, one of these enzymes, AnoACE9, is predicted to consist of two catalytic domains 
arranged in tandem, as seen in sACE, which indicates that this arrangement has been 
selected for on more than one occasion, hence must be advantageous in some way 
(Burnham et al., 2005). Finally, the role of A. gambiae as a vector for the transmission 
of P. falciparum, a causative agent of malaria, makes targeting AnoACEs in insecticides 
an exciting long term prospect.  
 
The aim of the work involving AnoACEs that is presented in this thesis was to focus on 
one of these enzymes, AnoACE3, and to work towards its expression and purification. 
The longer term aim of this being to use the purified enzyme in structural and activity 
based studies to learn more about its biological functions. 
 
AnoACE3 shares 54 % sequence identity with AnCE and all three of the N-linked 
glycosylation sites present in AnCE are predicted to be conserved. First attempts to 
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express AnoACE3 were made using the methylotropic yeast P. pastoris, which has been 
used successfully for the recombinant expression of AnCE. 
 
As detailed in Chapter 7, in spite of significant efforts, no detectable AnoACE3 
expression was achieved. There are many possible reasons why this may have been the 
case, but perhaps the most likely explanation is that the unique nature of the AnoACE3 
N-terminus impeded expression in some way. 
 
AnoACE3 has a unique sequence at its N-terminus that is not conserved in AnCE, the 
function of which is entirely unknown. It is possible that this region undergoes extensive 
post-translational modifications, which could not be reproduced in P. pastoris, that are 
in someway essential for stability. 
 
Both the AnCE and AnoACE3 constructs used for P. pastoris expression contain an N-
terminal α-factor signal sequence that targets the proteins for secreted expression. This 
sequence must be cleaved from the protein by the enzyme Kex2 so that the protein can 
move from the Golgi apparatus into vesicles for secretion. The different nature of the N-
terminus of the AnoACE3 construct may have impeded this process, leading any protein 
that was expressed to be “stuck” at this stage of the pathway.  
 
Ultimately, the decision was made to try and express AnoACE3 using higher eukaryotic 
systems (Chapter 8). This work was completed concurrently with AnCE and a second D. 
melanogaster ACE homologue, ACER.  
 
Expression trials were performed using both HEK293T and Sf9 cells and there was 
evidence of expression of all three proteins using both systems. This is an important step 
forward and is the first time that recombinant expression of an ACE homologue from A. 
gambiae has been achieved. 
 
The work on the AnoACEs is in its very early stages and there is a lot of scope to build 
on the results that have been achieved. The immediate task is now to scale-up the 
expression. Ideally this should be performed in both the HEK293T and the Sf9 cells. 
This is because, based on the molecular weights of the species produced (Figures 8.3 
and 8.4), the glycosylation profiles of the enzymes produced by the two cell lines seems 
to be quite different. It would be really interesting to see if this has any effect on the 
activity and stability of the enzymes.  
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Once pure protein has been obtained it should then be possible to conduct a series of 
activity assays to try and determine what some of the substrates of AnoACE3 are. A 
good place to start here would be considering the activity of the enzyme towards 
angiotensin I and bradykinin, which are both well characterised as substrates of ACE 
and AnCE. Studying the action of known ACE inhibitors towards AnoACE could also 
provide more information about the biochemical properties of this enzyme. 
 
Structural data would be highly useful to complement this data, providing insights into 
the reasons for the observed substrate and inhibitor binding preferences. This work may 
be somewhat challenging due to the extensive post-translational modifications evident 
by the sizes of the expression products seen in Figures 8.3 and 8.4. It may be necessary 
to use glycosidases to cut back the glycan chains to some extent and possibly, as was the 
case for sACE, to mutate any glycosylation sites that are not essential for stability and 
activity (Anthony et al., 2010; Gordon et al., 2003). 
 
9.7 Concluding Remarks 
In conclusion, the work presented here includes some important progress in the 
understanding of angiotensin converting enzymes from mammals and insects. By using 
the D. melanogaster ACE homologue AnCE as a model in structural studies to 
investigate the binding of different inhibitors, a number of interactions with the active 
site have been identified that could potentially be used in the development of new 
inhibitors, for which there is clearly a need. 
 
In addition to this, the structural basis of inhibition by small dipeptide fragments has 
been investigated and illustrates how it may be possible to create potent, domain specific 
inhibitors, by enhancing interactions with a relatively small area of the active site. 
 
Finally, recombinant expression of an ACE homologue from A. gambiae has been 
reported for the first time. Future work should now involve both structure and activity 
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